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The long saphenous vein (LSV) is commonly used as a conduit in coronary artery bypass grafting 
(CABG); however, long term patency remains limited by the development of intimal hyperplasia 
and superimposed atherosclerosis. Upon engraftment of the LSV, there is a necessity to 
accommodate a vastly increased flow rate and wall shear stress, the effect of which, remains 
poorly defined. Venous endothelial cell (vEC) activation induced by vein harvest and the acutely 
altered shear stress rates (or acute high shear stress (AHSS) at 12dyn/cm2) is thought to be 
pivotal for development of later-stage pathologies, but little is known about the signalling 
pathways involved. In this thesis, the involvement of two transcription factors, NF-κB and Nrf2, 
in vEC activation were assessed in the context of AHSS. 
Firstly, NF-kB was activated in the LSV endothelium and HUVECs, in response to AHSS. This was 
further supported by the detection of AHSS-induced NF-kB target inflammatory genes including 
MCP-1, which was reduced with NF-kB inhibition prior to the onset of AHSS. Additionally, AHSS 
enhanced monocyte adhesion to the endothelium, in vitro and  ex vivo, and reduced endothelial 
cell-cell contacts, both of which were reversed with NF-kB inhibition prior to the onset of AHSS. 
The second aim was to promote cellular defence prior to the onset of AHSS, through activation 
of the Nrf2-Keap1 antioxidant regulatory system.  In response to AHSS in vitro, there was an Nrf2 
target gene transcriptional response; however, not induced by increased Nrf2 translocation, but 
rather, increased dissociation from and nuclear export of Keap1. When Nrf2 was pre-activated, 
however, far from preventing the pro-inflammatory response to AHSS, the inflammatory 
response of venous ECs was increased. This contradictory finding appears to be mediated in part 
by the dysregulation of Keap1 under AHSS, suggesting that this cellular defence system is not a 
suitable target in the treatment acute vein graft inflammation. 
Pharmacological modulation of vein graft patency has proven to be exceedingly difficult, with 
the identification of suitable targets providing the primary hurdle, due to the complex disease 
aetiology and multicellular pathology. This thesis, provides evidence that inhibition of acute EC 
activation and inflammation as a result of AHSS may represent an exciting and unexplored 
strategy for improving vein graft outcome, with the NF-κB transcription factor emerging as a 
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1.1 ISCHAEMIC HEART DISEASE AND MANAGEMENT 
Ischaemic heart disease (IHD) remains the leading cause of morbidity and mortality in the 
Western world (Mozaffarian et al., 2015). It occurs as a result of mismatch in oxygen supply and 
demand, usually due to atherosclerosis in one or more of the coronary arteries leading to 
significant stenosis in the coronary circulation. With an epidemiological transition occurring 
globally, developing, low to middle income countries are also facing dramatically increasing 
rates of death from IHD accounting for up to 28% of mortality in these regions (Gaziano et al., 
2010). Disease prevalence is exacerbated by extrinsic and intrinsic factors. Extrinsic risk factors 
include smoking, socioeconomic status and a diet high in saturated fat. By their very nature, 
extrinsic risk factors are relatively easily modified, and their effects are preventable. Whereby, 
the cessation of smoking or improvement of diet offer huge benefits in reducing cardiovascular-
associated diseases. Intrinsically, IHD is worsened by certain genetic predispositions and 
hyperlipidaemia, which also contribute significantly to the progressive pathology of 
atherosclerosis and correlate strongly with increased morbidity (Davignon et al., 1988; Barter et 
al., 2007). With its’ current and burgeoning burden across the world, it is essential that 
treatments for IHD are advanced through improved understanding of molecular aetiology of 
both pharmacological and interventional strategies. 
Management of IHD can be problematic, given the differing severities of stenosis and speeds of 
progression; however, management approaches fall into two categories. The first of these is 
non-invasive management. This can involve alterations to extrinsic risk factors, including 
modified diet and cessation of smoking, or use of pharmacological agents aimed at moderating 
thrombotic events, blood pressure regulation and lipid accumulation. Alternatively, IHD can be 
managed through invasive means, either catheter based (invasive cardiology) or surgical, which 
both function to re-vascularise cardiac tissue distal to the site of stenosis, thus re-balancing the 
mismatch in oxygen supply and demand (Hansson Hansson, 2005). Percutaneous coronary 
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interventions (PCI), such as balloon angioplasty and stenting (FIGURE 1.1.A. and B., respectively), 
aim to unblock the coronary stenosis. Whereas, coronary artery bypass graft (CABG) surgery 
(FIGURE 1.1.C.) diverts blood flow from the aorta to the obstructed coronary artery, distal to the 
site of blockage, with the use of an autologous, non-diseased vessel, most commonly the long 
saphenous vein (LSV) and internal mammary artery (IMA). CABG remains the gold standard 
intervention in many patients in the presence of complex coronary disease, diabetes and poor 
ventricular function (Alderman et al., 1997; Eagle et al., 2004; Serruys et al., 2009; Mohr et al., 
2013).   
 
 Interventional treatment strategies for IHD 
Diagrammatic representation of interventional approaches for the treatment of IHD. This figure 
was created using images from the Servier medical art library (smart.servier.com). 
A. Catheter and balloon angioplasty 
B. Catheter and bare metal stent 











1.2 SAPHENOUS VEIN GRAFT FAILURE 
The LSV is the most commonly used conduit for CABG in patients with multi-vessel coronary 
artery disease (CAD) because it is easy and quick to harvest, and it can provide enough length to 
bypass multiple diseased coronaries (Eagle et al., 2004; Serruys et al., 2009; Wan et al., 2012). 
The left internal mammary artery (LIMA) to left anterior descending coronary artery (LAD) 
(FIGURE 1.1.A.) is the graft of choice for patients receiving a single graft or two neighbouring 
grafts (as a Y or sequential graft) due to its higher long-term patency of approximately 85-95% 
after 10 years, compared with 50-60% patency in LSV grafts, as well as the improved long-term 
survival benefit (Lytle et al., 1985; Sabik, 2011; Garatti et al., 2014).  The use of LIMA, however, 
is mainly restricted by its length. In contrast, for patients with multi-vessel CAD, at least one or 
more LSV grafts will still be used and, despite increases in the usage of multiple arterial grafts, 
the LSV remains a highly important conduit in CABG (Goldman et al., 2011; Garatti et al., 2014). 
The use of LSV is not without limitations, however. Its longevity continues to be complicated by 
the development of vascular inflammation, intimal hyperplasia (IH) and superimposed 
accelerated atherosclerosis leading to compromised graft efficacy and ultimately, vein graft 
failure (VGF) (Newby et al., 2000).    
1.2.1 TEMPORAL PATHOGENESIS OF VGF 
VGF can be separated into two distinct temporal categories; firstly, early graft failure defined as 
occurring within one month to one-year post-implantation and which arises in 3-15% of venous 
grafts (FIGURE 1.2.). This early graft failure is due to occlusive thrombotic events and is most 
commonly due to technical mismanagement of surgery. It is considered that the use of high 
pressure distension, as an attempt to avoid venospasm prior to implantation, and the removal 
of the vasa vasorum during vessel harvest, which induces tissue ischaemia and a loss of 
innervation deep into the medial layer of the vessel, are major contributors to early graft failure 
(Rousou et al., 2009; Dashwood et al., 2013). Both venospasm and stripping of the pedicle of the 
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LSV lead to decreases in the vessel distensibility, and reductions in oxygen supply to both intimal 
and medial layers. These in turn induce EC and VSMC dysfunction, respectively, which contribute 
significantly to thrombotic events (Souza et al., 2002). Both of these practices also cause focal 
disruption to the endothelial monolayer, triggering fibrin deposition and, in turn, platelet and 
erythrocyte aggregation to the surface of the vein graft wall. Once aggregated to the site of 
injury, platelets become activated, secreting thrombospondin, fibrinogen and β-
thromboglobulin, amongst numerous other clotting factors, contributing largely to early 
thrombotic events in SVGs (Dobrin et al., 1992; Verrier et al., 1996; Wan et al., 2012). In addition 
to the platelet-driven clotting factor secretion, venous conduits also possess innately reduced 
antithrombotic abilities as compared with arterial equivalents (Cox et al., 1991; Motwani et al., 
1998). The advent of both low-pressure distension, for vein preparation, and the ‘no-touch’ 
technique, for graft harvest and implantation, can reduce the possibility of thrombotic events 
early in the life of the graft, in addition to greatly extending long-term patency (Angelini et al., 
1990; Dashwood et al., 2013; De Souza et al., 2017). 
Pharmacological interventions targeting thromboses are also widely used for the prevention of 
early graft failure. Commonly, this includes treatment with anti-platelet agent, aspirin, which 
drastically reduces the risk of thrombosis when initiated early, following CABG (Stein et al., 
2004). Additionally, aspirin may be used in conjunction with clopidogrel as part of a dual anti-
platelet therapy; not only has this dual therapy been shown to be effective at increasing early 
graft patency rates, but it also halves 30-day mortality when compared with aspirin alone (Deo 
et al., 2013). Another advantage of clopidogrel treatment is its ability to reduce VSMC 
proliferation, an important contributor to late VGF (Deo et al., 2013). Late stage graft failure is 
characterised initially by endothelial dysfunction, followed by the progressive development of 
intimal hyperplasia and superimposed atherosclerosis, which leads to graft occlusion after 
rupture of atherosclerotic plaques and thrombosis. Vein graft occlusion due to late stage VGF 
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occurs in approximately 50-60% of vein grafts within 10 years (FIGURE 1.2.) (Harskamp et al., 
2013). As such, the remainder of Section 1.2. will focus on the events leading to late stage VGF. 
 
 
 Early and late stage vein graft failure 
Vein graft failure (VGF) occurs early or late after implantation. Early VGF occurs within one 
month to one year after surgery as a result of thrombosis, mainly caused by technical issues with 
surgery. Late stage VGF is a slower process characterised by early EC injury and activation, which 
precedes IH development, superimposed atherosclerosis and, ultimately, occlusion of the 
lumen. 
EC: endothelial cell; ROS: reactive oxygen species; ECM: extracellular matrix; VSMC: vascular 
smooth muscle cell; SS: shear stress; 10m: 10 minutes; 2wks: 2 weeks; 1 yr: 1 year. This figure 
was partly created with the Servier medical art library (smart.servier.com). 
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1.2.2 HAEMODYNAMIC CONTRIBUTION TO VGF 
Endothelial Cells (ECs) play a pivotal role in regulating vascular homeostasis, with the quiescent 
endothelium protecting the vascular tree through the promotion of an anti-coagulant and anti-
inflammatory environment, as well as regulating lipoprotein permeability (Chiu et al., 2011). The 
role of ECs in the development of VGF, however, remains relatively poorly understood; previous 
studies have suggested that ECs may not be important as they are lost following surgery (Komori 
et al., 2002; Xu et al., 2003; Torsney et al., 2004; Isaji et al., 2017). Most of these studies, 
however, observed late time points, from between 24 hours to 1 week after implantation, and 
did not address the immediate changes in ECs (i.e. <24 hours). Moreover, it has not been 
determined whether EC denudation and loss are purely due to vessel manipulation and 
biomechanical changes occurring during harvest and immediately after implantation; or are 
driven by EC activation and apoptosis in response to acute changes in unconditioned ECs 
following graft implantation. Endothelial loss as a result of grafting is thought to further 
exacerbate processes involved in early IH pathogenesis, such as platelet aggregation, 
inflammatory cell infiltration and mitogenesis (Owens, 2010; Osgood et al., 2014). Circulating 
endothelial progenitor cells are known to limit the duration of such processes, via the 
restoration of the endothelial monolayer from roughly one week after vessel implantation (Xu 
et al., 2003; Zampetaki et al., 2008). This re-endothelialisation is vitally important to re-
establishing the homeostatic function of the endothelium. However, in the interval between 
implantation and endothelial restoration, the path to pathogenesis has already begun, perhaps 
irreversibly. 
It is widely accepted that harvesting and implantation of the LSV impacts on EC integrity to some 
degree, despite continued attempts to better preserve the endothelium through minimising 
manipulation (Hwang et al., 2012; Harskamp et al., 2013; Sen et al., 2013). However, many of 
these studies into EC integrity in the LSV fail to address the degree of dysfunction in the 
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preserved endothelium. In fact, studies using an ex vivo perfusion model of LSV, demonstrated 
that venous ECs are preserved, but activated, in response to graft preparation (Kwei et al., 2004; 
Osgood et al., 2014). These findings are corroborated by the demonstration that acute exposure 
of LSV to high shear stress is associated with minimum denudation and significant pro-
inflammatory response in venous ECs (Zakkar et al., 2011). There remain radical and unavoidable 
changes to the environment of the saphenous vein after implantation that are inherent in the 
procedure. Immediately after implantation of the LSV into arterial circulation, the vessel is 
exposed to a much higher rate of blood flow, resulting in significant increased longitudinal wall 
shear stress (from 0.5-4 dyn/cm2 to 12-30 dyn/cm2) (Dobrin et al., 1989). These changes result 
in the vein graft acutely experiencing new haemodynamic forces considerably greater than it is 
able to accommodate (Chiu et al., 2011). This arterial environmental transformation contributes 
significantly to the acute inflammatory response known to be associated with endothelial 
dysfunction and the development of intimal hyperplasia (IH), though the exact mechanism 
remains unclear (Lytle et al., 1985; Amano et al., 1991; Motwani et al., 1998; Sarjeant et al., 
2002; Harskamp et al., 2013). In addition to the involvement of arterial haemodynamics in the 
development of IH, the configuration of the vessel and the graft-artery anastomosis also 
influences focal development of IH (Ghista et al., 2013). Similar to the focal nature of plaque 
distribution at bifurcations in atherosclerosis, disturbed flow patterns at sites of graft 
anastomosis induce vascular injury, which, in turn, triggers inflammatory cascades, IH 
pathogenesis and accelerated atherosclerotic lesions (Keynton et al., 2001; Ghista et al., 2013). 
1.2.3 PATHOLOGY OF INTIMAL HYPERPLASIA AND ACCELERATED ATHEROSCLEROIS 
IH is the result of chronic structural changes occurring in vein grafts due to abnormal migration 
and proliferation of vascular smooth muscle cells (VSMCs) accompanied by an increase in 
extracellular matrix (ECM) degradation and deposition (Bryan et al., 1994; Sarjeant et al., 2002; 
Mitra et al., 2006).  Within a normal ‘healthy’ vessel, interactions between ECs and VSMCs, and 
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between VSMCs and ECM, sustain a quiescent phenotype in VSMCs (West et al., 2001). Despite 
the LSV graft generally being considered as ‘non-diseased’, this cell-cell or cell-matrix interaction 
has already gone awry, and many veins possess a degree of intimal thickening and fibrosis even 
before implantation (Thiene et al., 1980).   
Following initial endothelial injury, and subsequent EC dysfunction, however, the balance of 
physiological intimal thickening is tipped in the direction of pathogenesis. Aggregated platelets 
adhered to the graft wall secrete mitogenic and inflammatory factors affecting VSMCs and ECs 
alike, including platelet derived growth factor (PDGF), transforming growth factor β (TGF-β) and 
interleukin 1 (IL-1) (de Vries et al., 2016). Redox balance is also extremely important in the 
maintenance of normal functionality in the vascular wall. The bioavailability of endothelium 
derived relaxing factors, nitric oxide (NO) and prostaglandin (PGI2), is fundamental to the 
maintenance of vascular tone, as well as to the regulation of EC quiescence and VSMC 
proliferation, migration and contractility (FIGURE 1.9.) (West et al., 2001).  The dysregulation of 
NO balance has profound effects on the vascular wall, particularly in the context of the vein 
graft. Whereby the tipping of this balance towards reduced NO availability and increased ROS 
production, in particular, superoxide (O2•-) generation, partly through eNOS uncoupling by 
combined actions of NADPH oxidase (NOX) and arginase enzymes, significantly potentiates IH 
pathogenesis (West et al., 2001; Guzik et al., 2005; Forstermann, 2008; Siragusa et al., 2016). 
Increased superoxide generation functions to scavenge NO (together forming peroxynitrite 
(ONOO-)) and directly regulate VSMC proliferation, which begins the development of a highly 
atherogenic environment, initiated by endothelial dysfunction (Zakkar et al., 2015). These 
factors together help contribute to the phenotypic switching in VSMCs, from a contractile to 
synthetic state, and the initiation of migration of VSMCs into the intima and their proliferation 




 Mechanism of late-stage VGF 
Temporal development of late stage vein graft failure beginning from surgical trauma and 
altered haemodynamics, ultimately leading to intimal thickening and vascular remodelling 
through the combined actions of multiple vascular cell types and extracellular matrix 
interactions. EC: endothelial cell; ECM: extracellular matrix; VSMC: vascular smooth muscle cell; 
IEL: internal elastic lamina; EEL: external elastic lamina. 
 
VSMC migration is not only driven by the presence of chemo-attractants and matrix 
metalloproteinase (MMP) proteolytic action, but also requires the additional remodelling of the 
cytoskeleton and contacts with the ECM (Newby, 2005). MMPs play a fundamental role in VGF 
due to their wide-ranging capabilities in degradation of ECM components. The ability of MMPs 
to regulate degradation of the ECM of the basement membrane, as well as cell-cell contacts 
(cadherins) between VSMCs, also provides VSMCs with the capacity to de-differentiate from a 
contractile to synthetic VSMC, migrate into the intima and, once there, proliferate (FIGURE 1.3.) 
(Newby, 2005; Rzucidlo et al., 2007).  Between 2 and 4 weeks after surgery, intimal thickening 
is apparent, owing to the accumulation of VSMCs and extensive collagen and proteoglycan 
 11 
deposition, which leads to the inward enlarging of the intimal layer (FIGURE 1.3.) (Owens, 2010). 
The multitude of elements contributing to IH occurring between one month and one year after 
bypass, result in widespread remodelling throughout the SVG. Within one year, the thickened, 
fibrotic, stiffer vessel becomes the ideal environment for the formation of atherosclerotic 
lesions (Walts et al., 1987; Motwani et al., 1998; Owens et al., 2015).  Atherogenic-type lesions 
predominate in the SVG after the first year; though they do not develop quite as they do in the 
arterial system. Lesions, although more pronounced at sites of anastomosis, are much more 
diffuse throughout the length of the vessel as compared with the focally distributed 
atherosclerotic plaques commonly found in the coronary vasculature (Ratliff et al., 1989; Yahagi 
et al., 2016). Besides the obvious differences in speed of progression and lesion localisation, SVG 
atheromas still share many features with coronary atheromas, such as the presence of both 
VSMC- and macrophage-derived foam cell populations, presence of a thin fibrous cap and intra-
plaque haemorrhage (Yahagi et al., 2016). SVG lesion development predisposes the graft to 
constant risk of plaque rupture and relapse of symptoms of coronary atherosclerosis, including 
acute myocardial infarction. With the huge complexity of the processes ultimately leading to 
late-stage VGF, and the dangers that this poses to patients, there is a drastic need for improved 
understanding of the molecular nature of all stages of the pathology. 
1.2.4 CABG CONDUIT COMPARISON 
LSV and IMA differ vastly in structure and functional capability. Structurally, the IMA is a very 
elastic artery with a medial layer formed of distinct sheets of interspersed wave-like collagen 
and VSMCs arranged circumferentially with very little variability (Canham et al., 1997). 
Interestingly, the IMA shares a great deal of structural homology with the LAD, with the primary 
differences being that the LAD possesses a smaller VSMC medial area and more elastin (Prim et 
al., 2016). Whereas the LSV is considerably more varied in size and structure, with a much 
narrower medial layer composed primarily of collagen, fenestrated elastic laminae, less elastin 
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and fewer VSMCs (FIGURE 1.4.) (Canham et al., 1997). Thus, the LSV suffers from compliance 
mismatch under higher physiological pressures, when implanted into the arterial circulation. 
This results in the vessel being less able to passively expand to accommodate the higher-
pressure due to its inherently thinner, less dense medial layer and its highly aligned collagen 
structure (Ghista et al., 2013).  
 
 
 Structural differences between large arteries and veins 
The walls of large arteries and veins are structurally different. The arterial wall is considerably 
thicker than the venous wall, with a larger density of elastic fibre and VSMCs within the medial 
layer, allowing the vessel to accommodate much higher pressures. In contrast, both the medial 
and adventitial layers of veins are less densely populated, compared to arteries. ECs within the 
intima are also vastly different between these two branches of the vasculature, with arterial ECs 
more elongated and aligned with the direction of flow, compared to shorter, rounder, non-




Structural differences between the arterial and venous vasculature have been understood since 
the 17th century; however, the structurally discrete features of the endothelium in these two 
tissues was not appreciated until the mid-20th century (Weibel et al., 1964; Florey, 1966). In 
development, arterial and venous vascular beds emanate from molecularly distinct foundations, 
and differences in ephrin B2/EphB4, Vascular endothelial growth factor A (VEGF-A) and Notch 
signalling pathways, amongst several others, define vessel identity even before initiation of 
circulatory flow (Aitsebaomo et al., 2008). These very early features of the developing 
vasculature indicate the predetermined nature of the arteriovenous endothelium. However, due 
to the extremely heterogeneous and structurally diverse tissue locations of the endothelium 
throughout the body, its composition and structure is tissue dependent and heavily influenced 
by extrinsic factors.  
Within mature healthy blood vessels, the endothelium is typically continuous and non-
fenestrated, with each cell within the monolayer being attached through intercellular tight or 
adherens junctions (Aird, 2007). Arterial ECs (aECs) exhibit many more tight junctions per cell 
than venous ECs (vECs), owing to the considerably higher pressure within the arterial system 
(Dejana, 2004). Greater tight junction distribution in aECs functions to prevent para-cellular 
transport, thus reducing endothelial permeability to solutes and lipids (Bazzoni et al., 2004). 
Moreover, different haemodynamic patterns between the arterial and venous tree result in aEC 
alignment with the direction of flow, as such, they become elongated and flattened, whereas 
vECs do not align with flow and are morphologically shorter and wider (Aird, 2007). Interestingly, 
such morphological features can be reversible both in vivo and in vitro suggesting that EC 
phenotypes maintain a degree of plasticity (Flaherty et al., 1972). This adaptability is particularly 
evident in vitro, with the loss and gain of numerous expressed genes characteristic of EC type 
(or location) once cells have been passaged, clearly showing the impact of cellular 
microenvironment on EC phenotype (Lacorre et al., 2004). When comparing the impact of 
altered haemodynamics (mainly shear stress), Zakkar et al. observed that vECs respond to acute 
 14 
changes in shear stress by inducing a pro-inflammatory profile mediated by the activation of 
MAPK signalling pathways, while aECs remained resistant to such stimuli through action of 
atheroprotective signalling pathways (Zakkar et al., 2008) (FIGURES 1.5 and 1.9.). This 
differential response is in part related to the fact that aECs react to shear stress by upregulating 
anti-inflammatory mediators such as MAP kinase phosphatase 1 (MKP-1), Nrf2 and KLF2; 
whereas this response appears to be innately reduced in vECs (Dekker et al., 2006; Zakkar et al., 
2008; Zakkar et al., 2009).  
It has also been suggested, however, that it is not only environmental influences that determine 
mature EC fate, but that epigenetic modifications also function to more rigidly and locally define 
the role of the endothelium (Chi et al., 2003). In a study by Deng et al., human coronary aECs in 
culture showed greater increases in adhesion-, proliferation- and apoptosis-related genes when 
stimulated with oxidised LDL than ECs from human LSV (Deng et al., 2006). This phenotypic 
intransience in vitro can help in our understanding of inherent susceptibility to atherosclerosis 
in aECs, as compared with vECs; and, perhaps also in the early response of vECs to conditions of 
the arterial environment after CABG surgery. Heterogeneity in the endothelium, due to its 
vascular origin, is an integral property of the cell type, allowing it to be governed by both its 
surrounding environment and pre-determined cell fate. However, this same heterogeneity 
makes understanding vascular disorders, and subsequent therapeutic targeting of the 
endothelium, increasingly complex.  
1.2.5 CURRENT STRATEGIES TO IMPROVE SVG PATENCY AND EC INTEGRITY 
Owing to the finite lifespan of vein grafts, the likelihood that patients may have to have  
follow-up procedures or receive a form of prophylaxis is relatively high. However, to date, 
despite the wealth of studies investigating graft maintenance, no effective treatment exists for 
the extension of SVG patency (Wan et al., 2012). Despite the obvious benefits to prolongation 
of patency on patient’s lives, if left untreated, vein graft failure can further contribute to the 
 15 
recurrence of angina or development of myocardial infarction (MI). Intraoperative measures, 
such as the ‘no-touch’ technique, whereby, during harvest of the LSV, the perivascular fat 
surrounding the vessel is preserved, have been found to ameliorate thrombotic events related 
to early graft failure; however, their effect later in the life of the graft still remains unclear (Souza 
et al., 2002). Of particular growing interest, is the potential benefit of perivascular adipose tissue 
(PVAT) preservation on the pathophysiology of the vein graft. PVAT has long been overlooked in 
vascular biology, far from being simply an energy source, PVAT releases and receives a number 
of functional substances known to influence vessel behaviour, affecting functions as diverse as 
relaxation to inflammation (Szasz et al., 2012). It is well recognised that the use of the ‘no-touch’ 
technique results in greater preservation of the endothelium following harvest; however, what 
is less well documented is the function that remaining PVAT has in maintaining VSMC quiescence 
and contraction (Dashwood et al., 2013; Fernandez-Alfonso et al., 2017). The refinement of LSV 
surgical harvest and preparation techniques has enabled a reduction in conduit damage prior to 
implantation; however, pharmacological advances do not appear to be progressing at the same 
speed, or with anything like similar results (Souza et al., 2002; Alexander et al., 2005; Alexander 
et al., 2005; Taggart et al., 2015).  
Another perioperative intervention effectual in both animal and human models is the use of 
external sheaths around the graft, first described in 1963 (Parsonnet et al., 1963). Use of an 
external, porous stent surrounding the saphenous vein in a porcine model of arteriovenous 
bypass grafting resulted in significant reductions in intimal thickening (Angelini et al., 1996; Izzat 
et al., 1996; Jeremy et al., 2004). Two primary features of the sheath are: porosity, to allow for 
angiogenic growth of microvessels in order to keep the newly forming ‘neoadventitia’ 
oxygenated (in essence, the regrowth of the absent vasa vasorum) (George et al., 2001); and 
non-restrictiveness, permitting the formation of a matrix between the vessel and sheath for 
outgrowth of microvessels (Jeremy et al., 2007). External sheaths have also been shown to 
prevent effects associated with the distension of the graft under arterial pressure and resultant 
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regions of disturbed flow appear to be corrected in a porcine model of vein grafting (Jeremy et 
al., 2007). This finding was validated in the first successful in-man trial of external stenting, 
whereby stented vessels showed decreased deformation of the lumen and overall vessel 
structure, as well as a significant reduction in IH development with one-year post-implantation 
(Taggart et al., 2015). However, opposing results were seen the Extent trial, in which the external 
Dacron stent was utilised in CABG patients; disappointingly all stented vessels thrombosed 
within 19 months after surgery and the trial was stopped, perhaps due to the rigidity of the stent 
(Murphy et al., 2007). Despite the reasonably promising nature of external stenting seen in 
preclinical and small clinical studies, the development of a suitable material fulfilling a multitude 
of desired specifications remains the challenge faced by clinicians, chemists and biologists. 
Developments of pharmacologic interventions for the treatment of VGF continue to endeavour 
in pursuit of a suitable therapeutic target for both cellular specificity and efficacy. Secondary 
prevention of the symptoms of late VGF pharmacologically provides equally demanding 
questions relating to treatment strategy. Addressing maintenance of EC functionality after 
surgical trauma is of paramount importance, peri-operatively, for SVGs; this requires 
preservation of endothelial coverage, as well as preservation of the vasomotor actions of ECs 
(Woodward et al., 2016). Recent developments have led to the renewed interest in the 
pleiotropic effects of statins for preservation of EC function, due to their role in the conservation 
of redox balance in the endothelium and vascular wall (Margaritis et al., 2014). In addition to 
the widely understood lipid-lowering effects of statins, it has been reported that they are able 
to prevent activation of pro-oxidant systems whilst boosting cellular defence mechanisms 
(Cannon et al., 2004; Kulik et al., 2008; Kulik et al., 2011; Curl et al., 2016). Pre-treatment of 
CABG patients with Atorvastatin improved redox balance in patients after surgery, as well as in 
an ex vivo SVG model, shown by reduced plasma levels of monodialdehyde, a marker of 
oxidative stress, and inhibition of oxidant enzyme, nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidase (NOX) activity, respectively (Antoniades et al., 2010). Antoniades 
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and colleagues further showed that Atorvastatin ameliorates vascular redox state through eNOS 
coupling in the presence of its co-factor, Tetrahydrobiopterin (BH4), ultimately leading to 
reduced vascular superoxide (O2•) production and improved vessel function (Antoniades et al., 
2011). Additional agents targeting NADPH oxidase and NO generation which have shown some 
promise in pre-clinical studies, include nitroaspirins, NO donors, eicosanoids, phosphodiesterase 
inhibitors (e.g. sildenafil) and corticosteroids, such as dexamethasone (Muzaffar et al., 2005; 
Zakkar et al., 2011).  Finally, it is well understood that aspirin has a profound impact on reduction 
of early graft failure by prevention of thrombotic events due to its antiplatelet activity. However, 
aspirin alone, or in combination with clopidogrel, does not yet appear to significantly impact 
upon longer-term graft patency (Harskamp et al., 2013). 
In addition to more well-established treatments, the potential for gene therapy in VGF offers an 
interesting therapeutic direction. Intraoperatively, the saphenous vein is easily accessible, 
allowing in situ delivery of gene therapies directly to the tissue (Harskamp et al., 2013; George 
et al., 2011). Many pre-clinical trials of gene therapy show promise in these controlled settings, 
with very diverse targets including MMPs, tissue inhibitor of MMPs (TIMPs), MCP-1 and eNOS 
(George et al., 1998; George et al., 2000; West et al., 2001; Turner et al., 2005; Akowuah et al., 
2005; Schepers et al., 2006; George et al., 2011).  However, to date, only one randomised 
controlled trial has assessed gene therapy; the PREVENT-IV study (Alexander et al., 2005). The 
trial involved the use of a decoy oligonucleotide, edifoligide, which binds to the transcription 
factor, E2F, known to have a role in the initiation of IH (Giangrande Giangrande et al., 2007). 
Edifoligide appeared to have no benefit in preventing VGF at between 12 and 18 months post-
surgery and the trial failed at stage IV (Alexander et al., 2005).  
If late VGF is diagnosed, and the opportunity for pharmacological management has passed, 
medical or surgical interventions will be employed; however, the risks associated with 
revascularisation are significant.  Such management would involve either a repeat CABG surgery 
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or percutaneous interventions depending on patient characteristics and occlusion status 
(Harskamp et al., 2013). Cases of in-stent restenosis and recurrent VGF after multiple CABG 
surgeries or PCI are common. Despite showing reasonable revascularisation rates, repeat 
surgeries are associated with high morbidity rates and return of symptoms, including MI and 
angina, are frequent (Harskamp et al., 2013). The obvious successes seen with CABG surgery are 
unquestionable, nevertheless, late vein graft failure, despite many surgical and preclinical 
advances, remains a significant and, as yet, pharmacologically untreated clinical challenge.  
 
1.3 VASCULAR INFLAMMATION AND THE ENDOTHELIUM 
Vascular inflammation is a complex response to acute and chronic harmful stimuli involving all 
aspects of the vascular wall including the endothelium and ECM as well as circulating immune 
system cells (neutrophils, monocytes and lymphocytes) (Sprague et al., 2009). Activators of the 
inflammatory response are numerous and include circulating cytokines, platelet products, 
reactive oxygen species (ROS), reactive nitrogen species (RNS), angiotensin II and biomechanical 
factors (Sprague et al., 2009). Once activated, ECs initiate complex networks of adhesion 
molecules, cytokines and recruitment of inflammatory cells, which act to disseminate 
physiological changes within the endothelium and the vascular wall through interactions with 
VSMCs and ECM (Szmitko et al., 2003). Vasospasm, surgical trauma and hypoxia during 
harvesting of the LSV typically result in EC activation (Bryan et al., 1994; Motwani et al., 1998). 
The induction of pro-inflammatory signalling pathways and EC activation, which can be partly 
ameliorated by the utilization of minimum or ‘no touch’ techniques during the harvest process 
(Dries et al., 1992; Souza et al., 1999; Cornelissen et al., 2004). ECs are further activated by the 
sudden exposure to new mechanical forces in the arterial circulation, including distension and 
increased shear stress (Gosling et al., 1999; Golledge et al., 2000).   
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EC activation results in the triggering of the adhesion cascade characterised by the rapid 
expression of chemokines, such as monocyte chemotactic protein 1 (MCP-1)) and the expression 
of adhesion molecules, including those of the selectin family (E-selectin and P-selectin) and the 
cellular adhesion molecule family, intercellular adhesion molecule 1 (ICAM1), platelet 
endothelial cell adhesion molecule 1 (PECAM1) and vascular cell adhesion molecule 1 (VCAM1) 
(Berk et al., 2001; Bonetti et al., 2003,). Initial activation of the endothelium rapidly leads to 
leukocyte recruitment, which is in part mediated through changes in calcium (Ca2+) homeostasis 
and the Ras homologue (RHO) pathway (FIGURE 1.5.A) (Birch et al., 1994; Dixit et al., 2012). 
Activation of the RHO pathway, through ligand binding to G-protein coupled receptors (GPCRs), 
causes loosening of tight junctions between ECs and activates GTPases; whereas, increases in 
intracellular Ca2+ facilitates the movement of P-selectin to the luminal surface (Pober et al., 
2007). Together, these rapid actions of GPCRs and Ca2+ help to facilitate leukocyte trans-
endothelial migration (Ley et al., 2007). However, the actions of transduction through RHO and 
Ca2+ are transient and GPCRs quickly become desensitised (approximately 10 minutes post-
stimulus), this phase of acute inflammation is commonly known as type I (FIGURE 1.5.A.) 
(Gainetdinov et al., 2004).  
 Endothelial cell acute inflammatory responses 
The endothelium is the first point of contact for systemic sources of inflammation; as such, its 
response is hugely important in propagation of inflammatory stimuli through the vessel wall and 
beyond. (A) Upon insult of acute high shear stress, in vitro, vECs activate the Rho-GTPase 
pathway which affects downstream effectors and the cytoskeleton. Within the first 10 minutes 
of acute high flow there is also an increase in intracellular calcium leading to movement of P-
selectin to the luminal surface. Together these actions constitute type I (acute) inflammation. 
(B) Following this, there is activation of a more prolonged (type II) inflammatory response, which 
results in the activation of MAPK-mediated and NF-𝜅B pro-inflammatory pathways; resulting in 
expression of adhesion molecules, cytokines, chemokines and increases in intracellular ROS. The 
interplay between ECs and VSMCs acutely under shear stress remains unclear with the extent of 









Prolonged, or type II, inflammatory activation of ECs requires the sustained action of physiologic 
stress- or cytokine-mediated signalling through the involvement of mitogen activated protein 
kinases (MAPKs) and pro-inflammatory transcription factors such as nuclear factor kappa B (NF-
𝜅B) and activating protein 1 (AP-1) (Baeuerle et al., 1994; Ahmad et al., 1998; Dong et al., 2002; 
Van der Heiden et al., 2010). Typically, NF-𝜅B and MAPK mediated inflammatory responses 
involve the comparable, but not exclusive, expression of many genes associated with the 
adhesion cascade, cytokines, chemokines and MMPs in a time-dependent and evolving manner 
between 10 minutes and 24 hours after activation (FIGURE 1.5.B.) (Munro et al., 1989; Tak et 
al., 2001). Having such integral roles in the propagation of inflammatory responses makes these 
pathways exciting therapeutic targets for the treatment of vein graft inflammation, as well as 
many other vascular pathologies involving inflammation.  
 
1.3.2 NUCLEAR FACTOR KAPPA B SIGNALLING PATHWAY 
Since its discovery almost three decades ago, NF-𝜅B has become one of the most prominently 
studied cell signalling pathways due to its ability to modulate a multitude of cell behaviours (Sen 
et al., 1986; Napetschnig et al., 2013). NF-𝜅B transcription factors are a family of several distinct 
members (p50, p52, Rel-A (p65), Rel-B and c-Rel) which function as homo- or hetero-dimers in 
the regulation of gene transcription (Lawrence, 2009). The pathway can be activated by a range 
of stimuli from cytokines, including tumour necrosis factor alpha (TNF-a) and interleukin 1 (IL-
1), to physiologic stresses, such as ultraviolet light damage (Ghosh et al., 1998). These activators 
induce two separate branches of the pathway, classical and alternative, which regulate very 
diverse cellular responses including proliferation, differentiation and the immune response. 
Following receptor ligation of TNF-a with TNF receptor (TNFR) in the classical pathway (FIGURE 
1.6), there is a recruitment of adaptor protein complexes involving TNF-receptor associated 
death domain (TRADD), serine/threonine kinase receptor interacting protein 1 (RIP1) and TNF 
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receptor associated factor (TRAF2/5) (Bradley, 2008). In turn, this receptor-adaptor complex 
further recruits MAPKs, MEKK3 and TAK1, which phosphorylate and thereby activate the I𝜅B 
kinase (IKK) complex, consisting of IKK-a, IKK-b and NIK (Karin et al., 2000). Once activated, the 
IKK complex phosphorylates I𝜅Ba, inducing its dissociation from NF-𝜅B and subsequent 
ubiquitination and degradation (FIGURE 1.6.) (Karin et al., 2000). This allows the release of  
NF-𝜅B, p50/p65 heterodimer, into the cytosol and facilitates nuclear translocation (Baeuerle et 
al., 1994). Members of the I𝜅B family, when complexed with NF-𝜅B, are able to maintain the 
localisation (and inactivity) of the NF-𝜅B/I𝜅Ba complex through balancing the constant shuttling 
between the nucleus and the cytosol (Johnson et al., 1999). In order to maintain the movement 
balance between the cellular compartments, I𝜅Ba masks one of two NF𝜅B nuclear localisation 
sequences and itself has an exposed nuclear export sequence (Li et al., 2002). Interestingly, I𝜅Ba 
is one of multiple genes whose transcription is regulated by NF-𝜅B, as part of its transient 
activation and negative regulatory feedback system; the protein itself contains a nuclear 
localisation sequence allowing the displacement of NF-𝜅B from bound DNA (Verma et al., 1995). 
In addition to I𝜅Ba, negative regulation of the NF-𝜅B pathway involves the transcription of 
ubiquitin modifying enzymes, A20 and Cezanne (Enesa et al., 2008; Zakkar et al., 2015). Both 
enzymes function exclusively on the TNF-receptor mediated classical NF-𝜅B signalling pathway 
to limit further activation upstream to I𝜅Ba dissociation at the level of adaptor protein, RIP1, 
recruitment (Wertz et al., 2004; Enesa et al., 2008).  
By contrast, the alternative pathway employs the RelB/p52 NF-𝜅B heterodimer, and, for its 
activation, the constitutive processing of the p52 precursor and RelB inhibitor, p100, by an  
IKK-a homodimer is required (Hayden et al., 2008). Upstream activation of this non-classical 
branch of the pathway is also achieved by different ligand-receptor complexes, including LTβR 
and CD40 (Sun, 2011). The two branches of NF𝜅B regulate distinct sets of genes which account 
for the huge variation of biological responses mediated through both arms of this complex 
signalling pathway.   
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 NF-kB classical pathway 
Schematic representation of phosphorylation and proteasomal regulation of the classical NF-kB 
heterodimeric transcription factor (p50/p65). This figure was partly created with the Servier 
medical art library (smart.servier.com). 
 
 
1.4 ANTIOXIDANT RESPONSE AND SIGNALLING 
The homeostatic regulation of reduction and oxidation of oxygen and nitrogen products is 
essential for the normal, physiologic functioning of all eukaryotic cells. When the balance 
between oxidants and antioxidants, is tipped in the favour of the former, oxidative stress and 
subsequent induction of molecular damage occurs (Sies, 2015). It has long been appreciated 
that oxygen ‘toxicity’ occurs as a result of the creation of reduced forms of oxygen, causing 
formation of free, unpaired electrons within molecules, otherwise known as ROS (Gerschman et 
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al., 1954; Halliwell, 1996). ROS and RNS are generally produced as by-products in ordinary 
cellular metabolism (Valko et al., 2007). Their role in normally functioning cells is twofold; firstly, 
at low concentrations, ROS/RNS act as cell signalling intermediaries, particularly in the mitogenic 
response, as well as playing a role in cellular defence against infectious or noxious stimuli (Valko 
et al., 2007). The second function, for which they are more cellular foe than friend, occurs when 
ROS/RNS are over-produced and the balance maintained by antioxidants, both enzymatic and 
non-enzymatic, is inadequate to stem the tide of these damaging free radicals (Kovacic et al., 
2001; Cadenas, 1997). When oxygen or nitrogen free radicals are generated in high 
concentrations, they are capable of inducing irreversible oxidative damage to cellular structures, 
nucleic acids, lipids and proteins (Navarro-Yepes et al., 2014). Owing to the diverse and 
damaging effects on cell death and survival caused by redox imbalance, such high-level 
production of ROS/RNS has been implicated in numerous autoimmune, hyper-proliferative and 
inflammatory conditions, including atherosclerosis and IH (Schieber et al., 2014). 
With the numerous oxygenous and nitrogenous free radicals created by oxidative stress, an 
equally sophisticated and adaptable defence mechanism must act as its counter, namely the 
antioxidant defence system. The broad purposes of this system are to scavenge and detoxify 
ROS/RNS, interfere with ROS generating enzymes to prevent their over-production and 
sequester heavy metal ions (Masella et al., 2005). Antioxidant defences exist exogenously, 
through dietary intake, and endogenously, in the form of enzymatic or non-enzymatic 
antioxidants (Halliwell, 1996). Exogenous antioxidants, in particular, various polyphenols found 
in fruits, vegetables and wine, are able to induce eNOS, inhibit lipid peroxidation and 
lipoxygenases, having significant beneficial effects for the cardiovascular system (Kanner et al., 
1994; Pisoschi et al., 2015). Though their importance is clearly unquestionable in aiding innate 
systems, it has been proposed that the total cell potential for antioxidative action limits the 
benefit of such exogenous defences and that over-supplementation can actually induce pro-
oxidant stress (Poljsak et al., 2012; Poljsak et al., 2013). Primary defence against deleterious free 
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radicals, however, is performed by the endogenous, enzymatic antioxidant systems. These 
enzymes, including superoxide dismutases (SOD), heme oxygenases (HO), catalase and 
glutathione peroxidase (GPx), act to convert harmful radicals into non-toxic by-products through 
electron donation or acceptance (Lu et al., 2010).  
Research into the regulation of redox homeostasis has been extensive and the biological and 
chemical actions of the involved pathways are extensively documented. However, despite the 
known involvement of ROS and RNS in endothelial dysfunction, these pathways remain 
relatively unexplored as modifiable targets in vein grafting (Powell et al., 1998; Shukla et al., 
2012; Weaver et al., 2012; Osgood et al., 2014). Superoxide, and its principal producer, the NOX 
enzyme family, are known to be up-regulated early in the vein graft by ECs during vessel hypoxia 
and contribute to early endothelial dysfunction (Griendling et al., 2000; Guzik et al., 2005). 
Whereas, Peroxynitrite, a product of interaction between NO and O2•-, is suggested to reduce 
bioavailability of NO within the vascular bed through the uncoupling of eNOS, having serious 
deleterious mitogenic effects on VSMCs (Tsapenko et al., 2012; Osgood et al., 2014). As alluded 
to earlier (in section 1.2.5.), a few studies have shown promise clinically in modifying redox 
regulation in vein grafting using commercially available statins (Antoniades et al., 2010; 
Margaritis et al., 2012; Spadaccio et al., 2014), though these studies remain relatively scarce. 
Therefore, targeting oxidative stress production in VGF, at the level of transcriptional control of 
redox balance, may be beneficial in the prevention of ROS-induced endothelial dysfunction in 
CABG surgery.  
1.4.1 TRANSCRIPTIONAL CONTROL AND REDOX BALANCE 
The intricate balance between oxidant and antioxidant responses in eukaryotic cells is mediated 
by two master conductors. The first of these is NF-kB, which in addition to its role as a primary 
regulator of the immune response, is additionally responsive to redox regulation (Flohe et al., 
1997). It has long been recognised that oxidants, including O2•- and hydrogen peroxide (H2O2), 
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are among the numerous activators of NF-kB (Oliveira-Marques et al., 2009). Both of these 
oxidants are produced by NOX systems, though the route to activation remains debatable 
(Brigelius-Flohe et al., 2011). The rationale behind this comes from the overlap between 
activators of NOX and NF-kB. It appears that this may be explained, in part, by the effect of 
differing initial activating stimuli (Flohe et al., 1997). Following binding of pro-inflammatory 
cytokines, IL-1b or TNF-a, or growth factors to their respective receptors (IL-1R, TNF-R and Toll 
like receptors (TLRs)), intracellular, receptor-bound phosphatidylinositol-3 kinase (PI3K) triggers 
downstream cascades leading to the joint activation of NOX and NF-kB (Park et al., 2004; Oakley 
et al., 2009). This cascade, although well documented for NF-kB activation, through the 
induction of Protein Kinase B (Akt) followed by phosphorylation of the IKK complex, remains 
unclear for the co-activation mechanisms of NOXs downstream of PI3K and most likely differ 
depending on tissue, receptor and stimulus (Lassegue et al., 2010; Wenzel et al., 2017). Despite 
this confusing picture, O2•-, H2O2 and NF-kB activity remain inextricably linked and the 
concomitant activators of NF-kB, GPx’s and NOX’s are all of paramount importance for mounting 
of the redox response. Furthermore, this self-regulating NF-kB system continues to perpetuate 
ROS production through targeted transcription of IL-1 and TNF-a, both of which continue to 
activate the NOXs which were initially co-activated with NF-kB in the first place (Xu et al., 2016). 
The chronic transcriptional response of NF-kB, in addition to pro-oxidant, self-propagating ROS 
production, also consists of several anti-oxidant and protective targets. Among these are 
members of the SOD enzyme family, which catalyse simultaneous oxidation and reduction 
reactions (otherwise known as dismutation) to convert O2•- into H2O2 (Morgan et al., 2011). 
Owing to the complex and transient involvement of ROS at numerous places within a single 
pathway, as well as the dual role played by NF-kB in activation of, and protection against, 
oxidative stress, there remains much more to be clarified about this evolving dichotomy. 
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1.4.2 NRF2/KEAP1 SIGNALLING PATHWAY 
Nuclear factor erythroid 2-related factor 2 (Nrf2), a member of the Cap ‘n’ Collar (Cnc) family, is 
another transcription factor which responds to a variety of oxidative stresses. Cnc proteins are 
evolutionarily conserved amongst all metazoan life, with diverse homeostatic and 
developmental functions (Sykiotis et al., 2010). Arguably the most important of all of these is 
Nrf2, considered the ‘master regulator’ of the antioxidant and cellular defence response (Gorrini 
et al., 2013; Vomund et al., 2017). Following its discovery in 1994 (Moi et al., 1994; Itoh et al., 
1995), and subsequent uncovering that Nrf2 was a positive regulator of the antioxidant response 
element (ARE), a huge number of studies propagated, to attempt to link Nrf2 to transcription of 
a myriad of stress responsive detoxifying enzymes, anti-inflammatory genes, proteasome 
production and glutathione synthesis (Venugopal et al., 1996; Sykiotis et al., 2010; Hybertson et 
al., 2011). Additionally, perturbation in the regulation of Nrf2 is becoming of interest in many 
chronic conditions, from cancers to chronic obstructive pulmonary disorder (COPD), where 
oxidative stresses play vital roles (Sykiotis et al., 2010; Sporn et al., 2012; Niture et al., 2014). 
With a growing appreciation for the importance of Nrf2 in conserved cellular defence responses, 
across tissues and species, knowledge of the molecular mechanisms of Nrf2 control and 
activation continues to advance. 
Regulation of the activity of Nrf2 is achieved primarily through physical interaction with its 
innate repressor, Kelch-like ECH-associating protein 1 (Keap1), which is required for both 
cytosolic sequestration and continuous targeted degradation of the transcription factor (FIGURE 
1.7.). Under basal conditions (i.e. absence of oxidative stress), Keap1 functions to regulate Nrf2 
by three distinct, but concomitant mechanisms; firstly, in the cytosol, the Nrf2-ECH homologous 
domain (Neh2) and Kelch domains are bound to form a complex of a single Nrf2 and a Keap1 
homodimer in a 1:2 ratio (Dinkova-Kostova et al., 2005). Within the Neh2 domain, there are 2 
distinct motifs to which each Kelch domain of the Keap1 dimer binds (Chen et al., 2015). This 
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interaction is known as the “hinge and latch” model, with the first of these Neh2 motifs, ETGE, 
acting as a ‘latch’ with a high affinity for Kelch, in order to secure the binding of Nrf2 to Keap1 
(Tong et al., 2006; Kensler et al., 2010). The second motif, DLG, has a much weaker affinity; 
however, in the absence of oxidants, it is able to bind the second Kelch to act as a ‘hinge’, 
fastening Nrf2 to Keap1 and exposing a Lysine rich region of Nrf2. This region can then be 
ubiquitinated and continually targeted for proteasomal degradation, thus, basal conditions 
permit only low levels of free Nrf2 and target gene transcription (Tong et al., 2006; Sykiotis et 
al., 2010). Secondly, Keap1 acts as an adaptor protein to the Cullin3 E3 ubiquitin ligase (Cul3), 
which, in the above described model, is responsible for ubiquitinating Nrf2 (Suzuki et al., 2017). 
Thirdly, Keap1 itself is also able to shuttle between the cytosol and nucleus, though the 
importance and function of this process remains under question (Nguyen et al., 2005; Velichkova 
et al., 2005; Sykiotis et al., 2010). Nucleo-cytoplasmic shuttling of Keap1 has been suggested to 
play a role in the targeting of Nrf2 to specific regions of the genome, through direct interaction 
with chromatin (Tashiro et al., 2004). However, perhaps more convincingly, it has also been 
reported that nuclear localisation of Keap1 either enables nuclear export of Nrf2 or targets Nrf2 
for degradation from within the nucleus, consequently attenuating the antioxidant, defence 
response (Sun et al., 2007; Niture et al., 2009). 
Activation of the Keap1/Nrf2 system is achieved with numerous stress-sensing mechanisms, 
both intrinsically, within the complex itself, and extrinsically, through stress-responsive MAPK-
controlled phosphorylation (Hybertson et al., 2011). Commonly, Nrf2 activation will result as a 
combination of these two mechanisms acting together. Firstly, upon exposure to electrophiles 
or oxidants, the Keap1-Cul3 complex will be inhibited and undergo a conformational change 
(Suzuki et al., 2017). Amongst these Nrf2 inducers are Michael acceptors, isothiocyanates, heavy 
metals and trivalent arsenicals; all of which target the highly reactive cysteine residues (Cys) in 
Keap1, as such, Keap1 is considered as a true oxidant sensor (Kensler et al., 2007). Additionally, 
Nrf2 is phosphorylated by PKC, which functions to prevent Keap1 binding and facilitate Nrf2 
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translocation, and sequestome-1 interaction with Keap1 may disrupt the loosely bound complex 
entirely (Huang et al., 2002; Bloom et al., 2003; Komatsu et al., 2010).  
Once the complex is dissociated and Nrf2 is inside the nucleus, it interacts with small Maf 
transcription factors and is able to bind the ARE motif within its broad range of target genes and 
initiate transcription (Nguyen et al., 2009). Arguably most important of these, are Nrf2 targets 
involved in oxidant and electrophile metabolism. These include HO-1, which, in conjunction with 
bilirubin reductase, generates carbon monoxide and bilirubin; NADPH quinone dehydrogenase 
1 (NQO1), which catalyses the reduction of quinones to reduce global ROS generation, and 
glutamylcysteine ligase (GCLM), which is involved in catalysis of the biosynthesis of the 
important antioxidant, glutathione (Baird et al., 2011; Nguyen et al., 2009). The list of Nrf2 target 
genes is extensive and still growing. Though, briefly, the transcription factor also targets genes 
involved in proteasome production, cell survival, molecular chaperoning, drug metabolism, 
nucleotide excision repair and autophagy. These far-ranging functions perhaps endow Nrf2 with 





 Keap1/Nrf2 pathway under basal and oxidative stress conditions 
Schematic representation of activation and inhibition of the Keap1/Nrf2 pathway under stressed 
and basal conditions, respectively. This figure was partly created with the Servier medical art 
library (smart.servier.com). 
 
1.5 INTERACTIONS BETWEEN THE NRF2/KEAP1 AND NF-kB PATHWAYS 
Many eukaryotic transcription factors (TFs) exist, in their basal states, sequestered in the cytosol 
through the direct and indirect action of an inhibitory, multi-component complex, from which, 
dissociation must occur in order to activate the TFs (Brigelius-Flohe et al., 2011). As alluded to 
in sections 1.3.2 and 1.4.2., NF-kB and Nrf2 are no different; in their ‘inactive’ states, these two 
TFs are sequestered in the cytosol by IkBa and Keap1, respectively. Dissociation from their 
respective innate repressors, (i.e. TF activation) occurs under largely, but not entirely, exclusive 
means (Brigelius-Flohe et al., 2011). However, these two pathways do share similarities in the 
general dissociation/activation processes. In order to be inactivated, both repressors require 
ubiquitination and subsequent targeting for degradation; nevertheless, both the activation 
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sensing steps and ubiquitination machinery involved are vastly different. The study of 
interactions between these two critical homeostatic TFs is the subject of great interest in disease 
states involving oxidative stress and inflammation (Wakabayashi et al., 2010). Interactions 
between the pathways can occur directly, via protein-protein interactions, such as NF-kB and 
Keap1, or indirectly, due to secondary messenger actions on target gene transcription, for 
example via HO-1-induced Carbon Monoxide (CO) production and activation of NF-kB (Lee et 
al., 2009; Washington et al., 2017). Generally, under basal conditions, both pathways perform 
homeostatic functions in regulation of the cell cycle and maintenance of a stable redox balance 
(Brigelius-Flohe et al., 2011). In contrast, under acute pathological oxidative stress conditions, 
there is a shift towards transcriptional activation of NF-kB and inflammation, as well as 
deregulation of Nrf2, which may be in part mediated by NF-kB (Li et al., 2008). However, the 
degree of crosstalk between these two pathways in inflammatory and stressful conditions 
remains the subject of intensive research. 
1.5.1 DIRECT INTERACTIONS 
With similar mechanisms of action between the Nrf2 and NF-kB pathways (in their regulation 
by multicomponent, inhibitory complexes), it appears that much of the direct interaction occurs 
through modulation of their innate repressors, Keap1 and IkBa, respectively. Keap1 has been 
extensively shown to negatively regulate NF-kB signalling via its binding and subsequent 
suppression of IKKb-induced NF-kB activation (Lee et al., 2009). Similar to its suppression of 
Nrf2, Keap1 is able to directly bind to IKKb through its ETGE motif, acting as a ‘latch’ to secure 
itself to IKKb (Kim et al., 2010). This Keap1 binding obscures IKKb phosphorylation sites, 
preventing the triggering of downstream IkBa phosphorylation, whilst at the same time, 
ubiquitin targeting IKKb for proteasomal degradation (Lee et al., 2009). In contrast, an example 
of a direct interaction acting in the reverse direction is the effect of NF-kB on Keap1. Yu et al., 
reported that NF-kB is able to physically associate with Keap1 and induces its translocation into 
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the nucleus; once within the nucleus, Keap1 is able to perform its Nrf2-repressive function and 
prevent the Nrf2-ARE transcriptional response (Yu et al., 2009). However, the mode of action of 
this direct NF-kB-Keap1 interaction remains to be uncovered. 
1.5.2 INDIRECT INTERACTIONS 
Numerous studies have found modulatory interactions, either repressive or activating, between 
the antioxidant and inflammatory pathways, most often with the use of small molecule 
activators of Nrf2 or chemokine-based activation of NF-kB (Jeong et al., 2004; Chen et al., 2006; 
Zakkar et al., 2009). Furthermore, studies of Nrf2-/- mice have been shown to express increased 
NF-kB activation upon inflammatory insult or traumatic injury (Wakabayashi et al., 2010). 
However, cause and effect in many of these studies cannot be realistically deduced. For instance, 
Nrf2-/- mice will have an inherently reduced capacity to cope with oxidative stress, as such, many 
inflammatory and pro-oxidant pathways will be activated following injury, which may, indirectly 
lead to activation of NF-kB, perhaps via increased NOX activity and superoxide production. What 
seems more compelling, is the transcriptional interplay between these two pathways and the 
processes of interaction occurring indirectly through genome interaction. Once NF-kB is 
phosphorylated at Ser276 and translocates, it binds to the transcriptional co-activator CREB-
binding protein (CBP), in order to initiate transcription (Chen et al., 2004). At the same time, 
Nrf2 is unable to bind CBP (also its co-activator), thus NF-kB indirectly prevents Nrf2-ARE 
transcription through competitive binding to CBP (Wakabayashi et al., 2009). An additional 
mechanism of Nrf2-ARE repression is through NF-kB-mediated HDAC3 recruitment to the ARE, 
which functions to prevent further Nrf2 transcription (Liu et al., 2008). Much of what is known 
about the interactions between NF-kB and Nrf2 comes from the concomitant or opposing 
actions of their target genes. Though, as we begin to tease apart transcriptome interdependence 
further with new genome-wide techniques, much more will be elucidated on the pathway 
interactions between these two homeostatic ‘master regulators’ in health and disease. 
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1.6 SHEAR STRESS AND THE ENDOTHELIUM 
1.6.1 TRANSDUCTION OF MECHANICAL FORCES IN THE VASCULATURE 
Circulating blood flow applies several mechanical forces on the walls of blood vessels. Firstly, 
shear stress, which is the tangential frictional force acting longitudinally on the vessel wall 
imposed by fluid motion on a solid boundary parallel to the fluid direction (FIGURE 1.8.) (Zakkar 
et al., 2015). It can be defined as force divided by wall area (e.g. dyn/cm2) and is the force that 
interacts directly with the endothelium. Secondly, hydrostatic pressure is the force acting 
perpendicularly on the vessel wall; and, finally, circumferential stretch created by pulsatility 
exerts a force (or strain) on the entire circumference of the vessel wall (FIGURE 1.8.) (Zhao et 
al., 1995). 
 
 Mechanical forces in the vasculature 
Mechanical forces exerted by blood flow, longitudinally (shear stress), along the wall of the 
vessel, and perpendicularly (hydrostatic pressure and circumferential stretch) against the vessel 





Mechanotransduction through the endothelium allows the vessel to convert these mechanical, 
haemodynamic signals into biological responses within the vascular wall; the process requires 
the direct transmission of mechanical force into tangible biological functions. Integral to this 
conversion of mechanical force is a mechanosensory complex consisting of PECAM-1, which 
conducts mechanical force directly for transmission, vascular endothelial cell (VE)-Cadherin, 
which acts as an adaptor, and VEGF receptor 2 (VEGFR2), which activates PI3K, that in turn 
activates integrins (Tzima et al., 2005). Integration of complex biomechanical signals by ECs also 
intimately involves proteins located on EC surface including G-proteins, caveolae and ion 
channels; small GTPases and signalling intermediaries, such as c-Src, Ras, Raf and protein kinase 
C (PKC); mitogen activated protein kinases, such as p38, extracellular-regulated kinase 1/2 
(ERK1/2) and c-Jun N-terminal kinase (JNK); effector molecules, including nitric oxide (NO) and 
prostacyclin (PGI2); and, lastly, transcription factors such as KLF2, Nrf2, ATF2, NF-𝜅B (Noris et 
al., 1995; Traub et al., 1998; Tzima et al., 2002; Resnick et al., 2003; Chien, 2007; Hsieh et al., 
2014; Abe et al., 2014; Zakkar et al., 2015).  Diverse responses in both ECs and VSMCs are 
affected by the mechanotransduction pathways, from proliferation to cell-matrix interactions 
(Katsumi et al., 2004). Shear stress has long been considered of particular importance in vascular 
homeostasis, due primarily to its wide-ranging impact on a number of pathologies, and also its 
contribution to the maintenance of normal vessel structure and functioning. 
1.6.2 PROLONGED LAMINAR SHEAR STRESS AND PROTECTIVE SIGNALLING 
Regions of the vasculature associated with a healthy phenotype are commonly characterised by 
a quiescent endothelium, with an anticoagulant and anti-inflammatory profile. (Boon et al., 
2009; Marin et al., 2013). Such vascular environments are commonly seen in linear regions of 
vessels experiencing laminar shear stress, where blood flows in a uniform, streamlined, pulsatile 
pattern with the cardiac cycle, but importantly with a positive mean flow rate (Chiu et al., 2011). 
Adaptive, morphological changes of ECs are observed in linear regions of arteries resulting in the 
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reorganisation of F-actin filaments to confer an elongated and flatter shape (Chiu et al., 1998). 
Typically, these portions of vessels are considered atheroprotective due to the reduced 
likelihood of developing atherosclerotic lesions and prolonged laminar shear stress (LSS) has 
long been considered the reason for this (Ku et al., 1985; Frangos et al., 1985; Malek et al., 1999; 
Cunningham et al., 2005; Berk, 2008).  
Aside from morphological changes, prolonged LSS significantly influences the state of oxidative 
stress within the endothelium. The bioavailability of endothelium derived relaxing factors, NO 
and PGI2, is fundamental to the maintenance of a quiescent endothelium (Chiu et al., 2011). 
Under elevated, sustained LSS, endothelial NO synthase (eNOS) is upregulated and continually 
produces NO, supporting functions including vasodilation, inhibition of VSMC growth, inhibition 
of platelet aggregation and altered lipoprotein metabolism (FIGURE 1.9.) (Noris et al., 1995; 
Traub et al., 1998; Chiu et al., 2005; Dardik et al., 2005; Jacot et al., 2008). NO also functions in 
the quiescent endothelium to homeostatically regulate the production and distribution of 
damaging ROS, such as O2•-, lipid- and hydroxyl-radicals (Cai et al., 2000). Preservation of a highly 
antioxidant and quiescent EC state is not dependent only on the oxidative stress system, but 
also requires the synergistic action of a number of transcription factors. Among the few 
transcription factors associated with prolonged laminar flow and protective signalling in the 
endothelium, none appear to be more important than KLF2. KLF2 is known to be elevated 
continuously for seven days in vitro under sustained laminar flow (Dekker et al., 2002; Dekker et 
al., 2005). Furthermore, KLF2 overexpression resulted in quiescent endothelium even in the 
absence of shear stress (Dekker et al., 2005). It was also observed that KLF2 systematically 
controlled numerous genes involved in migration (VEGFR2 and Semaphorin 3F (SEMA3F)), 
vascular tone (eNOS) and haemostasis (tissue plasminogen activator (TPA) and von Willebrand 
factor (vWF)) (Dekker et al., 2006; Fledderus et al., 2007). Interestingly, KLF2 overexpression 
alone was able to alter endothelial morphology to appear similar to ECs exposed to shear stress 




 Protective signalling in the quiescent endothelium 
Within the quiescent endothelium experiencing laminar shear stress (LSS) (i.e. in veins with 
normal flow without venous reflux, venous insufficiency or stasis and long straight portions of 
arteries), ECs upregulate levels of KLF2 and Nrf2 dependent genes, including eNOS and HO-1, 
and secrete gasotransmitters NO and PGI2. 
 
Another element of the complex atheroprotective transcriptome is Nrf2; as mentioned earlier 
(section 1.4.2), Nrf2 is essential for the expression of numerous antioxidant genes including HO-
1 and NQO1 (FIGURE 1.9.) (Zakkar et al., 2008). Regulation of Nrf2 has been inextricably linked 
to laminar shear stress and KLF2; the latter is not required for shear stress activation of Nrf2, 
but interestingly, acts to enhance its transcriptional activity (Fledderus et al., 2008). Nrf2 has 
been shown in vivo, in the murine aorta, to contribute to atheroprotection via the suppression 
of p38 mediated VCAM1 signalling. Acting on two distinct aspects of this pathway, Nrf2 firstly 
inhibits the activity of an upstream MAPK kinase 3/6 (MKK3/6) and, secondly, enhances the 
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activity of MAPK-phosphatase 1 (MKP-1), which functions to inactivate p38 (Zakkar et al., 2008). 
Through synergistic actions of transcription factors, KLF2 and Nrf2, as well as balanced ROS/RNS 
formation and scavenging, the endothelium is able to suppress chronic vascular inflammation in 
‘atheroprotective’ portions of the vascular tree (FIGURE 1.9.). 
1.6.3 CHRONIC INFLAMMATION AND ABNORMAL HAEMODYNAMICS 
Atherosclerotic lesions are primarily localised to regions of the arterial vasculature which 
experience chronic oscillatory and disturbed shear stress (OSS and DSS, respectively), such as 
branches and bifurcations. In response to chronic OSS/DSS, activation of NF-𝜅B is observed both 
in vitro, using a step-flow channel, and in vivo, in multiple animal models, such as with the use 
of vascular cuffs and hyperlipidaemic models (Van der Heiden et al., 2010; Chiu et al., 2011). 
Remarkably, endothelial cell specific inhibition of NF-𝜅B greatly reduced atherosclerotic plaque 
formation in apolipoprotein E knockout (ApoE-/-) mice, indicating the crucial role of NF-𝜅B in 
atherogenesis (Gareus et al., 2008). Dysfunction in the endothelium at atheroprone sites is also 
characterised by EC proliferation; this is in part mediated by flow-induced NF𝜅B activity which 
stimulates transcription of cyclin D1, allowing quiescent ECs to re-enter the cell cycle and 
become proliferative (Collins et al., 2001).  
The proinflammatory response mediated by JNK and p38, seen in regions of disturbed flow, is 
nullified by MKP-1 in the vascular endothelium of atheroprotected regions (Zakkar et al., 2008; 
Zakkar et al., 2008). Additionally, within atherosusceptible sites, JNK1 is known to have an effect 
on apoptosis and inflammation through the increasing expression of apoptotic facilitators, 
procaspase 3 and RIP1, and regulation of toll like receptor 4 (TLR4); in part explaining 
observation of its increased expression in atherosclerotic plaques and activation by oxidised LDL 
(Chaudhury et al., 2010). Interestingly, JNK has been shown to induce VCAM-1 related pro-
inflammatory signalling in response to aberrant shear stress through two mechanisms: firstly, 
through activation of activating transcription factor (ATF2) alone; and secondly, through ATF2 
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dependent induction of NF-𝜅B (Cuhlmann et al., 2011). It is proposed that ECs could be 
sensitised to expression of other NF-𝜅B target genes, via the JNK-ATF2 mechanism, and thus, 
facilitate pro-inflammatory cascades seen in chronic vascular injury (Cuhlmann et al., 2011). 
Abnormal and disturbed flow strongly influences the chronically inflamed environment 
observed in atherosclerotic lesions; however, the understanding of the molecular biology of the 
pathways involved under sustained, aberrant flow is complex in vitro, due to temporal 
limitations of many experimental models. Despite this, as will be elaborated upon in the next 
section, much that we know of the effect of shear stress on vascular inflammation comes from 
studies observing the acute onset of LSS and DSS.   
1.6.4 ACUTE EXPOSURE TO HIGH SHEAR STRESS AND INFLAMMATORY ACTIVATION 
Physiologically, acute increases in shear stress rates are observed relatively infrequently, such 
as during physiologic exertion and in therapeutic interventions, including CABG (Han et al., 
2012). Venous transposition into the arterial circulation is a particularly striking example of an 
acute increase of shear stress rates, with vECs having to adapt to up to 10-fold increased shear 
stress. Dramatic increases in shear stress result in the very early development of signs of vascular 
inflammation, with expression of MCP-1 and the infiltration of monocytes, which contribute to 
seeding the environment for atherogenesis (as explained in section 1.2.) (Hoch et al., 1994; Stark 
et al., 1997). Interestingly, depletion of macrophages or knock-down of ICAM1 significantly 
reduced rates of vein graft disease (Hoch et al., 1999; Zou et al., 2000), illustrating that 
inflammatory cells and adhesion cascades are inextricably linked to vein graft intimal 
hyperplasia development.  
Arterial grafts are known to be comparatively unaffected by inflammatory processes in bypass 
(Cameron et al., 1995; Taggart et al., 2016; Gaudino et al., 2017), further substantiating that it 
is the arteriovenous transposition which is distinctly responsible for creating an early 
inflammatory environment within the LSV graft. Moreover, acute venous arterialisation is 
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known to induce activation of pro-inflammatory MAPKs, ERK1/2 and p38, but not JNK, as quickly 
as 30 minutes post-implantation in a canine in vivo model of carotid artery bypass grafting 
(Saunders et al., 2004). From literature investigating acute shear stress in vivo, it is evident that 
endothelial dysfunction is induced during bypass grafting and that, occasionally, the 
endothelium can be depleted; however, it is still largely unknown whether EC loss is purely a 
mechanical effect of increased shear stress or is in fact secondary to apoptosis and 
inflammation. Despite a reasonable knowledge of these acute physiological responses under 
shear stress, in vivo models of vein grafting and reperfusion are still limited in their ability to 
provide a truly temporal profile of the response at the molecular level. As such, it is required to 
investigate acute effects of shear stress in vitro, either using laminar or oscillatory flow (acutely, 
they activate very similar events), or ex vivo, to better understand initial and immediate 
responses within the vein graft endothelium. 
Immediately following the onset of shear stress, in vitro, a plethora of biochemical events are 
rapidly induced. Within 30 seconds, ion channels are opened, small GTPases and kinases (PI3K 
and c-Src) are activated via the mechanosensory complex consisting of PECAM-1, VEGFR2 and 
VE-cadherin (Tzima et al., 2005; Ward et al., 2017). At cell-cell junctions, there are responses of 
altered tension across these complexes; PECAM-1 senses an increase in tension, whereas VE-
cadherin transduces signals from the detection of a decreased tension between ECs (Conway et 
al., 2013). These alterations in tension are associated with a general relaxation of cell-cell 
attachments, as such it remains difficult to determine whether acute shear stress is in fact 
detected and transduced by this mechanosensing complex, the process is a passive response by 
the cytoskeleton or in fact whether there remains an as yet undiscovered mechanosensor 
upstream of the cytoskeletal modulation (Tzima et al., 2005). Soon after initial 
mechanosensation there exists a complicated, poorly characterised period of signal 
transduction. A rapid, transient and calcium dependent response is required for endothelial 
activation by shear stress involving PKC, Ion channels and cGMP, altering permeability (FIGURE 
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1.5.A) (as described in section 1.2.1) (Berk et al., 1995). An alternative, more sustained response 
to acute shear is mediated in a calcium independent manner, whereby PI3K activates integrins 
and small GTPases, RhoA and Ras, as well as focal adhesion kinase (FAK) complexes (Ishida et 
al., 1996; Hahn et al., 2008; Hahn et al., 2009). Surapisitchat et al., 2001, showed that laminar 
flow alone decreased JNK activation and activated ERK1/2 and p38 between 10 and 60 minutes 
after exposure to shear stress. Whereas, when stimulated with TNF-α and IL-1 alone for 15 
minutes, all three pro-inflammatory MAPKs were activated; interestingly however, when cells 
were pre-exposed to flow prior to cytokine stimulation, JNK activation was inhibited 
(Surapisitchat et al., 2001). Inhibition of JNK by flow (and subsequent expression of E-selectin) 
appears to be dependent on ERK1/2 activation, strongly suggesting a role for inhibitory MAPK 
crosstalk in response to shear stress (Berk, 2008). Finally, ERK5 (or BMK1) appears to be 
activated by acute shear stress and induces myocyte enhancer factor 2 (MEF2) transcription 
factor; however, this kinase is implicated primarily in the atheroprotective endothelial 
phenotype, suggesting its role is as a shear stress activated kinase, but does not necessarily 
confer a negative effect on the endothelium (Yan et al., 1999; Pi et al., 2004) 
Much is evident in the literature regarding the activation of MAPKs by shear stress and the 
associated pro-inflammatory response that they mediate, even if the upstream events in their 
activation remains to be fully elucidated. However, induction of the NF-𝜅B transcription factor 
in response to acute shear stress is still relatively poorly understood. For over two decades, it 
has been known that NF-𝜅B becomes activated under conditions of acute shear stress as well as 
chronic oscillatory shear stress, which has allowed for a considerable amount of research into 
the function of NF-𝜅B in atherogenesis and, to a certain extent, reperfusion injury (Lan et al., 
1994; Van der Heiden et al., 2010). Acute shear stress appears to function to activate NF-𝜅B in 
an integrin dependent manner. Once integrins are activated by PI3K, they are able to begin 
inducing signals which include activation of small GTPases, RhoA and Ras-related C3 botulinum 
toxin substrate 1 (Rac1) (Bhullar et al., 1998). Here we see huge similarities with inflammatory 
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MAPK activation by acute shear, indicating that the two pathways have concomitant and 
overlapping activators and perhaps functions. In turn, Rac1 induces NOX enzymes, producing 
ROS, which function to stimulate the critical NF-𝜅B kinases, IKK-b and NIK, which together trigger 
classical activation of the NF-𝜅B pathway (Tzima et al., 2002; Orr et al., 2008). Activation of the 
NF-𝜅B pathway by shear stress is most likely not as singular or simple as has been suggested, 
there exist many other elements involved for ultimate transcriptional activation, many of which 
perhaps remain unidentified. For example, FAKs are crucial members of the integrin-dependent 
shear stress induced endothelial activation mechanism, though do not explicitly stimulate NF-
𝜅B translocation, but rather, are responsible for phosphorylation of the transcription factor, 
which is intimately linked to its transcriptional activity (Petzold et al., 2009). Whereas, p21-
activated kinase (PAK), which is also flow dependent, also functions as a crucial element in the 
oxidant dependent activation of NF-𝜅B through NIK, though, unlike Rac1, has absolutely no 
effect on ROS production (Orr et al., 2008). Interestingly, Orr et al., observed differential 
activation of NF-𝜅B under acute shear stress dependent also on the type of sub-endothelial ECM 
(Orr et al., 2005). ECs cultured on fibronectin and fibrinogen show considerably greater NF-kB 
translocation compared to those cultured on collagen type I after one-hour exposure to acute 
shear stress (Orr et al., 2005). Taken together, these studies into the flow induced activation of 
NF-𝜅B describe a relatively confusing picture with many overlapping components and perhaps 
many more left to be uncovered. Nevertheless, focal inhibition of acute shear stress mediated 
induction of NF-𝜅B represents an exciting therapeutic direction in the treatment of vein graft 






1.7 RATIONALE FOR THIS THESIS 
Endothelial dysfunction is induced in SVGs due to the sudden exposure to acute changes in 
haemodynamics once within the arterial system. Such dysfunction is causally linked to the 
development of late stage graft failure, and therefore, prevention of early endothelial activation 
in SVGs is an attractive, but currently unachievable, therapeutic strategy due to the lack of 
robust identification of a suitable target. NF-kB and Nrf2 are involved in endothelial dysfunction 
as an inducer and protector, respectively. The first aim of this thesis was to investigate 
endothelial cell-specific responses of NF-kB and Nrf2 pathways under conditions of acute shear 
stress; and, secondly, to investigate whether these pathways could be therapeutically targeted 
to reduce acute shear stress-induced endothelial inflammation. 
1.7.1 HYPOTHESES 
The following hypotheses were tested in this thesis: 
• Acute shear stress induces a pro-inflammatory response in vECs in vitro and in LSV ECs 
ex vivo, which is driven by NF-kB classical pathway activation and, when this pathway is 
blocked, inflammation in response to acute high shear stress can be prevented. 
• Acute shear stress inhibits Nrf2 activation and the antioxidant response in vECs, and pre-
activation of Nrf2 in vECs prior to acute shear stress exposure prevents inflammation 






1.7.2 EXPERIMENTAL APPROACH 
The following experimental approaches were adopted to test the above hypotheses: 
• Pro-inflammatory mRNA and protein profiles were studied in vECs exposed to acute high 
shear stress, in human umbilical vein ECs (HUVECs) in vitro and LSV ECs ex vivo. 
• Activation of the NF-kB classical pathway in vECs was investigated under conditions of 
acute shear stress in vitro using HUVECs and ex vivo using human LSV. 
• Pro-inflammatory mRNA and protein profiles were studied in vECs pre-treated with 
pharmacological or gene-therapy based NF-kB inhibition and subsequently exposed to 
acute high shear stress. 
• The functional effects of NF-kB inhibition in vECs were examined, by both permeability 
measures and activation of the adhesion cascade, under conditions of acute high shear 
stress. 
• Antioxidant mRNA and protein profiles were studied in vECs exposed to acute high shear 
stress, in HUVECs, in vitro. 
• Activity of the Nrf2 pathway in vECs was investigated under conditions of acute shear 
stress in vitro using HUVECs. 
• The effect of Nrf2 activation on EC responses to acute high shear stress was investigated 
directly, with an Nrf2 inducer and gene-therapy based overexpression, and indirectly, 










All reagents were of the highest grade and obtained from Sigma, unless otherwise stated 
2.1.1 REAGENTS USED IN TISSUE AND CELL CULTURE 
For culture of human umbilical vein endothelial cells (HUVECs), cyropreserved c-pooled HUVECs 
were purchased from Promocell (catalogue number: C-12203). Ready to use Endothelial Cell 
Growth Medium (Promocell; catalogue number: C-22010), Endothelial Cell Basal Medium 
(Promocell; catalogue number: C-22210) and M-199 GlutaMax Medium (with L-Glutamine; 
Gibco; catalogue number: 11150059) were used to culture human umbilical vein endothelial 
cells (HUVECs). M-199 GlutaMax medium was also used in the culture of human LSV under 
perfusion, as were the reagents listed below. Other reagents used for LSV and EC culture were 
as follows: heat-inactivated foetal bovine serum (FBS: Gibco; catalogue number: 10082147), 
trypsin-ethylene diamine tetraacetic acid (PAA Laboratories; catalogue number: L11-003), L-
glutamine (PAA Laboratories; catalogue number: M11-004), penicillin and streptomycin (PAA 
Laboratories; catalogue number: P11-010), Dulbecco’s phosphate-buffered saline (DPBS: Ca2+ 
and Mg2+ free; Gibco; catalogue number: 14080055) and gelatin solution (EC in vitro only) 
(catalogue number: G1393). Pharmacological compounds used included the inhibitor of NF-κB, 
BAY11-7085 (Santa Cruz Biotechnology; catalogue number: sc-202490), and activator of Nrf2, 
Sulforaphane (Sigma Aldrich; catalogue number: S6317). Additionally, recombinant human 
Tumour Necrosis Factor-α (TNF-α) (Miltenyi; catalogue number: 130-094-017), was used as an 
inducer of inflammation and NF-kB.   
Roswell Park Memorial Institue-1640 medium (RPMI-1640 buffered with 25mM HEPES; Gibco; 
catalogue number: 42401018) was used for the culture of THP-1 cells (ATCC® TIB-202™). Other 
reagents used in THP-1 culture were as follows: heat-inactivated foetal bovine serum (Gibco; 
catalogue number: 10082147), trypsin-ethylene diamine tetraacetic acid (PAA Laboratories; 
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catalogue number: L11-003), L-glutamine (PAA Laboratories; catalogue number: M11-004), 
penicillin and streptomycin (PAA Laboratories; catalogue number: P11-010). 
2.1.2 IMMUNOCHEMICAL REAGENTS 
The immunochemical reagents used in experiments outlined in this thesis are listed in TABLE 
2.1, TABLE 2.2 & TABLE 2.3; whilst the company locations are outlined in  TABLE 2.4. 
Abbreviations used in all tables are as follows: WB – Western blotting; ICC – 





COMPANY CATALOGUE # 
Anti-NF-kB (p65) (c-20) Rabbit 
WB: 0.1µg/mL 
ICC/IF: 0.2µg/mL 
IF (en Face): 0.33µg/mL 
Santa Cruz BT Sc-372 
Anti-Phospho p65(Ser276) Rabbit WB: 0.4μg/mL Santa Cruz BT Sc-101749 
Anti-Phospho p65(Ser536) Rabbit WB: 0.4µg/mL Santa Cruz BT Sc-33020 
Anti-IκBα (c-21) Rabbit 
WB: 0.2µg/mL 
ICC: 0.4µg/mL 
Santa Cruz BT Sc-371 
Anti-Nrf2 (c-20) Rabbit WB: 0.2µg/mL Santa Cruz BT Sc-722 
Anti-Nrf2 (h-300) Rabbit WB: 0.2µg/mL Santa Cruz BT Sc-13032 
Anti-MCP-1 Rabbit 
ICC: 3.33µg/mL 
IF (en face): 9.99µg/mL 
Abcam Ab9669 
Anti-GAPDH Mouse WB: 3.33µg/mL Millipore MAB374 
Anti-Lamin A/C (h-110) Rabbit WB: 0.2µg/mL Santa Cruz BT Sc-6215 
FITC-Conjugated Anti-vWF Sheep 
ICC/IF: 200µg/mL 
IF (en face): 200µg/mL 
Abcam Ab8822 
Anti-VE-Cad Mouse ICC/IF: 4µg/mL Santa Cruz BT Sc-9989 
Anti-Keap1 Goat WB: 0.4µg/mL Santa Cruz BT Sc-15246 
Anti-HO-1 Mouse WB: 4µg/mL Abcam Ab13248 
Anti-mouse IgG  
ICC/IF: equal to 
concentration of primary 
Ab used 
  
Anti-rabbit IgG  
ICC/IF: equal to 
concentration of primary 
Ab used 
  





COMPANY CATALOGUE # 
Anti-Mouse Alexa Fluor 
488 
Goat ICC/IF: 1:200 Invitrogen A-11001 




IF (en face): 1:200 
Invitrogen A-11011 
Anti-Rabbit IgG HRP Swine WB: 1:2000 Dako P0217 
Anti-Mouse IgG HRP Goat WB: 1:2000 Dako D0486 




COMPANY CATALOGUE # 
TO-PRO 3 IF (en face): 1:1000 Invitrogen T3605 
DAPI Dilactate ICC/IF: 1:1000 Invitrogen D3571 
Fluoromount-G Applied dropwise Invitrogen 00-4958-02 
 Details of fluorescent nuclear labels and mounting medium 
COMPANY LOCATION 
Abcam Cambridge, UK 
Santa Cruz BT Dallas, USA 
Invitrogen Carlsbad, USA 
Dako Santa Clara, USA 
Millipore Burlington, USA 
 Locations of companies where immunochemical reagents were purchased 
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2.1.3 ADENOVIRUSES 
Four recombinant replication incompetent adenoviral constructs were used in this project: 
• Wild-type porcine IκBα overexpressing recombinant adenovirus (WT-IκBα) kindly gifted 
by Dr Mark Bond, University of Bristol. The original WT-IκBα was constructed as stated 
in Wrighton et al., 1996. Homology between the amino acid sequences of human and 
porcine IkBa is greater than 90% and the porcine IkBa adenoviral construct has in fact 
been found to be more effective in human ECs than porcine (Wrighton et al., 1996; 
Rupec et al., 1999). 
• GFP-tagged, wild-type human Nrf2 overexpressing recombinant adenovirus (WT-Nrf2) 
kindly gifted by Professor Paul Evans, University of Sheffield. The original WT-Nrf2 was 
constructed as stated in Kraft et al., 2004. 
• GFP-tagged, dominant negative (DN) human Nrf2 overexpressing recombinant 
adenovirus (DN-Nrf2) kindly gifted by Professor Paul Evans, University of Sheffield. The 
original DN-Nrf2 was constructed as stated in Kraft et al, 2004. 
• Silent expression cassette (rAd66) was used as a control for three viruses above (WT 
and DN adenoviruses) 
All adenovirus preparations were produced and titrated by Dr Graciela Sala-Newby and Mrs Jill 
Tarlton (University of Bristol). Briefly, viral preparations were purified on a caesium chloride 
gradient and aliquots were stored at -80°C until use. The number of plaque-forming units (pfu) 




2.2 CULTURE OF HUVECS  
HUVECs were cultured in endothelial cell growth medium (ECGM) supplemented with 
endothelial cell growth supplement mix, containing final concentrations of 0.004 ml/ml 
endothelial cell growth supplement, 0.1 ng/ml recombinant human epidermal growth factor, 
1ng/ml recombinant human basic fibroblast growth factor, 90µg/ml heparin, 1µg/ml 
hydrocortisone, 100μg/ml penicillin, 100iu/ml streptomycin and 2mM L-Glutamine at 37°C in 
5% CO2. ECs were quiesced for 18 hours in 2% FBS (v/v) endothelial cell basal medium (ECBM) 
supplemented with 100μg/mL penicillin, 100IU/mL streptomycin and 2mM L-Glutamine; but 
lacking the growth factors listed above. 
2.2.1 CELL PASSAGE 
On reaching confluence, cells were passaged using trypsin digestion. Briefly, cells were washed 
once with DPBS, incubated with trypsin-EDTA (0.05%(w/v) trypsin, 0.02%(w/v) EDTA) at 37°C for 
3-4 minutes or until all adherent cells were displaced. ECGM was added to the trypsin at a ratio 
of 1:2 to neutralise trypsin activity. The cell suspension was centrifuged at 300g for 5 minutes, 
the supernatant discarded, and the cell pellet re-suspended in 1mL pre-warmed ECGM. Cell 
suspensions were divided 1:3 and cultured in ECGM at 37°C in 5% CO2. Cells were used for 
experiments between passage 2-6. 
2.2.2 CRYOPRESERVATION AND RESUSCITATION 
For storage, cells were trypsinised as in 2.2.1 and resuspended in 1mL 10% (v/v) dimethyl 
sulphoxide (DMSO) in ECGM and the cell suspension pipetted into cryovials (ThermoFisher; 
catalogue number: 5000-1020). Cryovials were immediately stored at -80°C in a freezing 
container that freezes cells at a rate of -1°C/minute; the following day, cells were transferred 
into liquid nitrogen for long term storage. For resuscitation, cells were thawed quickly using a 
37°C waterbath, upon defrosting, transferred immediately into 20-25mL pre-warmed ECGM in 
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flasks and incubated at 37°C in 5% CO2. ECGM was replaced 16-24 hours later to ensure removal 
of DMSO. 
2.2.3 CELL COUNTING 
Cells were counted using a Neubauer haemocytometer and the concentration of cells per mL 
was calculated with the following formula: 
  Average cells per 1mm2 = Cell № × 104 = Cells/mL 
2.3 CULTURE OF THP-1 CELLS 
THP-1 monocytic-like cells were cultured in suspension in RPMI medium supplemented with 
10% FBS(v/v), 100μg/mL penicillin, 100IU/mL streptomycin and 2mM L-Glutamine. 
2.3.1 CELL SUBCULTURE 
For subculturing, every 3 to 4 days, cell density was assessed by counting so as to not exceed a 
density above 1 × 106 cells/mL. Briefly, any loosely adhered cells were dislodged using a cell 
scraper and the cell suspension was centrifuged at 300g for 5 minutes, the supernatant was 
discarded, and cell-pellet re-suspended in 1mL pre-warmed RPMI medium, a further 14mL was 
added to cell suspension, prior to cell counting as described in 1.2.4. Cells were then seeded into 
flasks containing 20mL of pre-warmed RPMI at a density of 1 × 105 cells/mL. For cryopresevation, 
cells were subcultured as described in 2.3.1 and resuspended at a density of 1 × 105 cells/mL in 
1mL 10% (v/v) DMSO in RPMI medium and the cell suspension pipetted into cryovials. Cells were 




2.4 OVEREXPRESSION OF NRF2, KEAP1, NF-kB AND IkBa 
2.4.1 ECTOPIC OVEREXPRESSION OF WT- IkBa, WT-NRF2 AND DN-NRF2 IN HUVECS 
Overexpression of WT or DN forms of IκBα or Nrf2 were achieved using recombinant 
adenoviruses described above in 2.1.3. The empty cassette (rAd66) was used as the negative 
control. Firstly, HUVECs were seeded in 6 well plates for assessment of overexpression or onto 
1% gelatin-coated glass slides at a density of 2x105/slide and cultured for 24 hours, as in 2.5.1., 
for shear stress exposure. The empty-cassette adenovirus (rAd66), and DN-Nrf2, WT-Nrf2 or  
WT-IκBα containing adenoviruses were diluted in ECBM to achieve a final concentration of 1x107 
pfu/mL. Cells were cultured with adenoviruses for 18 hours and after washing cells with DPBS 
fresh ECBM added for a further 48 hours to enable maximal expression of viral proteins. 
Expression of Ad-WT-Nrf2 and Ad-DN-Nrf2 was assessed by visualising GFP protein under a 
fluorescence inverted microscope. Cells were then analysed immediately for overexpression by 
WB or subjected to shear stress prior to analysis by either qPCR or ICC. 
2.5 SHEAR STRESS INDUCTION IN PARALLEL PLATE FLOW CHAMBER 
2.5.1 CELL CULTURE 
HUVECs were cultured and passaged as previously described in 2.2. Menzel standard glass 
microscope slides (1mm thickness) (Thermo Scientific; catalogue number: 10144633A) were 
sterilised in 70%(v/v) ethanol and air-dried in cell culture ready quadriPERMâ slide tray plates 
(Sarstedt; catalogue number: 94.6077.308). A physical barrier area to cell growth was 
established by adhering reusable flexiPERMâ cell culture chambers (Sarstedt; catalogue 
number: 94.6032.039) to the glass slide surface. The established growth area was coated with 
700μl 1%(w/v) gelatin for 1 hour at 37°C; the gelatin solution was then aspirated, prior to 
washing the slide with DPBS and subsequent addition of 3mL pre-warmed ECGM. Cells were 
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seeded at a density 2.5×105/slide and cultured using ECGM (described in section 2.1.1) for 48 
hours (unless otherwise stated) at 37°C and 5% CO2 until 100% confluence was achieved, then 
quiesced in ECBM overnight. For shear stress exposure, M-199 GlutaMax medium, 
supplemented with 2% FBS (v/v), 100μg/mL penicillin and 100IU/mL streptomycin, was used.  
2.5.2 SHEAR STRESS 
Endothelial cell exposure to shear stress was achieved by placing the cells on the glass slides into 
a parallel plate flow chamber (FIGURE 2.1.) (PPFC) constructed by Dr. Stephen White, 
Manchester Metropolitan University (based on Castier et al., 2009). The chambers were made 
from Polymethyl methacrylate (Perspex/Acrylic glass) in-house at the University of Bristol 
mechanical workshop.   
Using sterile forceps, glass slides coated with cultured ECs were placed into the slide groove of 
the PPFC base plate followed by a silicon gasket (0.25mm thick, white solid silicon sheeting from 
Tyms seals and gaskets; catalogue number: TYM0115) around the cell area, ensuring that the 
gasket did not come into contact with the cells. After pipetting 1 mL of pre-warmed M-199 
medium onto cell area, the top-plate was carefully placed onto the gasket (See FIGURE 2.1). 
Once assembled in groups of three, chambers were mounted into the frame and clamps were 
tightened using a torque wrench to create a seal around silicon gaskets. M-199 medium was 
aspirated into a 30mL pipette attached to silicon tubing loops (1.58mm internal diameter, silicon 
tubing, VWR; catalogue number: 228-1066, and 1.42mm internal diameter peristaltic pump 
tubing, Elkay Laboratory products; catalogue number: 116-MEDI-056), which in turn were 
attached to chambers by plastic cannulae/male luer fitting (3mm outer diameter, World 
Precision Instruments; catalogue number: 13162-100). Frames and chambers were placed into 
incubators at 37°C and 5% CO2 (FIGURE 2.2.B.).  Cells were exposed to laminar shear stress at 
0.5 or 12 dyn/cm2 using a multi-channel peristaltic pump (Watson-Marlow; 323E manual pump 
driver, catalogue number: 036.3124.00U, 314D pumphead, catalogue number: 033.4411.000). 
Shear stress rates used, were to simulate approximate venous (0.5dyn/cm2) and arterial 
(12dyn/cm2) shear stresses. Time-points of 30 and 90 minutes were selected to assess nuclear 
and cytosolic movement of transcription factors and their repressors. Time-points of 90 and 120 
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minutes were selected in order to detect an mRNA transcriptional response. Finally, time-points 
of 4 and 6 hours were selected to detect a target protein response and allow for mRNA 
translation. 
Shear stress rates were calculated for a slit die assuming the viscosity of water at 37°C, using the 
following equation: 
τ=6µǪ/wh2                         
Where τ represents Shear Stress; µ, viscosity; Ǫ, flow rate; w, width and h, height (of the silicon 












 Schematic diagram of the parallel plate flow chamber 
I. Top-plate of flow rig containing ports and openings for both inlet and outlet  (image 
drawn upside down to visualise openings). Arrows represent the direction of flow. 
II. Silicon gasket; used to seal plates together and provide the correct width and height 
(indicated by black arrows) of the slit dye for calculation of shear stress, using the 
equation above. 
III. Glass slide with HUVECs (blue) cultured on 1% gelatin within restricted growth area 

















        
 Parallel plate flow chamber model 
A. Cross section through parallel plate flow chamber (adapted from White et al., 2011) 
B. Parallel plate flow chambers in-situ 
2.6 IN VITRO REAL-TIME MONOCYTE ADHESION ASSAY 
Monocyte adhesion to an endothelial monolayer, in vitro, was assessed in real-time using the 
Bioflux 200 microfluidic channel system (Fluxion; catalogue number: 950-0092). Briefly, the 
Bioflux 200 system uses pressurised, sterile air, pumped through a fully-enclosed tubing, plate 
and microfluidic circuit to generate a modifiable shear stress through microfluidic channels, 
which are viewable under a microscope (FIGURE 2.3.). 
ECs up to passage 4 were cultured as in 2.2. Prior to seeding ECs into the microfluidic channel 
system of the Bioflux 200 48-well, low shear plates (Fluxion; catalogue number: 910-0004), 
channels were coated with 1µg/mL (w/v) bovine fibronectin (Sigma; catalogue number: F1141) 
for 1 hour at 37°C and 5% CO2. Unbound fibronectin was then removed from the wells and 
A B 
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flushed out of the channels with ECGM. ECs were seeded very quickly into the channels to 
prevent cell aggregation and blocking of microfluidic capillaries. ECs were seeded with viewing 
channels constantly in view under the ThermoFisher EVOS FL microscope (ThermoFisher, 
AMF4300). Seeding was performed into the outlet well and ECs were flushed through the 
channels with a shear stress of 5dyn/cm2 for less than 5 seconds (until ECs entered the viewing 
channels), and a cell density of 4×107 cells/mL in a total volume of 10µL of ECGM. ECs were 
cultured in the channels for 48 hours at 37°C and 5% CO2 with ECGM. Following these 48 hours, 
and prior to exposure to high shear stress, ECs were labelled with 10µmol/L CellTracker™  
CM-DiI (ThermoFisher; catalogue number: C7000) red fluorescent probe for three-hours, 
concurrently with pre-treatment of ECs with either 20µmol/L NF-kB inhibitor, 20µmol/L BAY11-
7085, or 0.2% (v/v) DMSO vehicle control at 37°C and 5% CO2. ECs were then exposed to 
unidirectional, pulsatile shear stress (at 12 dyn/cm2 and 1 hertz(Hz)) for 6 hours at 37°C and 5% 
CO2 using the Bioflux 200 system. THP-1 cell labelling was achieved by incubation of 3x106 THP-
1 cells/mL with 10µmol/L Calcein AM (ThermoFisher, catalogue number: C1430) for 30 minutes, 
in a 6-well plate. Cells were then centrifuged at 300g for 5 minutes, to remove unbound Calcein 
AM, and re-suspended at the same density of 3x106 cells/mL. Following labelling of THP-1 cells 
and exposure of HUVECs to 6 hours of shear stress, Calcein AM-labelled THP-1 cells at a density 
of 3×106 cells/mL were flowed over confluent endothelial monolayers (at 1dyn/cm2) for 10 
minutes and viewing channels were imaged in real-time using a Zeiss AxioObserver Z1 inverted 
fluorescent microscope. Adhered THP-1 cells were enumerated after 10 minutes and divided by 




 Bioflux 200, 48-well plate and integrated system 
A. 48-well plate with schematic of paired inlet and outlet wells, complete with viewing 
window containing microfluidic channels 
B. Integrated Bioflux system consisting of a highly accurate electro-pneumatic pump, 
tubing and the Bioflux pressure interface attached to the 48-well plate. Images from 
bioflux.fluxion.com 
2.7 EX VIVO HUMAN LONG SAPHENOUS VEIN PERFUSION MODEL 
Surplus segments of surgically prepared human LSV resected during CABG surgeries (Ethics 
number: REC 14/EE/1097) were placed into M-199 GlutaMax medium, supplemented with 10% 
FBS (v/v), 100μg/mL penicillin and 100IU/mL streptomycin. Segments of LSV were used 
immediately after resection, additionally segments with minimal side-branches and clips were 
preferred.  Appropriate length segments for either en face preparation, intimal RNA extraction, 
ex vivo monocyte adhesion or histology processing were cut transversely for use as 
static/baseline control and maintained in M-199 medium until the bioreactor was operating. For 
use in the bioreactor, segments of 6cm were cut transversely at each end to ensure minimal 
prior contact to the vessel in order to limit endothelial damage across vessel length. Vein 
segments were cannulated with Male Luer Fittings (1.5mm (1/16”) outer diameter, (World 
Precision Instruments; catalogue number: 13160-100) and secured with sterile 4-0 mersilk 
surgical suture (Ethicon; catalogue number: W586H). Secured segments were then attached to 
A B 
 59 
a perfusion circuit consisting of an in-house designed bioreactor, silicon tubing (FIGURE 2.4.A.) 
(suppliers as above in 2.3.2) and a multi-channel peristaltic pump. The perfusion system was 
maintained at 37°C and 5% CO2 (FIGURE 2.4.B.). Vein segments were perfused with pre-warmed 
M199 culture medium under mean arterial flow rate of 100mL/min, which equated to a shear 
stress of 12dyn/cm2, as calculated by the equation for shear through a non-deformable cylinder: 
τ=4µǪ/πr3 
where τ represents Shear Stress; µ, viscosity; Ǫ, flow rate; π, pi; r, radius (the radius of the outer 










 Ex Vivo perfusion system 
A. Cross section of ex vivo perfusion system 
B. Image of 3 ex vivo perfusion rigs for exposure of LSV to regulated levels of shear stress 




2.7.2 EN FACE PREPARATION 
For immunofluorescent analysis of the saphenous vein endothelium, a procedure involving 
confocal microscopy and microdissection was developed and optimised. Sections of vein (static 
control segments or segments exposed to flow in the bioreactor) were cut transversely into 
approximately 1cm lengths, washed once in DPBS and dissected longitudinally using fine forceps 
and fine spring scissors. The vessel was pinned to dental wax using 100A minutien pins (Fine 
Science Tools; catalogue number: 2600210) with the luminal surface facing upwards, the dental 
wax was arched slightly to tauten the luminal surface and fixed using 10%(v/v) formalin/distilled 
water for 48 hours (FIGURE 2.5.A.). Following fixation, tissue was transferred to PBS for 
microdissection. Microdissection was performed, mostly with tissue free-floating in PBS, using 
an Olympus SZ-PT stereomicroscope. Briefly, the intimal layer of the vessel was peeled gently 
away from adventitial and medial layers using fine forceps and, if necessary, further 
microdissection with spring scissors was performed to ensure thin, flat intimal sections for 
immunofluorescent analysis (FIGURE 2.5.B.). 
 
           
 En face preparation of LSV 
A. LSV pinned to dental wax and fixed in a 6-well plate 
B. En face prepared segment, pinned to sylgard coated glass petri dish for confocal imaging 
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2.7.3 INTIMAL RNA EXTRACTION 
For extraction of RNA from endothelial cells of the long saphenous vein, a technique was used 
which involves the flushing of the lumen of the vessel with a severe lysis buffer, in this case, 
Qiazol (Qiagen; catalogue number: 79306), to disrupt cells in the intimal layer, predominantly 
endothelial cells (Nam et al., 2009; Chen et al., 2015). Briefly, segments were cut transversely 
into 2-3cm lengths and washed in ice-cold DPBS. Using a 1mL syringe and 18-gauge unbevelled 
needle with the tip inserted a few millimetres into the vessel lumen, the vessel was flushed with 
ice-cold DPBS. Finally, the lumen was quickly flushed (3-6 seconds) with 350µL of ice-cold Qiazol 
and the eluate was collected in a 1.5mL Eppendorf tube. This eluate was subjected to the RNA 
isolation protocol as in section 2.10.2. 
2.7.4 EX VIVO MONOCYTE ADHESION 
Following exposure to high shear stress, or maintenance in a static condition in M199 medium, 
for 6 hours, veins were sectioned transversely into approximately 1cm segments. Vessels were 
then dissected as above and pinned to a sterile glass petri dishes coated with sylgard silicone 
elastomer. Pinned samples were incubated with 1×106 THP-1 cells labelled with 10µM Calcein 
AM for 15 minutes then washed thoroughly with DPBS, twice. Veins were then placed directly 
into Immersol W2010 aqueous immersion medium (Zeiss; catalogue number: 444969) on a glass 
slide with the luminal side facing downwards, a coverslip placed on top and viewed immediately 
with the Zeiss AxioObserver Z1 fluorescent microscope. Due to the undulating and uneven 
endothelial surface of the LSV, sequential Z-stack images were taken to ensure sufficient 
coverage of the endothelial surface was captured, with individual slices separated by 1µm gaps 
and the depths of Z-stacks ranging from 5µm to 100µm. Z-stacks were taken at 5 equally 
distributed points across the surface of the vessel, i.e. four at the four points of a cross and one 
centrally. Z-Stacks were then processed, and maximum intensity projections were produced in 
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order to create a 2D image from  a 3D stack. Total numbers of adhered cells were then counted 
using the ‘Identify Primary Objects’ feature with CellProfiler 2.0. software (See section 2.7.5.). 
2.7.5 VALIDATION OF AUTOMATED THP-1 CELL ENUMERATION 
CellProfiler was used to count the number of adhered monocytes to the LSV endothelial surface. 
CellProfiler is an open-source, freely available software and allows automated, quantitative and 
reproducible analysis of light microscopy images (Carpenter et al., 2006). The method used was 
the ‘Identify Primary Objects’ module (see TABLE 2.5.), which employed a two-class thresholding 
approach, whereby object detection works in an almost binary way, as there are large 
differences in intensities between objects and background in the image. Size limitation was also 
a very important feature to factor in to the enumeration due to the clumped nature of the 
adhered monocytes. 
 
 CellProfiler output from adhered monocyte counts 
CellProfiler was used for automated counting of adhered THP-1 cells to the endothelial surface, 
outputs of the analysis are shown here to prove validity of the method. Clockwise from top left, 
panels include grayscale original image (i), randomly assigned colour representation of image 
showing segmentation (ii), quantitative data outputs (iii) and original image with segmented 
outlines (iv). 
A. Identify primary objects – Identification and counts of labelled monocytes. Magnified 
region represented by dotted white box 
B. Magnification of A 
A i ii 
iii iv 
B i ii 
iii iv 
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2.8 IMMUNOCYTOCHEMISTRY  
2.8.1 DUAL IMMUNOCYTOCHEMISTRY FOR MCP-1/IkBa AND VE-CADHERIN  
HUVECs were cultured on glass slides, as in section 2.5.1., and either exposed to shear stress or 
maintained in static conditions. Slides were washed twice with ice-cold DPBS prior to fixation in 
500µL of 3% (w/v) paraformaldehyde/PBS for 10 minutes. Following fixation, slides were washed 
three times for 5 minutes each, in PBS. Permeabilisation was achieved by incubation in 0.1% 
(v/v) Triton X-100/PBS three times for 5 minutes each. Slides were again washed once for 5 
minutes in PBS and blocked for 45 minutes with 20% (v/v) goat serum/PBS at RT. Cells were 
washed for 5 minutes with PBS and then incubated with 120µL of 3.33µg/mL rabbit anti-MCP-1 
IgG (Abcam; catalogue number: ab9669), 120µL of 0.4µg/mL rabbit anti-IκBα IgG (Santa Cruz 
Biotechnology; catalogue number: sc-371), or rabbit anti-IgG isotype controls at matched 
concentrations to primary antibodies, diluted in 1% (w/v) bovine serum albumin (BSA)/PBS 
overnight at 4°C. The following day, slides were washed three times in PBS for 5 minutes each 
and incubated with 120µL AlexaFluor568 conjugated goat anti-rabbit IgG (Invitrogen; catalogue 
number: A-11001) diluted 1:200 in 1% (w/v) BSA/PBS for 1 hour at RT. From this point onwards, 
care was taken to prevent direct exposure to either sunlight or artificial light by covering slide 
boxes with aluminium foil. Slides were washed three times for 5 minutes in PBS and incubated 
with 120µL of 4 µg/mL mouse anti-VE-Cadherin (F-8) IgG (Santa Cruz Biotechnology; catalogue 
number:  sc-9989), or mouse anti-IgG isotype controls at matched concentrations to primary 
antibodies, diluted in 1% (w/v) BSA/PBS for 1 hour at RT. Slides were washed three times for 5 
minutes in PBS and incubated with 120µL AlexaFluor488 conjugated goat anti-Mouse IgG 
(Invitrogen; catalogue number: A-11011) diluted 1:200 in 1% (w/v) BSA/PBS for 1 hour at RT. 
Nuclei were stained using 1:1000 dilution of DAPI-dilactate (Invitrogen; catalogue number: 
D3571) in PBS for 1 hour. Following three final 5-minute washes in PBS, the remaining PBS was 
carefully removed and slides were mounted with Fluoromount-G (Invitrogen, catalogue 
 64 
number: 00-4958-02) and then stored in the dark at 4°C until imaging was performed with the 
Zeiss AxioObserver Z1 fluorescent microscope using a 20x lens coupled with an AxioCamMRC 
Zeiss camera. 
Image analysis was performed using CellProfiler2.0 software (Carpenter et al., 2005). 
Quantification of arbitrary fluorescence intensity (or ‘Integrated Fluorescence Intensity’ as 
defined by CellProfiler) was calculated as total fluorescence across the objects (cells) divided by 
the total number of cells. Measurements of cell morphological features were also calculated 
with CellProfiler; these measurements are also expanded on in TABLE 2.5. For each condition, 
20 fields were imaged across each slide, which equated to approximately 2000 cells per 
condition. 
2.8.2 IMMUNOCYTOCHEMISTRY ANALYSIS 
Immunocytochemistry images were analysed using CellProfiler (Carpenter et al., 2006). 
CellProfiler has a toolbox of executable modules which are user-configured and run 
consecutively in a logical pipeline format. The primary pipeline utilised for image analysis 
consisted of 12 modules, outlined in TABLE 2.5., below. Briefly, the user selects a number of 
modules depending on quantitation required from the image sets. Each module used requires 
the user to define a number of image-processing settings, including thresholding, de-clumping 








MODULE SETTINGS FUNCTION 
Identify Primary Objects 
Global thresholding using Otsu 
approach; based on object size 
Detect Nuclei using DAPI image 
Identify Secondary Objects 
Watershed method across the 
image; Adaptive thresholding 
using Otsu approach 
Detect cell boundaries using Nuclei as 
seed; using primary stain (e.g. MCP-
1/VE-Cadherin) 
Identify Tertiary Objects Subtraction Subtract 1° object from 2° object to give cytosolic area 
Measure Object Intensity 
Select primary stain (of 
interest) and objects 
Measures of intensities for each cell 
individually in total cell, nucleus and 
cytosol 
Measure Object Neighbours 
Select secondary stain (i.e. VE-
Cadherin) and objects 
Measures proximity of objects, 
percent of objects in contact and 
other neighbour features 
Measure Image Area 
Occupied 
Select objects to measure 
Measures of total area covered by 
cells and sum of cell perimeters  
Measure Image Intensity 
Select primary stain (of 
interest) and objects 
Measures of intensities of all 
cells/nuclei/cytosol 
Calculate Math Select features to define 
Calculate ratio of intensity between 
nucleus and whole cell 
Calculate Math Select features to define 
Calculate ratio of intensity between 
cytosol and whole cell 
Display Histogram Select features to define 
Provide histogram representation of 
intensity – for normal distribution 
Overlay Outlines Select overlays 
Overlay nuclei and cell outlines over 
primary stain 
Export to Spreadsheet Select features to export Export all data into excel format 
 Modules used in CellProfiler-based immunocytochemistry analysis 
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2.8.3 VALIDATION OF AUTOMATED MCP-1 AND IkBa INTENSITY ANALYSIS 
MCP-1/IkBa immunocytochemistry image sets were analysed for whole cell integrated 
fluorescence intensity (sum of intensities divided by number of cells per image). For the running 
of the analysis, the MCP-1/IkBa (red) channel was used as the primary stain for quantification. 
Initially, nuclei were identified, using the DAPI nuclear stain, to represent ‘seed’ regions (FIGURE 
2.7.A. and E). To determine cell boundaries, edges of MCP-1/IkBa immunofluorescence were 
expanded from seed regions (nuclei), with a boundary-based algorithm, until the intensity 
threshold detected crosses the lower limit, i.e. the cell/staining extremity (FIGURE 2.7.B. and F.). 
The final stage of segmentation of cellular compartments is a subtraction of nuclei from the 
whole cell (FIGURE 2.7.C. and G). Intensity of MCP-1/IkBa immunofluorescence and morphology 
data were then quantified for each cell compartment (nuclei, cytosol and whole cell). However, 
for quantification in this thesis, whole cell fluorescence was used. 
 
 
 Outputs from CellProfiler MCP-1/IkBa analysis 
Clockwise from top left, panels include grayscale original image (i), randomly assigned colour 
representation of image showing segmentation (ii), quantitative data outputs or outlines (iii) 
and original image with outlines or image representing subtraction of nuclei from whole cell (iv).  
A. Identify Primary objects – Identification of seed regions from DAPI nuclear stain 
B. Identify Secondary objects – Grows from seed region to boundary of cells from using 
MCP-1 immunofluorescence and step A as the seed 
C. Identify tertiary objects – Subtracts nuclei from whole cell to give cytosol segmentation 
D. Display Histogram – Outputs integrated intensity in the form of histogram for normality  
E. Magnification of A  
F. Magnification of B 
G. Magnification of C 









2.8.4 VALIDATION OF AUTOMATED VE-CADHERIN CELL-CELL CONTACT ANALYSIS 
Analysis of VE-Cadherin immunocytochemistry, in order to quantify endothelial barrier 
organisation, was done using CellProfiler software. The feature quantified was ‘Percent 
touching’, which gives a quantifiable measure of cell-cell contacts and gaps between cells, which 
was used as a surrogate marker to illustrate disruptions to the endothelial barrier. As it is a 
percentage calculation, 100% represents an entirely intact endothelial monolayer without 
distinguishable gaps. The analysis pipeline used was a similar process to that outlined in TABLE 
2.5, with the key difference being that the primary stain used was VE-Cadherin. The other 
differences are in the thresholding strategies for detection of object edges and addition of a 
‘measure object neighbours’ module. Also, here, an adaptive, watershed thresholding approach 
was used, which is preferred when there is a clear and distinct boundary between objects and 
the intensity gradient drops off or increases sharply at the border. Finally, the ‘measure object 
neighbours’ module expands object borders outwardly by a nominal, specified distance and 
quantifies features of neighbouring objects based on adjacent pixels. 
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 Outputs from CellProfiler VE-Cadherin analysis 
Clockwise from top left, panels include grayscale original image (i), randomly assigned colour 
representation of image showing segmentation (ii), original image with outlines or image 
representing subtraction of nuclei from whole cell (iii) and quantitative data outputs, 
visualisation of quantification or outlines (iv).  
A. Identify Primary objects – Identification of seed regions from DAPI nuclear stain 
B. Identify Secondary objects – Grows from seed region to boundary of cells from using VE-
Cadherin immunofluorescence and step A as the seed (N.B. MCP1whole (title) only 
represents naming system, as this pipeline was adapted from earlier (2.8.3)). 
C. Identify tertiary objects – Subtracts nuclei from whole cell to give cytosol segmentation 
D. Measure object neighbours – Measurement outputs including number of adjacent 
object neighbours (iii) and percent touching by object (iv) 
E. Display Histogram – Outputs histogram of total cell area to show distribution  
F. Display outlines – Final representation of original image (i) and original image complete 
with nuclear outline (blue) and outer border outline (green) superimposed  
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2.9 IMMUNOFLUORESCENCE ON TISSUE SAMPLES 
2.9.1 LSV DUAL EN FACE NF-kB/MCP-1 AND vWF IMMUNOFLUORESCENCE 
En Face prepared segments of LSV were maintained free-floating, in a total volume of 500µL per 
well at 4°C (unless stated otherwise), throughout the procedure, 24-well plates with the luminal 
side facing upwards. Firstly, segments were permeabilised with 0.2%(v/v) TritonX-100/PBS 
overnight at 4°C. Segments were then blocked in 20%(v/v) goat serum/PBS for 1 hour at RT. 
Primary antibody incubation was performed with 300µL of 1.33µg/mL rabbit anti-NF-kB IgG 
(Santa Cruz Biotechnology; Catalogue number: sc-372) or 300µL of 9.99µg/mL Rabbit anti- 
MCP-1 IgG (Abcam; catalogue number: ab9669), or rabbit anti-IgG isotype controls at matched 
concentrations to primary antibodies, diluted in 1%(v/v) BSA/PBS for 48 hours. After washing 
segments at RT, three times for 5 minutes with PBS with continual agitation, they were 
incubated with 1:200 dilution of AlexaFluor 568 conjugated goat anti-rabbit IgG in 1%(v/v) 
BSA/PBS overnight. Following three 5-minute washes in PBS, segments were incubated with 
200µg/mL FITC-conjugated sheep anti-vWF IgG (Abcam; Catalogue number: ab8822), or sheep 
anti-IgG isotype controls at matched concentrations to primary antibodies, diluted in 1%(v/v) 
BSA/PBS overnight. Segments were washed three times for 5 minutes with PBS. Lastly, segments 
were incubated for one hour at RT with TO-PRO3 iodide (ThermoFisher; Catalogue number: 
T3605) diluted 1:1000 in PBS. Samples were maintained in PBS at 4°C until confocal imaging was 
performed. For confocal microscopy, segments were placed onto a Sylgard (Dowsil; Catalogue 
number: 101697) coated petri dish and pinned at four corners as in FIGURE 2.5.B. and 
submerged in PBS for imaging with a water immersion lens. The Leica SP8 AOBS confocal 
scanning microscope attached to a Leica DM6000 upright epifluorescence microscope and 25x 
dipping lens were used for all en face imaging (Leica). Due to the undulating and uneven 
endothelial surface of the LSV, sequential Z-stack images were taken to ensure sufficient area of 
the endothelial surface was captured, with individual slices separated by 500nm gaps and the 
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depths of Z-stacks ranging from 15µm to 100µm. Z-stacks were taken at five equally distributed 
points across the surface of the vessel, i.e. the four points of a cross and one centrally.  
2.9.2 IMARIS EN FACE IMMUNOFLUORESCENCE ANALYSIS FOR NUCLEAR NF-kB  
Quantitative analysis of Z-stacks as 2D maximum intensity projections was not possible due to 
underlying VSMCs beneath the endothelial monolayer which also expressed the proteins of 
interest. As such, a protocol was designed to quantitatively analyse ECs alone, whilst removing 
underlying VSMCs, in 3D, using Bitplane Imaris software. En face image sets from section 2.7.2 
were analysed with the procedure outlined in TABLE 2.6 below. 
MODULE SETTINGS FUNCTION 
3D volume reconstruction N/A Create volume view of nuclei 
Surface rendering 
Threshold based on Absolute 
intensity; Smoothing objects to 
a resolution of 0.2µM 
Create surface rendered nuclei from 
nuclear stain 
 
Split touching objects 
Set seed point diameter of 
6µM 
Sets centre point of automatically 
detected objects and separates 
touching objects/nuclei  
Classify seed points 
Based on intensities of objects 
(‘Quality’), user defined  
Allows removal of some nuclei based 
on intensity 
Classify surface 
Based on ellipticity of objects 
(oblate/flattened at poles), 
user defined 
Allows removal of some nuclei based 
on their shape (e.g. VSMC nuclei – 
much longer and thinner) 
Cut surfaces 
Cutting in 3D; to remove or 
separate further touching 
objects 
Allows user to clip overlapping/joined 
objects manually 
Surface selection 
Select new surface (i.e. with all 
unwanted objects removed) 
To define quantitative measures for 
only nuclei of interest (EC) 
Export statistics Select features to export 
Export all morphometric and intensity 
data to Excel 
 Process of Imaris 3D en face immunofluorescence analysis 
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2.9.3 VALIDATION OF IMARIS 3D ANALYSIS PROCESS 
Due to the extremely contoured and uneven surface topology of the LSV, it was necessary, in 
order to capture enough ECs in one plane, to image the endothelium with Z-stacks. Using equally 
spaced, consecutive ‘slices’ through the Z-plane, Z-stacks give the user a volumetric, three-
dimensional representation of the surface of the vessel and the underlying cellular architecture. 
The imaging method used here was optimised to have consecutive slices through Z separated 
by 500nm spacing between slices and an image resolution of 110nm. This allowed for the 
capturing of very high-resolution 3D images of the LSV endothelium which, when re-constructed 
as a volume, were not subject to information loss and avoided the need for computationally 
expensive deconvolution techniques.  
 With the optimised image capturing complete, it was necessary to define an analysis method 
which allowed for true quantification and extraction of measurable features from the 3D 
volumes of nuclei. To analyse specifically the nuclear compartment required the use of Imaris 
Bitplane software, which permits the user to analyse object specific characteristics in 3D that 
would not be possible with another analysis method. Using Imaris the intensity of NF-kB 
immunofluorescence in LSV EC nuclei only was analysed, whilst removing underlying nuclei of 
other cell types from the analysis. This required first, the volumetric reconstruction of Z-stacks 
(FIGURE 2.9.A. and B.), and segmentation of all nuclei as surface rendered ‘objects’ (FIGURE 
2.9.C.).  
The process of filtering out of nuclei underneath the endothelial surface was then performed in 
three independent steps. Firstly, ‘seed points’ were identified based on object size and ‘quality’, 
which is the intensity at the centre of the ‘seed point’ (grey spheres) (FIGURE 2.9.D.). For the 
second stage, filtering of nuclei was performed based on their shape, in particular their oblate 
ellipticity, whereby objects that were more elongated (i.e. a large major axis length and small 
minor axis), were removed from the final analysis (FIGURE 2.9.E.). Finally, the semi-automated 
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algorithm-based segmentation was complete and the new surface objects were created (FIGURE 
2.9.F.). However, this algorithm-based segmentation was often not absolute, due to the fact that 
some nuclei were in very close proximity or some underlying nuclei did not satisfy the shape-
based criteria mentioned above. As such, it was necessary to manually select and remove some 
objects from the analysis or ‘cut’ objects that were touching in order to split them (FIGURE 2.9.G. 
and H.). Following the segmentation of only EC nuclei and removal of all other nuclei (blue and 
red objects respectively in FIGURE 2.9.I.), quantification of intensity could be performed 
























 Validation of Imaris 3D endothelial cell analysis process 
Imaris utilises 3D volumetric images (Z-stacks used here) to allow segmentation and 
quantification of images. The process represented here demonstrates the workflow undertaken 
for quantitative, volumetric analysis of solely the surface cells of the LSV, whilst removing the 
nuclei underneath the surface cell layer, from the analysis. 
A. 3D volume reconstruction – En face prepared LSV, with all three channels represented 
in volume (Red: NF-kB; Green: vWF; Blue: TO-PRO3 (nuclear stain)). 
B. 3D volume reconstruction – Nuclear stain only. 
C. Surface rendering – Creation of surface rendered and smoothed nuclei (Grey) for 
segmentation. 
D. Classify Seed points and Split touching objects – Semi-automated object detection 
allowing user defined inclusion or exclusion of objects based on ‘Quality’ or intensity of 
objects – each object should be individually represented by a grey sphere (set to 6µM 
for seed point (approx. lower boundary size of nuclei)). 
E. Classify surfaces – Removal of nuclei based on a morphological or intensity-based 
characteristic, in this case, oblate ellipticity (i.e. flat and elongated compared to a 
spheroid). 
F. Surface selection – Create new surface rendered selection with only objects of interest. 
G. Cut surfaces – Manual removal or clipping of objects – line in the yellow object (two 
adjoined nuclei), represents user defined ‘cut’ line (white arrow pointing to thin black 
line in the centre of the adjoining nuclei) for separation. 
H. Cut surfaces – Separated objects – now considered as two independent nuclei 
I. Two distinct sets of nuclei segmented, blue representing EC nuclei, red representing 
other. 
J. Final image to represent selected surface rendered objects on original image – 
Intensity and morphology statistics for all three channels to be exported from 






2.9.4 VALIDATION OF MCP-1 EN FACE IMMUNOFLUORESCENCE 
Due to the discontinuous nature of MCP-1 staining and the difficulty in defining the borders of 
the ECs in the LSV, en face, it was a challenge to find a suitable analysis method for these 3D 
data sets. Having tried numerous 3D analysis suites, including Imaris, CellProfiler and Volocity, 
ultimately, the preferred analysis method was using the ‘3D Object Counter’ module in 
FIJI/ImageJ. This module works based upon the user defined intensity threshold in order to 
segment objects (Bolte et al., 2006). The distribution of MCP-1 staining was highly localised to 
the perinuclear region and very intense at these points, as such, the threshold used was 
relatively high (50 AFI (out of 255 total)) and object volume was relatively low (1000 voxels), in 
order to best segment these regions only (Supplementary video 2. shows MCP-1 LSV en face 
staining with segmented objects overlaid). Only the MCP-1 channel was used for analysis. Due 
also to the high threshold setting, this also ensures that only the endothelial signal will be 
detected because, owing to the depth of the tissue, signal from underlying cells was much 
weaker and not significant enough to surpass the threshold, therefore the analysis was not 
often confounded by the analysis of non-endothelial (i.e.VSMC/fibroblast) MCP-1. 
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 FIJI-based analysis of MCP-1 en face immunofluorescence 
FIJI ‘3D Object counter’ uses Z-stacks as its input to segment objects that cross the user-defined 
intensity threshold.  
A. Column of images represent maximum intensity projections (MIP) from Z-stacks of  
MCP-1 (red) and nuclei (blue) 
B. MIP of coloured 3D object map calculated by FIJI (colour coding is randomly assigned) 





2.10 MOLECULAR BIOLOGY 
2.10.1 RNA EXTRACTION 
Total RNA extraction and purification was performed using the miRNeasy Mini kit (Qiagen; 
catalogue number: 217004). Cultured cells were washed twice in ice-cold DPBS and lysed in 350 
or 700μL Qiazol lysis reagent for approximately 30 seconds and then wells or slides were scraped 
using the rubber insert of a 1mL syringe. Lysates were kept on ice or stored at -80°C until 
purification. 
2.10.2 RNA PURIFICATION AND QUANTIFICATION 
RNA was purified following the manufacturer’s instructions. Briefly, samples were mixed with 
chloroform at a ratio of 1:0.2 (sample:chloroform) and centrifuged at 4°C for 15 minutes at 
12,000g. Once separated, the upper layer of chloroform from each sample was carefully 
removed and mixed with 1.5 volumes of absolute (100%) ethanol and the remaining phenol 
discarded. Samples were then transferred to purification columns and centrifuged at 12,000g; 
after three washes with wash buffer RNA samples were collected in 30µl RNAse free water and 
stored at -80°C until required. 
Total RNA was quantified using the QIAxpert spectrophotometer system (Qiagen; catalogue 
number: 9002340). The RNA concentration (ng/mL) was obtained by measuring absorbance at 
260nm. RNA contamination with ethanol or phenol was determined by measuring the ratio of 
absorbance at 260/230, with a ratio of ≤1.8 suggesting high levels of contamination. 
Contamination with nucleic acid was determined by the ratio of absorbance at 260/280, with a 
ratio <2.0 indicating high nucleic acid levels. If significant contamination was detected, samples 
were discarded. 
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2.10.3 QUANTITATIVE RT-PCR (RT-qPCR) 
Reverse transcription was on 80-500ng/mL purified RNA performed using the transcriptor first 
strand cDNA synthesis kit (Roche; catalogue number: 04896866001). Firstly, RNA secondary 
structures were removed. To do so, RNA levels were normalised to the same concentration with 
variable volumes of RNAse free water and RNA, and subsequently incubated with 2µL random 
hexamer primers for 10 minutes at 65°C using a thermal block cycler (Bio-Rad; model number: 
C1000). Secondly, according to manufacturer’s instructions, 4µL of reaction buffer, 0.5µL 
protector RNase inhibitor, 2µL deoxynucleotide mix and 0.5µL reverse transcriptase enzyme 
were added to each RT reaction to give final concentrations of: 1x, 20U, 1mM and 10U, 
respectively. Reactions were then incubated for 10 minutes at 25°C, 30 minutes at 55°C and 5 
minutes at 85°C.  A total of 20μL cDNA was synthesised and cDNA samples were stored at -20°C 
until analysis. Quantitative PCR analysis was performed using the LightCycler 480 real-time PCR 
instrument (Roche) and LightCycler 480 SYBR Green I Master (Roche; catalogue number: 
04707516001). Each 10μL reaction, in white 96-well plates (Greiner Bio-one; catalogue number: 
669 285), consisted of: 5μL SYBR Green, 3μL PCR grade water, 1μL primer sets (0.5 μL of both 
forward and reverse primers) and 1μL cDNA, water (as internal PCR control) or blank RT reaction 
sample (RT control). Plates were sealed (Greiner Bio-one; catalogue number: 676040) and 
centrifuged for 15 seconds at 250g (Labnet; Mini PCR plate spinner; catalogue number: C1000).  








STEP SUB-STEP TEMPERATURE/°C TIME 
Pre-
Incubation 
   
- 95 5 min 
   
Amplification 
(45 cycles) 
Denaturing 95 10 sec 
Annealing 60 10 sec 
Elongation 72 10 sec 
    
Melting 
 95 5 sec 
- 65 1 min 
 97 Continuous 
Cooling 
   
- 40 -1.5°C/sec 
   






PCR reactions were run in triplicate to allow for variation within wells and the average CT (Cycles 
of Threshold) values were used for calculating fold changes in expression. This value corresponds 
to the number of cycles whereby the amplified cDNA template reaches a detection threshold 
and is therefore only a relative measure of amplicon concentration. CT values within sample 
triplicates never differed by more than 1 cycle. The following equation was used to determine 
the relative expression difference between experimental and control conditions (or fold 
change):      
Fold change = 2-∆CT 
where  ∆CT = CT experimental - CT control 
To determine non-specific product contamination, melting curves were analysed. All primers 
used gave single melting curves indicating that only one PCR product was being amplified. 
2.10.4 PRIMER DESIGN AND SEQUENCES 
Design of primers for qPCR analysis was done using Primer-BLAST software. Filters for design 
included:  
• specificity for solely the target gene and its transcript variants  
• a product size of between 95 and 200 base pairs 
• an optimal melting temperature of 65°C  
• an optimal primer size of between 22 and 26 base pairs  
• a primer GC content of 40-65% 
• a requirement for the spanning of exon-exon junctions or separation of the primer pair 
by at least one intron on the corresponding genomic DNA 
• lack of secondary structures 
• lack of primer dimers 
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 List of primer sequences  
 
 
GENE NAME FORWARD SEQUENCE (5’->3’) REVERSE SEQUENCE (5’->3’) 
b-Tubulin (TUBB1) GCTGGACCGCATCTCTGTGTACT TTACCTGCCCCAGACTGACCAAAT 
Monocyte chemoattractant 
protein 1 (CCL2/MCP-1) 
CTCAGCCAGATGCAATCAATGCCC TTCTTTGGGACACTTGCTGCTGGT 
Interleukin 6 (IL-6) AAATTCGGTACATCCTCGACGGCA TTTTCACCAGGCAAGTCTCCTCAT 
Interleukin 8 (IL-8) TGTGAAGGTGCAGTTTTGCCAAGG AATTTCTGTGTTGGCGCAGTGTGG 
Intercellular adhesion 
molecule 1 (ICAM-1) 
GCAGACAGTGACCATCTACAGCTT GCCTCACACTTCACTGTCACCTC 
E-Selectin (SELE) TCAGCTCTCACTTTGGTGCTTCTCA TGCTGACAATAAGCACTGGCCTCA 
Vascular cell adhesion 
molecule 1 (VCAM-1) 
GGCCCAGTTGAAGGATGCGGG AGAGCACGAGAAGCTCAGGAGAA 






Glutamate cysteine ligase, 
modifier subunit (GCLM) 
TCAACCCAGATTTGGTCAGGGAGT CAGCTGTGCAACTCCAAGGACTGA 
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2.11 WESTERN BLOTTING 
2.11.1 SDS PROTEIN EXTRACTION  
Cells were washed twice with ice-cold DPBS and lysed using 1% Sodium Dodecyl Sulphate (SDS) 
lysis buffer (50mM Tris-HCl (pH 6.8), 10% (v/v) glycerol and 1% (w/v) SDS). Tissue culture wells 
or glass slides were rubbed with the insert of a 1mL syringe and samples were used immediately 
or stored at -80°C. 
2.11.2 NUCLEAR AND CYTOSOLIC PROTEIN FRACTIONATION 
Cells were washed twice with ice-cold DPBS and lysed using the NE-PER Nuclear and Cytoplasmic 
extraction reagents (Thermo-Fisher Scientific; catalogue number: 78835), volumes used were as 
per manufacturer’s instructions. Briefly, cells were lysed directly with buffer CER-I and rubbed 
with the insert of a 1 mL syringe. Samples were vortexed and stored on ice for 10 minutes, after 
which time buffer CER-II was added, tubes were vortexed and kept on ice for a further 1 minute 
and vortexed again. Following addition of both cytoplasmic buffers, samples were centrifuged 
at 14,000g for 10 minutes, the supernatant was transferred to a clean tube and stored at -80°C 
until analysis. The pellet was resuspended in ice-cold NER and vortexed for 15 seconds and 
placed on ice for 10 minutes; these steps were repeated 4 times until the nuclear pellet was 
largely dispersed. Samples were centrifuged a final time for 10 minutes at 14,000g; the 
supernatant was collected in a clean tube and stored at -80°C until analysis. 
2.11.3 PROTEIN ASSAY 
The concentration of protein in samples was determined using the Micro Bicinchoninic Acid 
(BCA) assay kit (Thermo-Fisher scientific; catalogue number: 23235). To clear bottom 96-well 
plates, 2.5µL of protein lysate was added to 145µL of HPLC grade water. Bovine serum albumin 
(BSA) at concentrations of 0, 0.1, 0.25, 0.5, 1.0, 2.5, 5.0 and 10µg/mL were used for production 
of a standard curve. All samples and standard measurements were conducted in duplicate. 
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Following addition of protein lysate or BSA, 150µL of Micro BCA reagents were added (combined 
solution of reagents A:B:C in a ratio of 25:24:1) and the plate was incubated at 37°C for 1 hour; 
after which time plates were read at 560nm using an ELISA plate reader (LabTech; catalogue 
number: LT-5000MS) and the protein concentrations of samples were calculated from the linear 
range of the standard curve. 
2.11.4 POLYACRYLAMIDE GEL ELECTROPHORESIS (PAGE) 
All PAGE analyses were performed using the Biorad Mini format 1-D electrophoresis system 
(Biorad; catalogue number: 1658004). Using the sample concentrations calculated in 2.11.3,  
5-20µL of the protein lysates were diluted using HPLC grade water to standardise the sample 
volume and protein concentration to ensure equal loading. Laemmli sample buffer (Biorad; 
catalogue number: 161-0737) supplemented with 5% (v/v) β-mercaptoethanol was added to 
samples (at a ratio of 1:1) prior to heating at 95°C for 5 minutes. For approximation of protein 
size, 10µL of BLUeye pre-stained protein ladder (Geneflow; catalogue number: S6-0024) 
supplemented supplemented with 2.5% (v/v) β-mercaptoethanol was also heated at 95°C for 5 
minutes and loaded with protein samples. Samples were loaded onto 4-15% Mini-PROTEAN TGX 
stain-free gels (Biorad; catalogue number: 456-1084) and subjected to electrophoresis at 300V 
for 15-25 minutes in 1×Tris/Glycine/SDS (TGS) running buffer (Biorad; catalogue number:  
161-0772). Following electrophoresis, the precast gel packs were opened using a gel opening 
lever; gels were wetted with running buffer, removed carefully and placed on the UV 
transilluminator tray of the ChemiDoc XRS+ imaging system (Biorad; catalogue number: 
1708265). Using ImageLab software, stain-free gels were activated and imaged to be used as a 
loading control for densitometry.  
2.11.5 PROTEIN TRANSFER AND PROTEIN DETECTION 
Following gel imaging, gels were transferred to a Trans-Blot turbo nitrocellulose transfer pack 
(Biorad; catalogue numbers: 170-4158, 170-4159) and, using the Trans-Blot turbo transfer 
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system, electrophoretic protein transfer was performed as per the manufacturer’s instructions. 
Non-specific binding was blocked by placing 0.2µM Nitrocellulose membranes in 5% (w/v)  
fat-free milk powder in PBS with Tween (PBS-T; 137mM NaCl, 0.1% (v/v) Tween 20; pH 7.6) for 
30 minutes. Following blocking, membranes were incubated and rocked with primary antibodies 
(see TABLE 2.1.) diluted in 5% milk/PBS-T for 1 hour at room temperature or overnight (16-18 
hours) at 4°C. Blots were then washed three times for 5, 10 and 30 minutes in PBS-T then 
incubated and rocked in HRP-conjugated secondary antibody (see TABLE 2.2.) in 5% milk/PBS-T 
for 1 hour at room temperature. Membranes were washed a further three times as above and 
then incubated with 3mL of Luminata Forte Western HRP substrate (Merck Milipore; catalogue 
number: WBLUF0500) for 3 minutes. Finally, membranes were imaged using the ChemiDoc XRS+ 
imaging system according to the manufacturer’s instructions. Western blots were exposed using 
this system for between 2-90 seconds, most commonly, experiments were run in triplicate and 
all WBs were exposed at the same time to avoid any bias in densitometric analysis. 
2.11.6 DENSITOMETRY 
The protein band density was determined using ImageLab software and the ChemiDoc XRS+ 
system and results were expressed as the adjusted sum of pixel intensities following global 
(whole gel) background subtraction. The density of protein bands detected was normalised 
using the Stain-Free loading control for each sample. 
2.12 NF-kB ACTIVITY ASSAY 
Cells were lysed as in 2.11.1 for whole cell lysates. To detect active NF-κB (p65) protein, the 
TransAM p65 DNA-binding ELISA kit (Active Motif; catalogue number: 40096) for 96 strip-well 
reactions was used. All incubations were performed at RT.  Briefly, cell extracts were incubated 
and gently rotated in wells for 1 hour, extracts were removed, and a primary antibody to NF-κB 
(provided in kit) was added to wells at a dilution of 1:1000 for 1 hour. The primary antibody was 
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washed and replaced with a HRP conjugated secondary antibody for 1 hour. Wells were washed, 
and the developing solution was added for approximately 5 minutes, or until wells turned a blue 
colour. Finally, a stop solution was added, wells were covered and, for quantitative analysis of 
NF-κB activity, the final absorbance was read at 450nm. Absorbance was expressed as arbitrary 
units and calculated relative to static control samples, normality range was verified by standard 
curve.  
2.13 STATISTICAL ANALYSIS 
For experiments where only two groups were analysed, data were subjected to a paired, two-
tailed t-test. For experiments where more than two groups were analysed, a one- or two-way 
ANOVA was used depending on the number of independent variables, followed by post-hoc 
pairwise comparisons with Bonferroni correction for multiple comparisons. If data-sets were 
large enough (for example for immocytochemical analyses, where 20 images were per sample 
were analysed), normal distribution was assessed with the D’Agostino-Pearson test; all data 
assessed passed normality tests. Sample number (n) when referring to in vitro use of HUVECs 
refers to pooled vials of HUVECs, each with a different lot number (i.e. pooled from 
new/different donors). Sample number (n) when referring to ex vivo use of LSV refers to tissue 
resected from different patients, each with a unique ethics number. The cut-off value for 
statistical significance was 0.05. Data are presented as means±SEM. All statistical analysis was 
performed with GraphPad Prism 7.0. 
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3. NF-kB ACTIVATION IN VENOUS 
ENDOTHELIUM IN RESPONSE TO ACUTE 
HIGH SHEAR STRESS 
 88 
3.1 INTRODUCTION 
Veins grafted into the arterial circulation are known to undergo pro-inflammatory activation, 
characterised by increased expression of chemokines and adhesion molecules, though the exact 
underlying mechanisms for this activation are still not fully understood (Ascione et al., 2000; Zou 
et al., 2000; Christiansen et al., 2004; Kwei et al., 2004). Endothelial expression of adhesion 
molecules, ICAM-1, VCAM-1 and E- and P-Selectins, in the vein graft, allows circulating 
leukocytes to adhere to and infiltrate the vascular wall soon after implantation (Hoch et al., 
1994; Golledge, 1997; Hoch et al., 1999; Kwei et al., 2004). It is also recognised that the triggering 
of the adhesion cascade, and subsequent leukocyte extravasation, contributes further to the 
pro-proliferative response of medial VSMCs through the direct secretion of growth factors and 
the action of inflammatory cytokines and growth factors on MMP induction (Newby et al., 2000; 
Newby, 2005; Newby, 2008; Wan et al., 2012).  
Over thirty years ago, Pearce et al. recognised the importance of the acute phase, immediately 
after implantation, on the inflammatory insult experienced by the vein graft endothelium in a 
canine interposition bypass model (Pearce et al., 1985).  They observed a significant neutrophilic 
response accompanied by a degree of endothelial loss within 6 hours after implantation of the 
vessel, which was reduced with anti-inflammatory pre- and post-treatments. Very few 
subsequent studies, however, have evaluated acute inflammatory changes in vein grafts, with 
many focussing on the inflammatory processes occurring less acutely, after 24 hours post-
implantation (Golledge et al., 2000; Kwei et al., 2004; Nguyen et al., 2016).  
The transcription factor, NF-kB has been implicated in a great number of cardiovascular 
pathologies, including atherosclerosis, heart failure, ischaemia/reperfusion injury and cardiac 
hypertrophy (Van Der Heiden et al., 2010). Due to its myriad roles in cellular behaviour,  
NF-kB activity in such disease models can be either protective or pathogenic; or, in the case of 
atherogenesis, both, depending upon the cell-type (Hayden et al., 2008; Lawrence, 2009; Van 
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der Heiden et al., 2010). NF-kB has been proposed to be involved in the systemic inflammatory 
response which occurs during cardiopulmonary bypass and CABG surgery, owing to the systemic 
production of cytokines and inflammatory mediators, including IL-1, IL-6, IL-8 and TNF-a, all of 
which are target genes of the classical NF-kB, p50/p65, transcription factor (Wan et al., 1997; 
Ascione et al., 2000; Zhang et al., 2004; Hinokiyama et al., 2006; Miyake et al., 2006; Suleiman 
et al., 2008; Miyake et al., 2014). In addition, to its role in co-ordinating acute and chronic 
inflammation in numerous cell types in the vasculature, NF-kB is also known to be 
mechanoresponsive (Lan et al., 1994; Bhullar et al., 1998; Lehoux et al., 2006). Consequently, it 
was hypothesised that acute high shear stress induces a pro-inflammatory response in vECs in 
vitro and in LSV ECs ex vivo, which is driven by NF-kB classical pathway activation and, when this 














3.2.1 ENDOTHELIAL CELL PRO-INFLAMMATORY RESPONSE TO ACUTE SHEAR STRESS IN 
VITRO  
3.2.1.1 AHSS ACTIVATED A PRO-INFLAMMATORY GENE PROFILE IN HUVECS 
To initially validate the model of pro-inflammatory acute shear stress, in vitro, fully confluent 
monolayers of HUVECs were exposed to AHSS at 12dyn/cm2 for 90 and 120 minutes. Relative 
mRNA transcript levels of four pro-inflammatory genes, MCP-1, IL-6, IL-8 and ICAM-1, were 
quantified in HUVECs exposed to AHSS and compared to the mRNA levels present in HUVECs 
maintained in static culture, using RT-qPCR. Significant increases of between 3- to 7-fold in 
relative levels of all four pro-inflammatory gene mRNA transcript levels were observed, at both 
time-points as a result of AHSS, compared to static controls (FIGURE 3.1.).  
 
 AHSS induced pro-inflammatory mRNA transcript profiles in HUVECs 
MCP-1, IL-6, IL-8 and ICAM-1 mRNA levels quantified by RT-qPCR from HUVECs exposed to 90 
and 120 minutes of AHSS (12dyn/cm2). mRNA levels were normalised to b-tubulin and expressed 
as a fold-change relative to static control. * indicates p<0.05, ** indicates p<0.01 vs. static 
control, One-way ANOVA followed by post-hoc pairwise comparisons with Bonferroni correction 
for multiple comparisons, n=6. 
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3.2.1.2 LOW SHEAR STRESS DID NOT INDUCE A PRO-INFLAMMATORY GENE PROFILE 
To further validate the pro-inflammatory effect of AHSS, fully confluent monolayers of HUVECs 
were exposed to acute low shear stress (ALSS) at 0.5dyn/cm2 for 90 and 120 minutes. Relative 
mRNA transcript levels of four pro-inflammatory genes, MCP-1, IL-6, IL-8 and ICAM-1, in HUVECs 
exposed to ALSS were then compared to the levels present in HUVECs maintained in static 
culture, by RT-qPCR. No significant increase in relative levels of all four pro-inflammatory gene 
mRNA transcript was observed, at either time-point, under ALSS, compared to static controls 
(FIGURE 3.2.). 
  
 ALSS did not induce pro-inflammatory mRNA profiles in HUVECs 
MCP-1, IL-6, IL-8 and ICAM-1 mRNA levels quantified by RT-qPCR in HUVECs exposed to 90 and 
120 minutes of ALSS (0.5 dyn/cm2). mRNA levels were normalised to b-tubulin and expressed as 
a fold-change relative to static control. One-way ANOVA followed by post-hoc pairwise 









3.2.1.3 AHSS INCREASED MCP-1 PROTEIN LEVELS 
Having established that AHSS, not ALSS, resulted in increased MCP-1, IL-6, IL-8 and ICAM-1 
mRNA levels, it was necessary to evaluate whether protein levels were also increased under 
AHSS exposure, at slightly later time-points than mRNA analysis to allow for protein translation. 
MCP-1 was chosen as a representative pro-inflammatory protein as its involvement in VGF, via 
monocyte recruitment to the endothelium and direct mitogenic effects on VSMCs, has been 
well-established (Stark et al., 1997; Schepers et al., 2006; Fu et al., 2012). As such, 
immunocytochemical analysis for MCP-1 was performed to determine whether the increased 
pro-inflammatory mRNA expression, in HUVECs exposed to AHSS, resulted in augmented protein 
production. HUVECs were exposed to AHSS at 12dyn/cm2 for 4 and 6 hours, then fixed and 
analysed by immunofluorescence. Mean arbitrary fluorescence intensity (AFI) of MCP-1 staining 
(red) was quantified in the whole cell using CellProfiler (FIGURE 3.3.A.) (sections 2.9.2. and 
2.9.3.). VE-Cadherin staining (green) was utilised as evidence of a confluent endothelial 
monolayer and therefore quantification was not required. 
Analysis revealed that basal levels of MCP-1 protein, in static control cells, were relatively low 
and expression was ubiquitously present throughout cells, though, most prominently at a 
distinct perinuclear site. However, following exposure to AHSS for 4 hours a significant increase 
in MCP-1 protein level was observed, compared to static controls (FIGURE 3.3.A. and B.).  By 6 
















 MCP-1 levels were increased in response to AHSS 
MCP-1 protein quantified by immunofluorescence in HUVECs exposed to AHSS for 4 and 6 hours, 
compared with static controls. 
A. Whole cell arbitrary fluorescence intensity (AFI) of MCP-1 staining by ICC and quantified 
by CellProfiler2.0. * indicates p<0.05, One-way ANOVA followed by post-hoc pairwise 
comparisons with Bonferroni correction for multiple comparisons, n=3. 
B. Representative images of MCP-1 protein detected by immunofluorescence, co-stained 
for VE-Cadherin (green), MCP-1 (red) and nuclei/DAPI (blue). Scale bars represent 15µm 


































3.2.2 PRO-INFLAMMATORY RESPONSE OF EX VIVO LSV ECs TO ACUTE SHEAR STRESS 
3.2.2.1 AHSS ACTIVATED MCP-1 IN HUMAN LSV ECs 
Once the pro-inflammatory response to AHSS was established in ECs in vitro, it was necessary to 
determine whether this response was corroborated in human LSV, ex vivo.  LSV sections resected 
from patients during CABG surgery were exposed to AHSS (as described in the methods (section 
2.7.)) using a flow apparatus or maintained in static conditions. Pro-inflammatory mRNA 
transcript levels were analysed by RT-qPCR. As with in vitro mRNA analysis of pro-inflammatory 
response, the four genes analysed were MCP-1, IL-6, IL-8 and ICAM-1. A significant increase in 
relative MCP-1 mRNA transcript levels was observed following exposure to AHSS for 120 
minutes, but not at 90 minutes (FIGURE 3.4.A.). No significant difference in the relative levels of 






 MCP-1 transcript levels were increased in LSV ECs within vein segments 
under AHSS, ex vivo 
Quantification of MCP-1, IL-6, IL-8 and ICAM-1 mRNA levels (A, B, C and D, respectively) in LSV 
ECs exposed to AHSS for 90 and 120 minutes, by RT-qPCR. mRNA levels were normalised to b-
tubulin and expressed as a fold-change relative to static control. * indicates p<0.05, One-way 









































































































































3.2.2.2 AHSS INCREASED LEVELS OF MCP-1 PROTEIN IN THE LSV ENDOTHELIUM 
Having observed a significant increase in MCP-1 mRNA transcript levels in LSV ECs following 120 
minutes exposure to AHSS and increases in protein levels of MCP-1 in vitro in responses to AHSS, 
levels of MCP-1 protein were evaluated using en face staining of the LSV endothelium (described 
in detail in 2.7.2. and 2.9.). Segments of fresh LSV were exposed to AHSS for 6 hours or 
maintained in static conditions. LSV segments were subjected to en face immunofluorescence 
analysis for MCP-1. Mean AFI of MCP-1 staining (red) was quantified in 3D using FIJI, which 
evaluated the highly localised MCP-1 staining found in the perinuclear regions of LSV ECs 
(Supplementary videos 1 and 2 show images in Z-stack and images with segmented objects, 
respectively). Whole cell MCP-1 immunofluorescence was not analysed, as in 3.2.1.3., owing to 
the discontinuous nature of the staining in en face prepared LSV. vWF co-staining (green) was 
used as an EC marker to identify the surface layer of cells as ECs. 
At baseline (static), MCP-1 levels in LSV ECs were very low and very few cells showed detectable 
levels of MCP-1 protein (FIGURE 3.5.A.). In contrast, intense perinuclear MCP-1 protein staining 
was observed almost ubiquitously after 6 hours of AHSS exposure (indicated by white arrows in 
FIGURE 3.5.B.). In agreement with data from ICC and RT-qPCR (sections 3.2.1.3. and 3.2.2.1., 
respectively), en face immunoanalysis revealed that MCP-1 was significantly increased following 
6 hours AHSS exposure in the LSV endothelium, compared with static control samples  (FIGURE 




















 AHSS exposure increased levels of MCP-1 in the LSV endothelium 
Total MCP-1 levels were quantified as mean arbitrary fluorescence intensity in the LSV 
endothelium following exposure to AHSS for 6 hours or maintenance in static conditions.  
A. Mean arbitrary fluorescence intensity of immunofluorescence for MCP-1 in en face 
prepared LSV endothelium, as calculated using FIJI/ImageJ. * indicates p<0.05; two-
tailed, two sample t-test, n=4. 
B. Representative maximum intensity projection (MIP) images of immunofluorescence for 
MCP-1 protein en face, co-stained for MCP-1 (red), vWF (green) and TO-PRO3/nuclei 
(blue). White arrows on MCP-1 panel indicate perinuclear MCP-1 protein within LSV ECs. 































3.2.3 NF-kB RESPONSE TO AHSS - IN VITRO  
3.2.3.1 AHSS ACTIVATED THE NF-kB CLASSICAL PATHWAY 
Having shown that vECs responded to AHSS with up-regulation of numerous pro-inflammatory 
markers, at the mRNA and protein level, both in vitro and ex vivo, the underlying mechanism of 
up-regulation was investigated. The four genes previously shown to be upregulated by AHSS are 
target genes of the transcription factor, NF-kB (p65), as such, it was selected as a potential driver 
of this response. In addition to this, NF-kB has a known role in inflammation regulation and as a 
mechano-stimulated transcription factor (Pahl, 1999; Lehoux et al., 2006).  
HUVECs were exposed to AHSS at 12dyn/cm2 for 30 and 90 minutes or maintained in static 
conditions. Cells were lysed into distinct cellular compartments, giving cytosolic and nuclear 
fractions. Analysis of these fractions by Western blotting revealed a significant, 3-fold increase 
in nuclear NF-kB levels comparative to static controls, following exposure to AHSS for both 30 
and 90 minutes (FIGURE 3.6.A. and C.). This was associated with a significant reduction in levels 
of cytosolic IkBa at both time-points, relative to static controls (FIGURE 3.6B. and C.). There 
were no significant changes in levels of cytosolic NF-kB, as seen in the representative blots (data 
















 AHSS activated NF-kB classical pathway 
Relative levels of nuclear NF-kB and cytosolic IkBa were quantified in fractionated cell lysates 
by Western blotting. Approximate molecular weights, in kDa, are indicated centrally, next to 
representative blots. * indicates p<0.05, ** indicates p<0.01, One-way ANOVA followed by post-
hoc pairwise comparisons with Bonferroni correction for multiple comparisons, n=5. 
A. Relative nuclear NF-kB protein level, normalised to stain free loading controls and 
expressed as a fold change relative to static. 
B. Relative cytosolic IkBa protein level, normalised to stain free loading controls and 
expressed as a fold change relative to static. 
C. Representative blots with complementary loading controls. Anti-clockwise from top left: 
nuclear NF-kB and loading control; nuclear and cytosolic LaminA/C; nuclear and 
cytosolic GAPDH; cytosolic NF-kB and loading control; cytosolic IkBa and loading 



































































3.2.3.2 AHSS ACTIVATION OF NF-kB TRANSCRIPTIONAL ACTIVITY 
Nuclear translocation of NF-kB and cytosolic degradation of IkBa are necessary, but often not 
sufficient, to induce transcriptional activation of NF-kB. Covalent modifications to the 
transcription factor enhance DNA binding and recruitment of co-factors required for complete 
transcriptional activation (Chen et al., 2004). As such, the transcriptional activity of NF-kB under 
AHSS and covalent changes to the transcription factor, between static controls and cells exposed 
to shear, were compared. HUVECs were either subjected to AHSS at 12dyn/cm2 for 30 and 90 
minutes or maintained in static conditions, after which, protein levels of phosphorylated NF-kB 
(phospho-NF-kB) at Serine residue 276 (Ser276), and transcriptional motif (kB) binding by  
NF-kB, were analysed.  
Western blot analysis and the ELISA-based DNA binding assay revealed low basal levels of 
phospho-NF-kB, and very little kB-binding in static controls, respectively. Following 30 minutes 
exposure to AHSS a small, but significant, increase in phosphorylation of NF-kB was observed, 
which decreased again by 90 minutes (FIGURE 3.7.A. and B.). This finding was supported by an 
increased binding of NF-kB to the kB binding motif after shear stress exposure for 30 minutes, 
which also reduced by 90 minutes to below basal levels (FIGURE 3.7.C.). Finally, these data 















 AHSS promoted transcriptional activation of NF-kB 
Relative levels of the phosphorylated form of NF-kB (Ser276) were detected by Western blot 
analysis and NF-kB DNA binding affinity to the kB oligonucleotide was examined an ELISA-based 
TransAm activity assay. * indicates p<0.05, One-way ANOVA followed by post-hoc pairwise 
comparisons with Bonferroni correction for multiple comparisons, n=3-6. 
A. Relative Phospho-NF-kB (Ser276) protein levels, normalised to stain free loading 
controls and expressed as a fold change relative to static.  
B. Phospho-NF-kB (Ser276) representative blot and stain free loading control. 
C. Relative binding affinity of NF-kB for the kB oligonucleotide, expressed as a fold change 
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3.2.4 NF-kB RESPONSE TO AHSS IN THE LSV ENDOTHELIUM - EX VIVO  
3.2.4.1 AHSS TRIGGERED NF-kB TRANSLOCATION LSV ECS 
Having shown that NF-kB is activated in venous ECs in vitro, in response to AHSS, NF-kB 
activation was evaluated in the LSV endothelium, using an ex vivo perfusion model. Briefly, 
segments of LSV were exposed to AHSS at 12dyn/cm2 for 30 and 90 minutes or maintained in 
static conditions. As in section 3.2.2.2, LSV segments were subsequently prepared for en face 
immunofluorescent analysis (Supplementary video 3 shows NF-kB immunofluorescent within Z-
stack images). To quantify nuclear translocation of NF-kB, mean AFI was evaluated in LSV EC 
nuclei only (red), in 3D, using Imaris (described in detail in 2.7.2. and 2.9.). Co-staining with vWF 
(green) was used to identify the surface layer of cells as ECs. 
In static conditions, nuclear NF-kB protein levels were low and very few EC nuclei appeared 
positive for NF-kB. AHSS exposure induced a significant increase in nuclear NF-kB translocation 
in LSV ECs after 30 minutes, which increased further after 90 minutes exposure, to over two-
fold greater than static, baseline levels (FIGURE 3.8.A.). This effect is clearly observed in the 
representative image at 90 minutes, where almost all nuclei are stained positive for NF-kB 
(FIGURE 3.8.B.). 
 AHSS induced NF-kB translocation in LSV ECs 
Mean arbitrary fluorescence intensity (MFI) of immunofluorescence for NF-kB protein was 
calculated in ECs from LSV samples exposed to 30 and 90 minutes shear stress or maintained in 
static conditions.  
A. Mean arbitrary fluorescence intensity calculated from volumetric analysis of LSV EC 
nuclei using Imaris software; * indicates p<0.05, ** indicates p<0.01, **** indicates 
p<0.0001, One-way ANOVA followed by post-hoc pairwise comparisons with Bonferroni 
correction for multiple comparisons, n=5. 
B. Representative MIP images of NF-kB protein detected by immunofluorescence, showing 
NF-kB localisation in LSV EC nuclei, co-stained for NF-kB (red), vWF (green) and 








































3.2.5 NF-kB INHIBTION AND vEC RESPONSE TO AHSS – IN VITRO 
3.2.5.1 PHARMACOLOGICAL INHIBITION OF NF-kB, AND RESPONSE TO TNF-a STIMULATION 
BAY11-7085 is a known, specific inhibitor of the NF-kB classical pathway, due to its targeted 
modulatory effects on the activation loop of IKK-b (of the IKK complex), which acts to prevent 
phosphorylation of IkBa and its dissociation from the p50/p65 NF-kB heterodimer (Pierce et al., 
1997). To validate BAY11-7085, the TNF-a induced gene response was assessed with and 
without the presence of the inhibitor in a dose-dependent manner.  The effect on NF-kB target 
gene expression was then measured using RT-qPCR for the same target genes as the original 
Pierce et al. paper; MCP-1, VCAM-1, E-Selectin and IL-8. HUVECs were pre-treated with 0.2% 
(v/v) DMSO-control (equivalent to maximal concentration of inhibitor) or varying concentrations 
of BAY11-7085 (1.25, 2.5, 5, 10 and 20 µmol/L) for one hour. Following pre-treatment cells were 
stimulated with 10ng/mL TNF-a for one hour. With the two highest doses (10 and 20µmol/L), 
there was a significant reduction in the mRNA levels of all four target genes following TNF-a 
stimulation (FIGURE 3.9.). As such, the highest dose of 20µmol/L was selected for use in all 
subsequent experiments in this thesis. 
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 BAY11-7085 prevented TNF-a induced gene response 
Quantification of MCP-1, VCAM-1, E-Selectin and IL-8 mRNA levels (A, B, C and D, respectively) 
in HUVECs pre-treated with DMSO control (BAY11-7085 0µmol/L) or increasing concentrations 
of BAY11-7085 prior to stimulation with 10ng/µL TNF-a for 1 hour, using RT-qPCR. mRNA levels 
were normalised to b-tubulin and expressed as a fold-change relative to DMSO control. * 
indicates p<0.05, ** indicates p<0.01, *** indicates p<0.001, **** indicates p<0.0001, One-way 
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3.2.5.2 BAY11-7085 PRE-TREATMENT REDUCED PRO-INFLAMMATORY RESPONSES TO AHSS 
IN VITRO 
Having shown both the induction of a pro-inflammatory response and activation of the NF-kB 
classical pathway in ECs under conditions of AHSS, it was hypothesised that inhibition of NF-kB 
activation would be associated with a reduction of the pro-inflammatory gene response under 
AHSS. HUVECs were pre-treated for one hour with 20µmol/L BAY11-7085 or 0.2% (v/v) DMSO 
control, prior to exposure to AHSS for 90 and 120 minutes, or maintenance in static conditions. 
The pro-inflammatory gene response was measured by the relative levels of MCP-1, IL-6, IL-8 
and ICAM-1 mRNA and expressed as a fold change from DMSO static control.  
mRNA levels of MCP-1, IL-6 and ICAM-1 in DMSO treated cells (controls) all significantly 
increased after 120 minutes AHSS, relative to DSMO treated static control, as in section 3.2.1.1 
(FIGURE 3.10.). BAY11-7085 was not able to reduce basal levels of mRNA compared to DMSO 
treated static control. However, under AHSS, mRNA transcript levels of all pro-inflammatory, 
except IL-8, genes were significantly reduced with NF-kB inhibition, compared with DMSO 











 NF-kB inhibition attenuated the pro-inflammatory mRNA response under 
conditions of AHSS 
Quantification of MCP-1, IL-6, IL-8 and ICAM-1 mRNA (A, B, C and D, respectively) in HUVECs 
exposed to 90 and 120 minutes of AHSS, with or without inhibition of NF-kB by BAY11-7085 pre-
treatment using RT-qPCR. mRNA levels were normalised to b-tubulin and expressed as a fold-
change relative to DMSO treated, Static control. * indicates p<0.05, ** indicates p<0.01 vs. 
DMSO control samples (equivalent time-points), $ indicates p<0.05 vs. DMSO static control, 
Two-way ANOVA followed by post-hoc pairwise comparisons with Bonferroni correction for 










3.2.5.3 ADENOVIRAL-MEDIATED OVEREXPRESSION OF IkBa 
In addition to pharmacological inhibition of NF-kB, a gene-therapy based approach was also 
adopted. This approach employed adenoviral-mediated overexpression using a wild-type form 
of the NF-kB, innate repressor, IkBa (WT-IkBa). The WT-IkBa adenoviral overexpression 
functions to sequester NF-kB in the cytosol and prevent its translocation, and thus, any 
activation of the pathway.  
Increasing concentrations of virus (pfu/mL) were used to determine the optimum infection 
efficiency in the overexpression of IkBa, compared to rAd66 empty viral cassette controls. 
HUVECs were infected with either WT-IkBa adenovirus or rAd66 control adenovirus at 3 
different concentrations (1´106, 1´107 and 1´108 pfu/mL), IkBa protein expression was then 
analysed by Western blotting.  Optimal overexpression of IkBa was achieved with the highest 
concentration of 1´108 pfu/mL WT-IkBa adenovirus, as such, this concentration was used for all 








 Overexpression of IkBa was achieved optimally with the highest dose of WT-
IkBa adenovirus 
IkBa protein levels were compared in HUVECs infected with WT-IkBa or rAd66 adenoviruses, 
by Western blot analysis. * indicates p<0.05, vs. rAd66 control samples (equivalent 
concentrations), Two-way ANOVA followed by post-hoc pairwise comparisons with Bonferroni 
correction for multiple comparisons, n=3. 
A. IkBa protein levels, normalised to stain free loading controls and expressed as mean 
pixel intensity within a given volume 
B. Representative IkBa blot and stain free loading control. Arrow with tail represents 


















































































3.2.5.4 OVEREXPRESSION OF IkBa ABROGATED AHSS-INDUCED PRO-INFLAMMATORY 
mRNA RESPONSE 
After validating adenoviral mediated over-expression of IkBa protein, HUVECS were infected 
with the WT-IkBa adenovirus and then exposed to AHSS at 12dyn/cm2 for 90 and 120 minutes 
and pro-inflammatory mRNA (MCP-1, IL-6, IL-8 and ICAM-1) levels were quantified by RT-qPCR.  
mRNA transcript levels of IL-6, IL-8 and ICAM-1 did not significantly increase under AHSS 
exposure in rAd66 control samples, despite a tendency to increase; only MCP-1 significantly 
increased significantly by 90 minutes (FIGURE 3.12.). Nevertheless, increase in levels of MCP-1, 
IL-6 and IL-8 were significantly blocked with adenoviral overexpression of WT-IkBa following 
exposure to 90 minutes AHSS. Of these three genes, only MCP-1 was significantly reduced 
following 120 minutes exposure to AHSS (FIGURE 3.12.). ICAM-1 was not significantly reduced 





















 Overexpression of IkBa prevented some pro-inflammatory gene responses 
under AHSS 
Quantification of MCP-1, IL-6, IL-8 and ICAM-1 mRNA (A, B, C and D, respectively) in HUVECs 
exposed to 90 and 120 minutes of AHSS, with or without inhibition of NF-kB by overexpression 
of WT-IkBa using RT-qPCR. mRNA levels were normalised to b-tubulin and expressed as a fold-
change relative to rAd66 static control. * indicates p<0.05, ** indicates p<0.01 vs. rAd66 control 
samples (equivalent time-points), $ indicates p<0.05 vs. rAd66 static control, Two-way ANOVA 














3.2.5.5 OVEREXPRESSION OF IkBa REDUCED MCP-1 PROTEIN LEVELS UNDER AHSS   
Having demonstrated that adenoviral-mediated overexpression of IkBa reduced mRNA levels of 
MCP-1 under AHSS, MCP-1 protein levels were examined by immunofluorescence, with and 
without WT- IkBa overexpression. HUVECS were infected as above and then exposed to 4 or 6 
hours of AHSS 12dyn/cm2, or maintained in static conditions, prior to detection of MCP-1 by 
immunofluorescence, as in section 3.2.1.3.  
MCP-1 protein levels in control-transfected cells tended to reduce with the application of AHSS, 
as opposed to increasing, as was observed in FIGURE 3.3. However, with overexpression of the 
NF-kB repressor, IkBa, there was a significant, transient reduction in MCP-1 protein levels at 4 
hours compared with rAd66 control, which had then tended to increase again by 6 hours, 
roughly to levels of control-transfected cells (FIGURE 3.13.A., B. and C.). 
 
 
 IkBa overexpression reduced MCP-1 under AHSS 
Quantification of MCP-1 arbitrary fluorescence intensity (AFI) levels in HUVECs exposed to AHSS 
with or without overexpression of WT-IkBa. 
A. Whole cell AFI of MCP-1 staining as assessed by immunofluorescence and quantified by 
CellProfiler2.0. * indicates p<0.05 vs. rAd66 control samples (equivalent time-point), 
Two-way ANOVA followed by post-hoc pairwise comparisons with Bonferroni correction 
for multiple comparisons, n=3. 
B. Representative images of MCP-1 protein detected by immunofluorescence in ECs 
infected with rAd66 empty viral vector adenovirus control; co-stained for VE-Cadherin 
(green), MCP-1 (red) and nuclei/DAPI (blue). Scale bars represent 15µm and apply to all 
images. 
C. Representative images of MCP-1 protein detected by immunofluorescence in ECs 
infected with WT-IkBa-overexpressing adenovirus; co-stained for VE-Cadherin (green), 


























































3.2.5.6 IkBa LEVELS INCREASED UNDER AHSS AFTER OVEREXPRESSION OF IkBa 
Inhibition of NF-kB dependent gene transcription was shown to be effective by two independent 
methods, both pharmacological and gene-therapy based, at the gene-expression and protein 
level. However, having also seen that MCP-1 reduction, by IkBa overexpression, was transient, 
The potentially transient nature of IkBa expression under flow was also evaluated by 
immunofluorescence. Experimental conditions were repeated as above (section 3.2.5.5.). Again, 
it was observed by a different method that, with adenoviral overexpression of WT-IkBa, 
expression levels of IkBa at static were significantly increased in comparison to rAd66 controls 
(FIGURE 3.14.A.). Interestingly, however, levels of IkBa actually increased following AHSS 
exposure with the WT-IkBa overexpressing adenovirus compared to both rAd66 controls and 
WT-IkBa static control (FIGURE 3.14.A., B. and C.) 
 
 
 IkBa overexpression increased levels of IkBa under AHSS 
IkBa arbitrary fluorescence intensity (AFI) levels in HUVECs exposed to AHSS with or without 
overexpression of WT-IkBa. 
A. Whole cell AFI of IkBa protein detected by immunofluorescence and quantified by 
CellProfiler2.0. * indicates p<0.05, ** indicates p<0.01, *** indicates p<0.001 vs. rAd66 
control samples (equivalent time-points); $ indicates p<0.05, $$ indicates p<0.01 vs. WT-
IkBa static control; Two-way ANOVA followed by post-hoc pairwise comparisons with 
Bonferroni correction for multiple comparisons, n=3. 
B. Representative images of IkBa protein detected by immunofluorescence in ECs infected 
with rAd66 empty viral vector control; co-stained for VE-Cadherin (green), MCP-1 (red) 
and nuclei/DAPI (blue). Scale bars represent 15µm and apply to all images 
C. Representative images of IkBa protein detected by immunofluorescence in ECs infected 
with WT-IkBa-overexpressing adenovirus; co-stained for VE-Cadherin (green), MCP-1 































































3.2.6 NF-kB INHIBTION AND vEC RESPONSE TO AHSS – EX VIVO  
3.2.6.1 BAY11-7085 REDUCED MCP-1 PROTEIN LEVELS UNDER AHSS IN LSV ECs 
Following the observation that NF-kB inhibition reduced the pro-inflammatory response to AHSS 
in ECs in culture, MCP-1 levels were investigated in LSV ECs exposed to AHSS, ex vivo. Upon 
collection of the vessel, appropriate length segments were cut, cannulated, and treated with 
50µmol/L BAY11-7085, or 0.5%(v/v) DMSO, for 3 hours prior to exposure to AHSS at 12dyn/cm2 
for 6 hours using the ex vivo perfusion model. Following shear stress exposure, MCP-1 protein 
levels were investigated in en face prepared LSV ECs using immunofluorescent analysis. 
Following 6 hours exposure to AHSS in DMSO control samples, MCP-1 protein levels were 
significantly increased in LSV ECs compared to both static controls (BAY11-7085 and DMSO). 
With BAY11-7085 pre-treatment MCP-1 levels under shear conditions were significantly 




 BAY11-7085 pre-treatment prevented increases in AHSS-driven MCP-1 
production in LSV ECs 
En face immunofluorescent analysis was used to investigate MCP-1 protein levels in LSV ECs 
exposed to AHSS, with and without pre-inhibition of NF-kB using BAY11-7085. 
A. Integrated fluorescence intensity of immunofluorescence for MCP-1 protein, calculated 
using FIJI; * indicates p<0.05, Two-way ANOVA followed by post-hoc pairwise 
comparisons with Bonferroni correction for multiple comparisons, n=4. 
B. Representative maximum intensity projection (MIP) images of immunofluorescence for 
MCP-1 protein en face, co-stained for MCP-1 (red), vWF (green) and TO-PRO3/nuclei 







3.2.7 NF-kB INHIBTION AND vEC PHENOTYPIC RESPONSE TO TNF-a AND AHSS  
3.2.7.1 BAY11-7085 REDUCED TNF-a-INDUCED LOSS OF VE-CADHERIN CELL-CELL CONTACT 
Permeability regulation to solutes and lipoproteins into the vascular wall is an integral property 
of a functional endothelium. To firstly address the relationship between NF-kB activation and 
endothelial integrity, TNF-a was utilised in order to initially interrogate the effects NF-kB 
activation and inhibition on endothelial monolayer structure and closely simulate the 
endothelial inflammatory activation under AHSS. Regulation of permeability is maintained by an 
intricate network of intercellular contacts situated in the cleft between endothelial cells, 
functioning as a selectively permeable barrier, amongst these homophilic cell-to-cell contacts 
VE-Cadherin is crucially important. Consequently, to examine endothelial barrier integrity, VE-
Cadherin contact attachment and organisation of the endothelial barrier structure, were 
assessed by immunofluorescence. This is used here as a surrogate, quantitative measure of   
cell-cell contact and quantification of gaps in the endothelial monolayer structure. 
HUVECs were pre-treated with 0.2% (v/v) DMSO-control or 20 µmol/L of BAY11-7085 for 3 
hours. Following pre-treatment, cells were stimulated with 10ng/mL TNF-a for 18 hours then 
subjected to immunofluorescence analysis for VE-Cadherin. Immunofluorescence analysis 
revealed that, in DMSO-treated controls, 18 hours of TNF-a stimulation significantly disrupted 
VE-Cadherin cell-cell contacts, as shown by the reduced percentage of objects (cells) in contact 
with neighbouring objects (cells). This disruption was rescued, however, with NF-kB inhibition 













 BAY11-7085 protected against TNF-a induced cell-cell contact 
Immunofluorescence for VE-Cadherin protein was used to quantify the percentage of ECs in 
contact with one another following chronic TNF-a stimulation, with and without a pre-
treatment to inhibit NF-kB, using BAY11-7085 or DMSO, respectively. 
A. Percentage of objects touching was calculated with immunofluorescence for VE-
Cadherin protein, using CellProfiler; * indicates p<0.05, two-tailed, two-sample t-test, 
n=3. 
B. Representative images of VE-Cadherin protein detected by immunofluorescence for 
both DMSO and BAY11-7085 treated ECs; co-stained for VE-Cadherin (green) and 




3.2.7.2 OVEREXPRESSION OF IkBa REDUCED AHSS-INDUCED LOSS OF ENDOTHELIAL CELL-
CELL CONTACT 
To address the contribution of NF-kB to VE-Cadherin cell-cell contact in the context of AHSS, 
IkBa was over-expressed via adenoviral-mediated delivery. Cells were then exposed to 4 or 6 
hours of HSS at 12dyn/cm2 or maintained in static conditions. Subsequently, HUVECs were 
analysed immunocytochemically as above (section 3.2.7.1.). 
Immunofluorescence analysis demonstrated in rAd66-infected control samples, that 4 hours of 
AHSS exposure significantly reduced the number of VE-cadherin positive EC cell-cell contacts, 
which subsequently recovered by 6 hours (FIGURE 3.17.A. and B.). Whereas, overexpression of 
IkBa prevented the flow-induced loss of EC cell-cell contact after 4 hours AHSS, relative to rAd66 
controls (FIGURE 3.17.A. and C.). 
 
 IkBa overexpression reduced AHSS induced disruption of endothelial barrier 
Immunofluorescence for VE-Cadherin protein was used to quantify the percentage of ECs in 
contact with one another following 4 and 6 hours exposure to AHSS, with and without 
adenoviral-mediated overexpression of IkBa. 
A. Percentage of objects touching was calculated with immunofluorescence for VE-
Cadherin protein, using CellProfiler; * indicates p<0.05 vs. WT-IkBa 4 hours; $ indicates 
p<0.05 vs. rAd66 static control, Two-way ANOVA followed by post-hoc pairwise 
comparisons with Bonferroni correction for multiple comparisons, n=3. 
B. Representative images of VE-Cadherin cell-cell contact detected by 
immunofluorescence in ECs infected with rAd66 empty viral vector control; co-stained 
for VE-Cadherin (green) and nuclei/DAPI (blue). Scale bars represent 15µm and apply to 
all images. 
C. Representative images of VE-Cadherin cell-cell contact detected by 
immunofluorescence in ECs infected with WT-IkBa-overexpressing adenovirus; co-
stained for VE-Cadherin (green) and nuclei/DAPI (blue). Scale bars represent 15µm and 


































3.2.7.3 EC ELONGATION UNDER AHSS IS ALTERED BY IkBa OVEREXPRESSION  
Elongation and increased ellipticity of ECs are considered a hallmark of arterial ECs, primarily 
resulting from prolonged exposure to high shear stress, whereas, venous ECs are generally much 
rounder in comparison (Aitsebaomo et al., 2008). Consequently, the shape of ECs was analysed 
as a marker of ‘arterialisation’ of vECs when NF-kB was inhibited through over-expression of 
IkBa, both under static and AHSS conditions. As in section 3.2.7.2, adenoviral mediated 
overexpression of IkBa was performed in HUVECs, prior to exposure to AHSS for 4 and 6 hours 
or maintenance in static conditions. Cells were then subjected to immunofluorescent analysis 
for VE-cadherin using CellProfiler. From this analysis, two features were obtained, the mean 
eccentricity and the mean major axis (longest) length of objects in an image. Major axis length 
simply refers to the length (in pixels) along the longest axis of a shape. Whereas, eccentricity 
refers to the flat- or round-ness of a shape and, as indicated in FIGURE 3.18.C., eccentricity (e) is 
calculated on a scale of 0 to 1, where e equal to 0 represents and 1 represents a line (though 0 
and 1 are degenerate cases). 
Elongation, represented by length of the major axis in number of pixels, was significantly 
increased in static conditions in WT-IkBa infected cells,  compared to rAd66 static controls 
(FIGURE 3.18.A., D. and E.). Following exposure to AHSS, EC elongation increased in both groups 
after 4 hours, to roughly similar levels, and, in both cases elongation was significantly increased 
relative to rAd66 static controls. Eccentricity, represented in FIGURE 3.18.C., however, was 
increased only after 6 hours of AHSS in both IkBa overexpression and rAd66 control groups and 
there was no difference observed between treatment groups, suggesting that it is AHSS, not  
NF-kB inhibition, which affects EC morphology (FIGURE 3.18.B.). No change was observed in 












































































































 AHSS, not IkBa overexpression, altered endothelial shape under flow 
Endothelial cell morphology characteristics under AHSS conditions with and without 
overexpression of IkBa; as shown by major axis length (A) and eccentricity (B and C).  
A. Endothelial elongation as a measure of the major axis length. * indicates p<0.05, ** 
indicates p<0.01, *** indicates p<0.001 vs. rAd66 static control; Two-way ANOVA 
followed by post-hoc pairwise comparisons with Bonferroni correction for multiple 
comparisons, n=3. 
B. Endothelial eccentricity. ** indicates p<0.01 vs. respective static controls; Two-way 
ANOVA followed by post-hoc pairwise comparisons with Bonferroni correction for 
multiple comparisons, n=3. 
C. Diagrammatic representation of eccentricity measures. 
D. Representative images of VE-Cadherin detected by immunofluorescence in ECs infected 
with rAd66 empty viral vector control; co-stained for VE-Cadherin (green) and 
nuclei/DAPI (blue). Scale bars represent 15µm and apply to all images. 
E. Representative images of VE-Cadherin detected by immunofluorescence in ECs infected 
with WT-IkBa-overexpressing adenovirus; co-stained for VE-Cadherin (green) and 











3.2.7.4 NF-kB INHIBITION REDUCED AHSS-INDUCED MONOCYTE ADHESION IN VITRO 
A hallmark of the vascular inflammatory response is the initiation of the adhesion cascade, 
leading to attachment of circulating monocytes to the endothelial surface and, ultimately, their 
extravasation into the vascular wall (Ley et al., 2007). Owing to the significantly reduced pro-
inflammatory response to AHSS seen with NF-kB inhibition, including diminished expression of 
MCP-1 and ICAM-1, the effect of NF-kB inhibition on the endothelial-monocyte interaction was 
evaluated. Prior to the onset of AHSS, cells were incubated for 3 hours with 20µmol/L BAY11-
7085, or 0.2%(v/v) DMSO, and 10µmol/L CM-DiI red fluorescent cell probe, concurrently. 
HUVECs were then exposed to pulsatile, laminar shear stress at 12dyn/cm2 and 1 hertz (Hz) 
frequency for 6 hours. Calcein-labelled (10µmol/L) THP-1 cells were then flowed over the 
activated ECs at a shear stress of 1dyn/cm2 and pulsatile frequency of 1Hz for 10 minutes whilst 
being imaged in real-time, using the Fluxion Bioflux microfluidic system.  THP-1 monocytic cell-
endothelial cell interactions were then evaluated in real-time (Supplementary video 4. shows 
adhesion in real time). A significant reduction of adhered monocytes was observed after AHSS 
when ECs were pre-treated with NF-kB inhibitor, BAY11-7085, as compared with the DMSO 




 BAY11-7085 pre-treatment reduced AHSS-induced monocyte adhesion 
Percentage of monocytes adhered to an endothelial monolayer was calculated by the number 
of adhered Calcein-labelled monocytes as a proportion of the total number of ECs, with and 
without treatment with NF-kB inhibitor. 
A. Percentage of monocytes adhered to ECs after 10 minutes of incubation, with and 
without BAY11-7085 pre-treatment. * indicates p<0.05; two-tailed, two sample t-test, 
n=3. 
B. Representative fluorescence images showing real-time monocyte (Calcein-AM, green 
fluorescent probe) adhesion to an endothelial monolayer (CM-DiI, red fluorescent 
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50µM 50µM 50µM Calcein-AM CmDiI Calcein-AM CmDiI Calcein-AM CmDiI 
BAY11-7085 
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3.2.7.5 NF-kB INHIBITION REDUCED AHSS-INDUCED MONOCYTE ADHESION TO THE LSV 
ENDOTHELIUM  
Having shown a reduction AHSS-induced monocyte adhesion in vitro, corroboration of this 
finding in an ex vivo setting with human LSV sections exposed to AHSS, was attempted. LSV 
segments were pre-treated with 50µmol/L BAY11-7085, or 0.5%(v/v) DMSO, for 3 hours. Vein 
sections were then exposed to AHSS for 6 hours using the ex vivo perfusion model. Following 
AHSS exposure, veins were then incubated in static conditions with THP-1 monocytes for 15 
minutes to permit adhesion. 
No difference was noted in static controls treated with BAY11-7085 or DMSO (FIGURE 3.20.A. 
and B.). However, exposure to AHSS significantly enhanced monocyte adhesion to the venous 
endothelial surface compared to levels observed in static controls and BAY11-7085 pre-






 BAY11-7085 retarded AHSS-induced monocyte adhesion to the LSV 
endothelium  
Calcein-labelled monocytes adhered to the LSV endothelium, both with and without NF-kB 
inhibition, were enumerated following exposure to AHSS or maintenance in static conditions 
and represented as a total number of monocyte adhered within a given area (0.6mm2) of the 
endothelium.  
A. Mean number of monocytes adhered to the LSV endothelium in 5 equally spaced images 
taken across the luminal surface. * indicates p<0.05; Two-way ANOVA followed by post-
hoc pairwise comparisons with Bonferroni correction for multiple comparisons, n=4. 
























































3.3.1 INTRODUCTORY SUMMARY 
Immediately after grafting of the LSV into the arterial circulation during CABG surgery, ECs 
become activated in response to altered haemodynamics, the precise impact of this on vein graft 
outcome still remains unclear. Many in vivo and ex vivo studies into IH development have 
focussed on reduction of lesion development at late time-points, and the early adaptive 
response of the vein graft is often overlooked or is considered to be of less consequence (Stark 
Stark et al., 1997; Shintani et al., 2002; Kwei et al., 2004; Jiang et al., 2009; Owens, 2010). An 
improved knowledge of the initiation and regulation of the acute response to grafting is 
therefore necessary for the design of therapies which may successfully affect both acute and 
chronic stages of vein graft pathogenesis. 
Activation of the endothelium requires the convergence of numerous elements of the adaptive 
and innate immune responses, from antigenic responses to secretion of chemokines (Pober et 
al., 2007; Gimbrone et al., 2016). It is recognised that such immune responses are triggered in 
the vein graft and many chemokines and cytokines have been implicated at various stages in the 
vein graft remodelling process (Ward et al., 2017). Several in vivo studies have explored the 
actions of MCP-1 and vein graft-monocyte interactions in the development of vein graft disease, 
both acutely and chronically (Weber et al., 1999; Roque et al., 2002; Schober et al., 2004; 
Schepers et al., 2006, 2006; Fu et al., 2012). Furthermore, Golledge et al. investigated the role 
played by biomechanical forces on acute endothelial activation in the vein graft. They were able 
to demonstrate that, after only 45 minutes of acute arterial, haemodynamic stimulation, there 
was an induction of ICAM-1 expression in the vein graft endothelium (Golledge et al., 1997; 
Golledge et al., 2000). However, the elements which drive the regulation of this inflammatory 
network acutely in the vein graft endothelium, are relatively poorly defined (Deshmane et al., 
2009). 
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Co-ordination of EC inflammatory activation is hugely complex and falls generally into two 
temporally distinct phases. Type I activation is a rapid response to harmful inflammatory stimuli, 
which is Ca2+-dependent and typically lasts less than 10 minutes, post-stimulus (Pober et al., 
2007). Whereas, type II activation is induced by more prolonged inflammatory stress stimuli; 
this type of activation, in response to biomechanical- or cytokine-induced stimulation, involves 
the convergence of MAPK, AP-1 and NF-kB signalling (Pober et al., 2007). These processes have 
been extensively characterised in cultured ECs and, as such, both types of EC activation have 
been observed in response to pro-inflammatory acute shear stress stimulation (Lan et al., 1994; 
Baeuerle et al., 1994; Khachigian et al., 1995; Bhullar et al., 1998; Ahmad et al., 1998; Dong et 
al., 2002; Hay et al., 2003). However, the actions of these distinct EC activation processes have 
been scarcely explored in the vein graft endothelium, where acute EC activation is known to 
occur. In this chapter, EC type II activation in the LSV endothelium in response to AHSS was 
investigated; focussing on the NF-kB classical pathway. 
3.3.2 PRO-INFLAMMATORY ACTIVATION OF vECs UNDER AHSS 
The development and characterisation of the endothelial inflammatory response to shear stress 
was established by many formative studies into mechanosensation and mechanotransduction 
(Dewey et al., 1981; Shyy et al., 1994; Nagel et al., 1994; Li et al., 1996; Gimbrone et al., 1997; 
Takahashi et al., 1997; Kim et al., 2001; Chiu et al., 2004; Li et al., 2005). In these studies, the 
pro-inflammatory transcriptional output of cytokines and adhesion molecules were used as 
surrogate markers for shear-activated ECs. In this chapter, known NF-kB target genes, MCP-1, 
IL-6, IL-8 and ICAM-1, were chosen as transcriptional markers of inflammation owing to their 
recognised roles in vein grafting and shear stress responsiveness (Pahl, 1999; Ascione et al., 
2000; Crook et al., 2000; Chiu et al., 2004; Schepers et al., 2006; Nguyen et al., 2016). Finally, 
MCP-1 was selected as the inflammatory marker to be examined in depth, as the chemokine has 
been relatively well established as partly causative in vein graft disease and, when the MCP-1 
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pathway is blocked, the potential implications for the resolution of IH are profound (Stark et al., 
1997; Roque et al., 2002; Schepers et al., 2006; Fu et al., 2012). In response to AHSS (at 
12dyn/cm2) for 90 minutes and 2 hours, transcript levels of all pro-inflammatory markers were 
increased in ECs in culture, consistent with previous studies (Resnick et al., 1995; Shyy et al., 
1994). Whereas ECs exposed to ALSS (at 0.5 dyn/cm2) did not up-regulate pro-inflammatory 
transcripts at either time-point. Thus, validating a venous, but not arterial, pro-inflammatory 
response to AHSS, and corroborating the formative mechanotransduction studies mentioned 
above.  
Following confirmation of a pro-inflammatory response to AHSS in venous ECs in culture, it was 
necessary to examine the same transcriptional response in LSV ECs ex vivo.  In the LSV, only 
transcript levels of MCP-1 were significantly increased after 2 hours exposure to flow.  The 
observed increased in MCP-1 increased at the transcript level in LSV ECs was also supported by 
augmented MCP-1 protein levels, following AHSS exposure for 6 hours. Schepers et al. 
demonstrated increased levels of endothelial MCP-1 and monocyte-endothelial interactions in 
a murine interpositional vein graft model, 6 hours after implantation of the vessel (Schepers et 
al., 2006). These concordant findings, from a human ex vivo model and murine in vivo model, 
support the hypothesis that it is early exposure to an altered haemodynamic environment which 
is the trigger for initiation of adhesion and inflammation (Schepers et al., 2006). However, levels 
of the other pro-inflammatory mRNA transcripts, IL-6, IL-8 and ICAM-1, did not increase by 120 
minutes, most likely due to the variability between samples. Increased experimental repeats are 
required in future experiments as the relative fold increase compared with static control was 
reasonably large. It is possible that these results may have been confounded by the analysis of 
a mixed population of vascular cells due to the EC RNA isolation method. Currently, no reliable 
method exists to directly isolate EC RNA from a vessel without mechanically removing the cells 
first, by trypsination, scraping or collagenase digestion and bead detection, which may affect 
gene expression (Jaffe et al., 1973; Vara et al., 2005; Luo et al., 2016). However, Nam et al. utilise 
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a method which allows the instant isolation of RNA from the intima, producing RNA largely from 
ECs (Nam et al., 2009). Although this technique is imperfect, owing to the extraction of intimal 
RNA, not solely EC RNA, it allows the immediate transcriptional state of the intima and ECs within 
it to be assessed. As such, the transcriptional response of the endothelium to AHSS, examined 
in the LSV, may have been influenced by the presence of a pre-existing neointima, containing 
diffuse VSMCs and fibroblasts (Wan et al., 2012; Prim et al., 2016). 
Further in vitro evidence of the acute nature of the pro-inflammatory response to shear showed 
that, after 4 hours of high shear, HUVECs had upregulated MCP-1 protein levels; a transient 
response which was lost in vitro by 6 hours. This was entirely in-keeping with a previous 
observation of a biphasic regulation of MCP-1 expression to shear stress, whereby transcript 
levels initially peaked after approximately 2 hours and reduced to below baseline levels by 4 
hours (Shyy et al., 1994). This initial spike, described by Shyy et al., was followed by a second 
increase in levels after 24 hours (Shyy et al., 1994). The potential reasons for this complex 
regulation may relate to the enhancer regions within the promoter of MCP-1, which contains 
multiple cis-regulatory elements acting to control transcription of the chemokine (Ueda et al., 
1994; Shyy et al., 1995; Shyy et al., 1995; Ueda et al., 1997; Yadav et al., 2010). Two NF-kB 
binding sites exist upstream of the transcriptional initiation site, which are both bound by  
NF-kB following cytokine-mediated activation via IL-1b or TNF-a (Ueda et al., 1997; Yadav et al., 
2010). Shyy et al. also discovered the existence of two further cis-regulatory elements in the 
proximal promoter region of MCP-1, which, under shear stress conditions (after 8 hours), are 
bound to by the trans-acting factor, AP-1 (Shyy et al., 1995). Furthermore, it has been proposed 
that cytokine-mediated MCP-1 expression requires the combined action of both NF-kB and AP-
1 (Martin, 1997). Consequently, the biphasic shear stress regulation of MCP-1 expression, at the 
transcript and protein levels, may be acutely driven by the action of NF-kB and later by the 
involvement of AP-1, between 8 and 24 hours (long after the latest time-points observed here).  
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3.3.3 ACTIVATION OF NF-kB UNDER AHSS 
Having established that ECs were activated under AHSS, both in vitro and ex vivo, the potential 
mechanism for the EC activation observed in the LSV endothelium was investigated. The NF-kB 
classical pathway was chosen owing to its established role in the initiation of EC activation in 
atherogenic lesions, as well as it’s shear stress responsiveness (Lan et al., 1994; Khachigian et 
al., 1995; Bhullar et al., 1998; Hay et al., 2003; Lehoux et al., 2006). Initially characterised in vitro 
by Lan et al., NF-kB is activated as quickly as 30 minutes after the onset of 12dyn/cm2 shear 
stress, with a peak at 60 minutes. These results are in concurrence with the data presented in 
this chapter, whereby a peak of NF-kB nuclear translocation at 30 minutes after AHSS onset and 
a reduction by 90 minutes were observed, though nuclear levels of NF-kB were still significantly 
above that of static controls at 90 minutes.  
The reciprocal reduction in IkBa levels due to degradation of the innate inhibitor are another 
hallmark of the activation of the NF-kB classical pathway (Hayden et al., 2008). This was 
confirmed by the findings within this chapter, in which a significant reduction in the cytosolic 
levels of IkBa was observed at both 30 and 90 minutes after AHSS onset. Previous studies have 
shown, however, that after an initial decrease, there is a recovery of IkBa expression to near 
baseline levels after 60 minutes exposure to AHSS (Bhullar et al., 1998). This disparity between 
the current data and previous findings may be explained by the use of ECs from different 
vascular beds and species. Bhullar et al. examined the IkBa response to shear stress with bovine 
arterial ECs (BAECs), as opposed to HUVECs used here. This discrepancy in the length of NF-kB 
classical pathway activation under shear stress, may be due to the fact that arterial ECs are 
innately less responsive to inflammatory, biomechanical stimulation compared with venous ECs. 
This most likely explains the rapid and transient degradation of IkBa in aECs compared to the 
more persistent reduction of IkBa in vECs (Aitsebaomo et al., 2008; Zakkar et al., 2011). 
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Translocation of NF-kB into the nucleus upon activation is necessary, but not always sufficient, 
to evoke a transcriptional response (Karin et al., 2000). Additional post-translational 
modifications are often required in order to reduce the affinity of interactions between NF-kB 
and the IkB proteins or to mount an effective transcriptional response (Hayden et al., 2008). 
Amongst the most important of the positive regulatory modifications is inducible 
phosphorylation. In response to AHSS, phosphorylation of NF-kB at Serine residue 276 (Ser-276) 
was observed transiently after 30 minutes and decreased again after 90 minutes AHSS exposure. 
Whereas, no change was observed in phosphorylation at Ser-536 (data not shown) under AHSS, 
Observation of covalent modification to NF-kB under AHSS provides further support to the 
conclusion that the NF-kB classical pathway is activated. As only one of the two primary 
phosphorylation sites were modified under flow, alteration of this site (Ser 276) provides a 
possible approach for the therapeutic targeting of flow-activated NF-kB in the vein graft 
endothelium.  
Ser-276 is located within the Rel Homology domain (RHD) of NF-kB (p65), which is directly 
responsible for DNA binding at the kB site and NF-kB subunit hetero-dimerisation (Hayden et 
al., 2008). Whilst the Ser-536 phosphorylation site is located within the transcription activation 
domain (TAD) of NF-kB, responsible for regulation of transcriptional activity (Christian et al., 
2016). Inducible phosphorylation at Ser-276 enhances the oligomerisation properties of NF-kB 
with transcriptional co-activators (p300 and CREB-binding protein (CBP)) and promotes the 
transcriptional response via a disruption of negative transcriptional regulator, Histone 
Deacetylase (HDAC1) complex (Chen et al., 2004). Phosphorylation at this site after 30 minutes 
exposure to AHSS is consistent with the observation that there was an increased binding affinity 
to the kB-oligonucleotide. A lack of phosphorylation at Ser-536, however, may be explained by 
the observation that Ser-536 phosphorylation has been linked to the resolution of inflammation, 
through promotion of increased NF-kB turnover and a subsequent reduction in its activity 
 136 
(Christian et al., 2016). It is entirely possible that, however, due to the rapid temporal dynamics 
of NF-kB covalent modifications, phosphorylation at Ser-536 may have been missed by  
time-point selection either before 30 minutes or between 30 and 90 minutes. Mutational 
analyses of both of these residues would be an intriguing follow up, to attempt to uncover 
whether the NF-kB response was abrogated under shear stress with one or both 
phosphorylation sites altered. 
Replication of the observations presented in formative studies by Bhullar et al. and Lan et al., in 
vitro, led to the development of a novel en face preparation method combined with novel 3D 
imaging and analysis in this chapter. This method was developed in order to interrogate NF-kB 
nuclear translocation, ex vivo, in the LSV endothelium. Using this technique, a significant 
increase in nuclear levels of NF-kB in LSV ECs under AHSS was apparent, following exposure for 
both 30 and 90 minutes. Nuclear translocation was more pronounced at 90 minutes in LSV ECs, 
compared with the observed 30 minutes, in vitro. This later NF-kB translocation in LSV ECs also 
supports the observation that NF-kB target gene transcript levels increase only after 2 hours, as 
opposed to 90 minutes in the in vitro setting. This provides the first evidence that NF-kB is 
activated in the LSV endothelium in response to the exposure to acute arterial haemodynamics 
and not, as Hinokiyama et al. suggest, in response to vein graft harvest and surgical preparation 
(Hinokiyama et al., 2006).  
3.3.4 NF-kB INHIBITION AND THE PRO-INFLAMMATORY RESPONSE 
Having established that NF-kB was activated, and MCP-1 levels were increased concurrently in 
the LSV endothelium following AHSS exposure, the proposed mechanism was then directly 
explored via inhibition of NF-kB before the onset of arterial flow, in vitro and ex vivo. Firstly, in 
vitro results showed that inhibition of NF-kB, both pharmacologically and using an adenovirus-
mediated gene delivery approach to overexpress IkBa (WT-IkBa), prior to shear exposure, 
prevented the subsequent transcriptional response of MCP-1 (as well as IL-6, IL-8 and ICAM-1). 
 137 
Furthermore, with WT-IkBa infection, there was a reduction in MCP-1 protein levels after 4 
hours of AHSS, an effect which was lost after 6 hours. Finally, the increase in MCP-1 levels at 4 
hours in rAd66 control samples was not observed as in untreated cells (as mentioned above). 
This may have been due to a heightened initial inflammatory response caused by the innate 
immune response induced by exposure to the adenoviral vectors (Gregory et al., 2011).  
In addition, these results were replicated in the LSV, ex vivo, whereby pre-treatment with an  
NF-kB inhibitor, significantly reduced MCP-1 protein levels to baseline after 6 hours exposure to 
flow. This observation was further substantiated, functionally, both ex vivo and in vitro; wherein, 
NF-kB pre-inhibition abrogated AHSS-induced monocyte adhesion to the venous endothelium. 
These data not only validate the mechanistic involvement of NF-kB in AHSS-driven 
inflammation, but also provide an exciting therapeutic target in the treatment of vein graft 
inflammation, as many pharmacological inhibitors of NF-kB are already approved for clinical use 
(Gilmore et al., 2006; Miller et al., 2010). Whilst NF-kB inhibition poses certain problems 
systemically, due to the pleiotropicity and homeostatic functions of the pathway, the harvest of 
autologous LSV uniquely sidesteps these problems, as it is possible to use the inhibitor locally, 
prior to implantation (Fraser, 2006). 
Several studies have shown that in vivo, local NF-kB inhibition, using a decoy cis-element (kB-
oligodeoxynucleotide(kB-ODN)), siRNA-mediated knockdown or alternative gene therapy 
approach to overexpress IkBa, limits IH development in multiple vein graft models (Shintani et 
al., 2002; Miyake et al., 2006; Wang et al., 2007; Miyake et al., 2007). These studies propose the 
same conclusions for their observed results; that it is the actions of NF-kB inhibition on reduction 
of medial VSMC proliferation and migration, which is ultimately responsible for reducing IH 
formation. The role of NF-kB in the acute adaptive response of the vein graft to its new 
environment is largely overlooked. Perhaps a combined approach of acute, rapid-acting, 
pharmacological NF-kB inhibition, locally in the LSV endothelium, in conjunction with a 
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prolonged, gene therapy approach, may represent a further improved therapeutic strategy in IH 
reduction. Therapeutic strategies to target the vein graft endothelium, in particular NF-kB, will 
be expanded upon in the general discussion 
In addition to the problems associated with systemic inhibition of NF-kB, there also exists the 
necessity for opposing apoptotic conditions between ECs and VSMCs in the vein graft. It has 
been suggested that, in vein graft VSMCs, NF-kB activation and anti-apoptotic functions, 
induced by cyclical stretch and oxidative stress, acts to counterbalance the action of pro-
apoptotic p38-MAPK pathways triggered under these conditions (Mayr et al., 2002; Lehoux et 
al., 2006; Castier et al., 2009; Pedrigi et al., 2017). Thus, when NF-kB is inhibited in vein graft 
VSMCs, the protective, anti-apoptotic role played by the transcription factor against cell death 
is lost and the balance is tipped in the favour of apoptosis. This indirect effect of increased 
apoptosis in VSMCs positively contributes to reduced intimal cell density and vessel wall 
thickness; features which are beneficial for IH reduction (Moore et al., 2001; Lehoux et al., 2006). 
In contrast, the loss of anti-apoptotic functions of NF-kB in ECs, and the potentially concomitant 
increased action of pro-apoptotic pathways, may be detrimental to the LSV endothelium, and 
thus, vein graft patency; which clearly represents a tentative aspect of this study. 
Owing to the extremely acute time-points addressed here and the investigation of the role of 
NF-kB in EC activation and inflammation, apoptosis was not focussed upon in LSV ECs in 
response to AHSS. Though it appears that, from observational, preliminary work performed, that 
even with a functionally active (and anti-apoptotic) NF-kB pathway, EC denudation may still 
occur under AHSS. This suggests that the anti-apoptotic activity of NF-kB is not sufficient to 
prevent EC loss. This gap in knowledge, regarding the potential mechanisms of denudation of 
the endothelium in the adaptive vein graft response, represents a substantial challenge in the 
field. Whether denudation is purely due to the mechanical effects of high shear stress, is a 
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mechanistic consequence of activation of the endothelium, is due to a loss of focal adhesions, 
or is to the result of loss of anti-apoptotic and protective pathways, remains to be answered.   
This question of the effect of NF-kB inhibition on later-stage EC preservation was loosely 
addressed by Miyake et al. in two in vivo models of IH. They propose that NF-kB inhibition helps 
to promote endothelial function and integrity in both a vein graft and balloon-catheter arterial 
injury model (Miyake et al., 2006; Miyake et al., 2014). However, direct damage to the native 
endothelium was not assessed in either model, either acutely or in a more prolonged context. 
Firstly, the murine vein graft was distended upwards of 300mmHg for 10 minutes in order to 
transfect the vessel with the kB-oligodeoxynucleotide (ODN); a pressure which induces 
considerable activation in the endothelium and stimulates considerable EC loss within 2 hours 
after grafting (Angelini et al., 1990; Hinokiyama et al., 2006; Miyake et al., 2006). In contrast, 
arterial injury models are known to almost entirely disrupt the integrity of the endothelium 
leaving very little intact endothelium (Xu, 2004). Both studies by Miyake et al., assessed 
endothelial properties of relaxation and endothelial coverage 28 days after implantation, 
making the results into EC function difficult to interpret, as the monolayer may have been 
primarily composed of new or re-endothelialised cells (Xu et al., 2003; Miyake et al., 2006; 
Miyake et al., 2014). Nonetheless, they also show an increase in active B-Cell lymphoma 2 (Bcl2) 
apoptosis regulator after 1 week in the remaining ECs, following treatment with kB-ODN 
containing nanospheres, suggesting that NF-kB inhibition in ECs may not affect the protective, 
anti-apoptotic functions of NF-kB (Miyake et al., 2014). This suggests that perhaps if the vein 
graft were to be minimally manipulated (i.e. not distended at high pressure as Miyake et al. did), 
then NF-kB inhibition may, in fact, be able to help preserve an intact monolayer upon grafting 
through promotion of NF-kB-driven Bcl2-mediated anti-apoptotic pathways. Thus, the 
preservation of a functional vein graft endothelium, with and without NF-kB inhibition, at later 
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time-points than those observed in the current results, and earlier than the 1 week in the study 
by Miyake et al., would certainly be of necessity for future investigations. 
NF-kB is known to have conflicting functions in both survival and inflammation, particularly 
under shear stress stimulation at acute and prolonged time-points (Partridge et al., 2007; Orr et 
al., 2008). It is not evident whether, beyond the acute phase of NF-kB inhibition proposed here 
(first 6 hours), there will be a delayed action of NF-kB or whether ECs will have been sensitised 
to, and therefore protected against, the effects of high shear stress. Prolonged exposure to high 
shear stress in ECs in culture, beyond 16 hours, activates cytoprotective transcriptional 
pathways, involving the switching of NF-kB to a pro-survival phenotype by PKCz and ERK1/2, as 
well as the activation of cytoprotective transcription factors, Nrf2 and Klf2 (Partridge et al., 2007; 
Boon et al., 2009; Mason, 2016). It may be possible that, beyond the initial activation phase in 
the vein graft endothelium (between 0-8 hours), ECs are sensitised to inflammatory flow 
stimulation and exhibit a cytoprotective phenotype. Certainly, data related to overexpression of 
IkBa, presented here, suggests that beyond the acute phase of shear exposure, there is a shift 
in EC phenotype towards protection and away from inflammation. This effect is shown 
particularly strongly by the transient disruption of endothelial cell-cell contacts, indicative of a 
leaky and activated endothelium, at 4 hours, and the subsequent recovery of the monolayer 
integrity by 6 hours, as well as the acute and transient response of MCP-1 to flow.  Sensitisation 
of ECs to pro-inflammatory shear and the switching of NF-kB to a pro-survival phenotype may 
also partially explain the observation of Miyake et al., whereby acute NF-kB inhibition led to 
later enhancement of Bcl2-mediated pro-survival pathways in the vein graft endothelium 
(Miyake et al., 2014).  
As with the studies of Miyake et al. mentioned above, the benefit of inhibiting acute EC 
activation at the transcriptional level, is that it provides a more comprehensive inhibition of 
inflammatory processes in vein grafts, despite the potential pleiotropic problems addressed 
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earlier. Prevention of the MCP-1 and adhesion cascade response represents a critical feature in 
the inhibition of vein graft inflammation. Many studies have linked the inhibition of the  
MCP-1/CC-motif receptor 2 (CCR2) axis with an improved outcome following induction of 
various injurious in vivo cardiovascular pathologies, from vein grafting to femoral artery wire-
induced injury (Schober et al., 2004; Schepers et al., 2006; Fu et al., 2012). Initially, in response 
to vascular injury, MCP-1 functions as part of the early, complex network of chemokines, 
including IL-8, RANTES, Fractalkine and CC-chemokine ligand 5 (CCL5), that drive the arrest and 
adhesion of circulating monocytes to the endothelium (Gerszten et al., 1999; Charo et al., 2004). 
This is then followed by a secondary surge in MCP-1 levels approximately 1 week after 
implantation of the graft (Stark et al., 1997; Schepers et al., 2006).  
Involvement of the MCP-1/CCR2 axis, and subsequent recruitment of monocytes, has been 
widely recognised as integral in the inflammatory-driven development of IH in the vein graft 
(Schober et al., 2004). Inhibition of the pathway, with a competitive CCR2 receptor antagonist 
(7ND-MCP-1) or homozygous CCR2-/- knockout rodent vein graft models, both show reductions 
in intimal thickness up to 28 days after surgery (Roque et al., 2002; Schepers et al., 2006). 
Interestingly, both of these studies highlight the importance of MCP-1 as a potent mitogenic 
stimulus for VSMCs and emphasise the significant impact that the paracrine actions of MCP-1 
have in IH development (Roque et al., 2002; Schepers et al., 2006). However, more recently, Fu 
et al. have suggested that alteration of the MCP-1/CCR2 axis in graft intrinsic VSMCs is of no 
bearing in enhancing VSMC proliferation or, ultimately, IH progression (Fu et al., 2012). They go 
further to suggest that it is, in fact, solely the depletion of this chemokine axis in graft extrinsic 
monocytes, which influences IH development in the vein graft (Fu et al., 2012). Despite this 
contention, if the MCP-1/CCR2 axis can be reduced, both acutely and chronically, in the vein 
graft endothelium via NF-kB inhibition, then monocyte adhesion, mediated by MCP-1 and a 
multitude of other related factors,  can altogether be prevented, thus preventing the ensuing 
mitogenic actions of invading monocytes (Weber et al., 1999). Thus, targeting of the MCP-
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1/CCR2 axis and other chemokines upstream, at the gene regulatory level, via NF-kB, represents 
a more wide-ranging therapeutic target in the prevention of initiation of the inflammation and 
ensuing deleterious monocyte adhesion. 
3.3.5 CONCLUSION 
The present chapter explored the pro-inflammatory activation of the venous endothelium under 
acute arterial shear stress, and the involvement of the NF-kB classical pathway in the co-
ordination of this response. In order to investigate these questions, parallel experiments were 
carried out in vECs, both in culture and in the LSV. It was initially established that AHSS induced 
a pro-inflammatory response in vECs in both settings, demonstrated by increased pro-
inflammatory cytokine production, monocyte adhesion and reduced cell-cell contacts between 
ECs. Most importantly, this study has, for the first time, identified NF-kB as a major orchestrator 
of this pro-inflammatory response to arterial haemodynamic stimulation in the vein graft 
endothelium. Further to this, it was shown that inhibition of this pathway prior to AHSS onset 
was sufficient to abrogate the pro-inflammatory response, both observationally and 
functionally. Taken together, these findings indicate the crucial role played by NF-kB in the 
control of the acute adaptive response of the vein graft endothelium to arterial flow, as well as 
providing insight into the pertinence of NF-kB inhibition in the prevention of this response. 
Moreover, several novel techniques to interrogate endothelial behaviour in cells in culture and 
human vessels have been developed to enable the analyses in this chapter, including analysis of 
monolayer structure in vitro and en face preparation and analysis of the endothelium in tissue. 
Further investigation as to the applicability of acute NF-kB inhibition in the treatment of vein 
graft inflammation ex vivo and in vivo, using the techniques developed in this chapter, would 
certainly help to elucidate the longer-term effects of such a therapeutic strategy in treatment of 





 EC involvement of the NF-kB classical pathway under acute shear stress 
Summary diagrams to represent findings from Chapter 3 to indicate the activity of NF-kB in ECs 
under (A) anti-inflammatory static conditions, venous shear stress or AHSS with NF-kB inhibition 
and (B) pro-inflammatory AHSS without NF-kB inhibition. Black block arrows represent pathway 
activation, black dotted arrows represent endothelial cell-cell contact organisation, green 









4. NRF2/KEAP1 RESPONSE TO ACUTE HIGH 







Underlying many vascular pathologies is a co-ordinated response to injury. Such injury can be 
commonly attributed to mechanical disruption of the vascular wall due to, for example, the 
actions of stenting and graft harvest, and deleterious haemodynamic stimulation, such as that 
following graft implantation or stent placement (Papaharalambus et al., 2007). Both of which 
induce damage to the endothelium, resulting in a loss of its homeostatic functions, causing 
increases in solute permeability, loss of vasomotor tone and promotion of leukocytic adhesion 
(Gimbrone et al., 2016). Loss of endothelial homeostasis in the vasculature is a feature 
implicated in the development of all vascular pathologies, and it may be partly explained by 
alterations of the balance from physiological redox regulation, towards pathological redox 
production (Brigelius-Flohe et al., 2011). Imbalance between the scavenging and oxidation of 
physiological gasotransmitters, such as NO and carbon monoxide (CO), and their conversion into 
oxygen radicals, including O2• - and ONOO-, is of paramount importance in the pathogenesis of 
atherosclerosis and IH (Jeremy et al., 2004; Mustafa et al., 2009; Brigelius-Flohe et al., 2011). 
Excess production of ROS enhances inflammation-induction through the indirect induction of 
cytokine production, and more directly induces dysregulation of VSMC apoptosis, proliferation 
and migration, monocyte adhesion and extravasation, and, ultimately, vascular lesion formation 
(Papaharalambus et al., 2007). 
Ordinarily, ROS generation is counterbalanced by the antioxidant and cytoprotective systems 
through redox regulation of transcription, either by Nrf2 and NF-kB (Brigelius-Flohe et al., 2011). 
Activation of these transcriptional systems is entirely context and stimulus dependent. However, 
their protective functions are primarily to promote enzymatic activities aimed towards 
elimination of deleterious ROS, co-operation to perform actions in drug and food metabolism, 
as well as removing harmful damaged proteins and DNA (Baird et al., 2011). Induction of 
signalling via the Nrf2-ARE system promotes the transcription of numerous enzymes involved in 
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responses to electrophilic, oxidative or heavy-metal based stresses, including GCLM, GCLC and 
NQO1. Though perhaps the most important of these in the cardiovascular system is HO-1, which 
is responsible for diverse vascular homeostatic functions from inflammatory protection to 
thrombosis prevention (Durante, 2010). Using an experimental murine model of interpositional 
vein grafting, HO-1-/- mice developed a significantly increased intimal area, rich with VSMCs, 
within 10 days post-operatively, which demonstrates  the anti-proliferative and cytoprotective 
dual actions of HO-1 upregulation in the vein graft wall (Yet et al., 2003). This anti-proliferative 
action of HO-1 in VSMCs is thought to be mediated directly through its ability to arrest VSMC 
cell-cycle progression. It is possible however, that this response was also partly the result of an 
indirect effect of improved endothelial protection and re-endothelialisation, induced by a lack 
of HO-1 activity in native ECs and endothelial progenitor cells (EPCs) (Durante, 2010).  
Numerous other studies have highlighted an anti-inflammatory role for Nrf2, independently, 
through the suppression of signalling via TNF-a, IL-1b, p38 and NF-kB (Chen et al., 2006; Zakkar 
et al., 2009; Ahmed et al., 2017). Within protected regions of the vasculature, typically exposed 
to prolonged laminar shear stress, vascular inflammation is generally at very low basal levels, as 
Nrf2 and Klf2 function synergistically to suppress inflammation through promotion of the 
antioxidant and cellular defence responses (Fledderus et al., 2008; Zakkar et al., 2009). Whereas, 
at atherosusceptible regions of the arterial tree, which are exposed to chronic disturbed or low 
shear stress, Nrf2 is suppressed and there is an increase in the activity of the p38-VCAM-1 axis 
(Zakkar et al., 2009). However, pharmacological induction of Nrf2 was able to partly reverse this 
deleterious, inflammatory effect of disturbed shear, suggesting that, in conjunction with other 
effectors and in certain biomechanical contexts, Nrf2 activation can prevent endothelial 
inflammation.  
The anti-inflammatory and mechanoresponsive potential of Nrf2 in the prolonged or chronic 
context, as well as it’s crucial role in cellular defence, have clearly been well defined previously 
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(Fledderus et al., 2008; Zakkar et al., 2009; Ali et al., 2009; Boon et al., 2009). As such, the activity 
and modulation of this pathway in ECs under acute biomechanical stimulation was assessed in 
this chapter. It was hypothesised that acute shear stress prevents activation of Nrf2 and its 
transcriptional response in vECs. Pre-activation of Nrf2 in vECs, prior to acute shear stress 
exposure, prevents a pro-inflammatory response and exerts a protective effect via an Nrf2 
transcriptional response. To investigate this, firstly, the activation of the Nrf2/Keap1 pathway in 
ECs subjected to AHSS was assessed, in vitro, by cellular localisation of the transcription factor 
and its innate repressor, Keap1. Secondly, endothelial expression of Nrf2 target genes and pro-
inflammatory genes were quantified in ECs subjected to AHSS with activation and inhibition of 








4.2.1 NRF2/KEAP1 RESPONSE TO AHSS 
4.2.1.1  AHSS UPREGULATED mRNA LEVELS OF NRF2 TARGET GENES      
To initially validate whether Nrf2 was activated in ECs as a result of exposure to AHSS, the levels 
of Nrf2 target, ARE mRNA transcripts were compared in HUVECs with and without exposure to 
AHSS. HUVECs were exposed to AHSS at 12dyn/cm2 for 90 and 120 minutes or maintained in 
static conditions. mRNA levels of HO-1, GCLM and NQO-1, were then quantified by RT-qPCR and 
expressed relative to static controls.  
A significant increase in the level of HO-1 and GCLM mRNAs was detected in ECs exposed to 
AHSS for both 90 and 120 minutes, relative to static; however, no significant difference was 
detected in NQO-1 (FIGURE 4.1.). 
 
  AHSS upregulated mRNA levels of HO-1 and GCLM, but not NQO-1. 
Relative mRNA levels of HO-1, GCLM and NQO-1 (A, B and C, respectively) from HUVECs exposed 
to AHSS for 90 and 120 minutes or maintained in static conditions. mRNA levels were normalised 
to b-tubulin and expressed as a fold-change relative to static control. * indicates p<0.05, One-
























































































4.2.1.2 AHSS UP-REGULATED HO-1 PROTEIN LEVELS 
With the establishment of increased mRNA levels of HO-1 and GCLM, it was necessary to 
investigate whether this effect was observed at the protein level. HO-1 was chosen as a 
representative protein of the Nrf2 response owing to the large (approximately 12-fold) increase 
in HO-1 mRNA levels following 90 minutes exposure to AHSS. Briefly, HUVECs were exposed to 
AHSS at 12dyn/cm2 for 4 and 6 hours, or maintained in static conditions, then HO-1 protein levels 
were quantified by Western blotting. 
At baseline (static), HO-1 protein levels were consistently low across samples and a significant 
increase in HO-1 protein level was observed after exposure to AHSS for 4 and 6 hours compared 
to static controls (FIGURE 4.2.). 
 
 AHSS increased HO-1 protein levels at 4 hours 
Relative protein levels of HO-1 were quantified by Western blotting from HUVECs exposed to 
AHSS for 4 and 6 hours, then normalised to stain free loading controls and expressed as a fold 
change relative to static. Approximate molecular weight in kDa is indicated adjacent to 
representative blots. * indicates p<0.05 vs. Static control, One-way ANOVA followed by post-
hoc pairwise comparisons with Bonferroni correction for multiple comparisons, n=3. 
A. Relative HO-1 protein level, normalised to stain free loading controls and expressed as 
a fold change relative to static 












































4.2.1.3  AHSS PROMOTED THE NUCLEAR EXPORT OF NRF2/KEAP1 
Having observed increased levels of Nrf2 target gene mRNAs in ECs following exposure to AHSS, 
the activation of the Nrf2 transcription factor was evaluated by examining Nrf2/Keap1 cellular 
localisation as an indicator of activity, using nuclear/cytosolic fractionation and Western 
blotting. The levels of Nrf2 and Keap1 were assessed in both the nuclear and cytosolic 
compartments of ECs exposed to AHSS at 12dyn/cm2 for 30 and 90 minutes and compared to 
ECs maintained in static conditions.  
Western blot analysis revealed that relative levels of Nrf2 in the cytosol remained constant at 
both time-points (FIGURE 4.3.A. and E.). In contrast, it was revealed that nuclear levels of Nrf2 
remained constant after 30 minutes of AHSS exposure and subsequently decreased after 90 
minutes (FIGURE 4.3.B. and E.).  Interestingly, an increase was observed in cytosolic levels of 
Keap1 after 30 minutes exposure to AHSS, which had reduced by 90 minutes (FIGURE 4.3.C. and 
E.). This was supported by the observation that Keap1 also appeared to be exported from the 
nucleus, as nuclear levels were decreased after exposure to AHSS for 90 minutes, relative to 
static (FIGURE 4.3.D. and E.).  Validation of the nuclear and cytosolic fractionation was 
demonstrated by very low levels of the nuclear marker, Lamin A/C, present in the cytosolic 








































































































































 AHSS triggers the nuclear export of Nrf2 and Keap1 
Relative levels of nuclear and cytosolic Nrf2 and Keap1 were quantified in cell fraction lysates by 
Western blotting. Detected bands were quantified by densitometry, normalised using band 
detected on stain free gel and expressed as relative protein level. Approximate molecular 
weights in kDa are indicated adjacent to representative blots. * indicates p<0.05, One-way 
ANOVA followed by post-hoc pairwise comparisons with Bonferroni correction for multiple 
comparisons, n=6. 
A. Relative cytosolic Nrf2 protein level, normalised to stain free loading controls and 
expressed as a fold change relative to static. 
B. Relative nuclear Nrf2 protein level, normalised to stain free loading controls and 
expressed as a fold change relative to static. 
C. Relative cytosolic Keap1 protein level, normalised to stain free loading controls and 
expressed as a fold change relative to static. 
D. Relative nuclear Keap1 protein level, normalised to stain free loading controls and 
expressed as a fold change relative to static. 
E. Representative blots with complementary loading controls. Anti-clockwise from top left: 
cytosolic Nrf2 and loading control; nuclear Nrf2 and loading control; nuclear and 
cytosolic LaminA/C; nuclear and cytosolic GAPDH; nuclear Keap1 and loading control; 
cytosolic Keap1 and loading control. Arrow with tail represents loading band analysed 










4.2.2 PHARMACOLOGICAL ACTIVATION OF NRF2 AND THE ENDOTHELIAL RESPONSE TO 
AHSS 
4.2.2.1 SULFORAPHANE INDUCED NRF2 TRANSLOACTION 
Sulforaphane (SFN) is an isothiocyanate found in cruciferous vegetables and is a known, potent 
activator of the Nrf2-driven antioxidant response (Thimmulappa et al., 2002). The compound 
has also been effectively shown to have anti-inflammatory functions against cytokine-induced 
inflammation (Garstkiewicz et al., 2017). The effect of SFN concentration on Nrf2 nuclear 
translocation was initially examined to validate the efficacy of the dosages to be used in this 
thesis. HUVECs were treated with varying concentrations of SFN (0.1, 0.5, 1, 2.5 and 5 µmol/L) 
or DMSO, at a standardised maximal concentration (0.05% (v/v)), for 4 hours. Following the  
4-hour treatment, cells were fractionated into compartments, as above, using a 
nuclear/cytosolic lysis approach. 
Significantly increased Nrf2 nuclear translocation, relative to DMSO, was observed with 5µmol/L 
of SFN, only (FIGURE 4.4.). However, for all subsequent experiments in this chapter, two 
concentrations were utilised, a low concentration of 1µmol/L, based on previous literature 








 Sulforaphane induced Nrf2 translocation at the maximal dosage. 
Quantification of protein levels of nuclear Nrf2 from HUVECs treated with varying 
concentrations of SFN (0.1, 0.5, 1, 2.5 and 5µmol/L) or DMSO (0.05% (v/v), represented 
graphically as 0), by Western blot analysis. Detected bands were quantified by densitometry, 
normalised using band detected on stain free gel and expressed as relative protein level. 
Approximate molecular weights in kDa are indicated adjacent to representative blots.  * 
indicates p<0.05, vs. DMSO, Two-way ANOVA followed by post-hoc pairwise comparisons with 
Bonferroni correction for multiple comparisons, n=3.  
A. Relative levels of nuclear Nrf2 protein normalised to stain-free loading control 
B. Representative Western blots of nuclear fractions for Nrf2 and nuclear protein, lamin 
A/C. Stain-free gel used as loading control. 
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4.2.2.2 SULFORAPHANE AND AHSS SYNERGISTICALLY ACTIVATED ARE-mRNA PRODUCTION 
Having observed increased levels of ARE-genes during the acute shear stress response, the same 
genes were assessed, with and without SFN pre-treatment at both high and low concentrations. 
HUVECs were pre-treated with 1 or 5µmol/L SFN or DMSO (0.05% (v/v)) for 4 hours, and 
subsequently exposed to AHSS for 90 and 120 minutes. After which time, relative mRNA levels 
of HO-1, GCLM and NQO-1 were measured by RT-qPCR. 
Treatment of HUVECs in static conditions with 5µmol/L SFN significantly increased the levels of 
HO-1 and GCLM, relative to DMSO controls, thus supporting the above observations of increased 
nuclear Nrf2 at this dosage. GCLM levels were also increased with 1µmol/L SFN treatment in 
static conditions, compared to DMSO-treated controls (FIGURE 4.5.). Levels of both HO-1 and 
GCLM in HUVECs treated with 5µmol/L SFN remained significantly greater than DMSO treated 
controls, following the application of 90 minutes of AHSS. As observed previously NQO-1 levels 
remained unchanged by exposure to AHSS, additionally SFN treatment had no effect on NQO-1 






 SFN pre-treatment increased levels of HO-1 and GCLM, which remained 
enhanced with AHSS exposure. 
Relative mRNA levels of HO-1, GCLM and NQO-1 (A, B and C, respectively) in HUVECs pre- 
treated with either 1 and 5µmol/L SFN, or DMSO (0.05% (v/v)), and subsequently exposed to 
AHSS for 90 and 120 minutes or maintained in static conditions. mRNA expression data were 
normalised to b-tubulin and expressed as a fold-change relative to DMSO static control. * 
indicates p<0.05, ** indicates p<0.01 and *** indicates p<0.001 vs. DMSO control (equivalent 
time-point); $$$ indicates p<0.001 vs. 1µM SFN (equivalent time-point), Two-way ANOVA 



























































































































4.2.2.3 SULFORAPANE DID NOT REDUCE PRO-INFLAMMATORY mRNA LEVELS IN ECs 
EXPOSED TO AHSS 
Many reports have linked SFN treatment to a reduction in inflammation following TNF-a 
induced activation of NF-kB and in other pro-inflammatory contexts (Kim et al., 2010; 
Garstkiewicz et al., 2017; Liu et al., 2017). Consequently, it was examined whether SFN pre-
treatment attenuated endothelial inflammatory responses in response to pro-inflammatory 
AHSS. As above in section 4.2.2.2, HUVECs were pre-treated with two concentrations of SFN (1 
and 5µmol/L) or DMSO (0.05% (v/v) – vehicle control) for 4 hours, and subsequently exposed to 
AHSS for 90 and 120 minutes. After which time, relative mRNA levels of MCP-1, IL-6 and IL-8 
were evaluated by RT-qPCR. 
As was observed in section 3.2.1.1., AHSS exposure led to a significant induction in mRNA levels 
of MCP-1, IL-6 and IL-8 at both time-points. Following AHSS stimulation at both time-points, 
1µmol/L SFN pre-treatment only significantly reduced levels of MCP-1 transcripts, relative to 
DMSO treated controls (FIGURE 4.6.A.). Pre-treatment with 5µmol/L of SFN was not able to 
reduce mRNA levels of pro-inflammatory genes, and, in fact, increased mRNA levels of IL-8 under 






 SFN pre-treatment did not consistently reduce pro-inflammatory levels as a 
result of AHSS 
Relative levels of MCP-1, IL-6 and IL-8 (A, B and C, respectively) from HUVECs pre-treated with 
either 1 and 5µmol/L SFN, or DMSO (0.05% (v/v)), and subsequently exposed to AHSS for 90 and 
120 minutes or maintained in static conditions. mRNA expression data were normalised to b-
tubulin and expressed as a fold-change relative to DMSO static control. * indicates p<0.05, ** 
indicates p<0.01 and **** indicates p<0.0001 vs. DMSO control (equivalent time-point); §§ 
indicates p<0.01 vs. 5µM SFN (equivalent time-point); $ indicates p<0.05 and $$$$ indicates 
p<0.0001 vs. 1µM SFN (equivalent time-point); # indicates p<0.05 and ## indicates p<0.01 vs. 
DMSO-treated, static control (utilised only as evidence of pro-inflammatory induction in DMSO 
controls), Two-way ANOVA followed by post-hoc pairwise comparisons with Bonferroni 



















































































































4.2.3 EFFECT OF ADENOVIRAL-MEDIATED OVEREXPRESSION OF NRF2 ON THE ENDOTHELIAL 
RESPONSE TO AHSS  
4.2.3.1 VALIDATION OF ADENOVIRAL-MEDIATED OVEREXPRESSION OF NRF2 PROTEIN  
In addition to pharmacological activation of Nrf2 with SFN, the effect of overexpression of Nrf2 
was also investigated. This gene-therapy based method of Nrf2 overexpression was used in 
order to increase the levels of Nrf2 protein, thus leading to a baseline increase in the activity of 
the pathway prior to the onset of AHSS. Adenoviral-mediated overexpression of a wild-type form 
of Nrf2 (WT-Nrf2), containing an EGFP tag to directly observe transfection was utilised. 
Increasing concentrations of virus (pfu/mL) were used to test the optimum infection efficiency 
in the overexpression of Nrf2, compared to rAd66 empty viral vector control and validate 
overexpression. Briefly, HUVECs were cultured in the presence of either 1x105, 1x106 or 1x107 
pfu/mL WT-Nrf2 adenovirus or 1x107 pfu/mL rAd66 control adenovirus for 18 hours. Following 
removal of the virus, cells were cultured for a further 48 hours and then Nrf2 protein expression 
analysed by Western blotting and fluorescence microscopy.  
Firstly, microscopy analysis of the GFP-tagged adenovirus showed that a more pronounced 
overexpression was achieved at with WT-Nrf2, compared with rAd66 controls and the lower 
concentrations of WT-Nrf2. The distribution also appeared to be generally homogenous 
throughout the whole cell (i.e. both nuclear and cytosolic), with the exception of a portion of 
cells (indicated with arrows), that appeared to contain high nuclear levels of the protein (FIGURE 
4.7.C.). Secondly, WB analysis showed significantly increased levels of Nrf2 in HUVECs 
transfected with WT-Nrf2 at concentrations of both 1x106 and 1x107 pfu/mL, compared with 
both rAd66 controls and 1x105pfu/mL WT-Nrf2; Nrf2 protein levels were over 20-fold higher 
with 1´107 pfu/mL WT-Nrf2, compared even with 1x106pfu/mL. As above in section 4.2.2.1., two 
concentrations (1x106 and 1x107 pfu/mL) were chosen to assess the activity-dependent effect 
of Nrf2 activation under shear stress. 
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 Validation of adenoviral-mediated overexpression of WT-Nrf2 
Relative Nrf2 protein levels were compared in HUVECs infected with WT-Nrf2 or rAd66 control 
adenoviruses at varying concentrations, by Western blot analysis and EGFP assessment viewed 
under fluorescent light. ** indicates p<0.01 and **** indicates p<0.0001, One-way ANOVA 
followed by post-hoc pairwise comparisons with Bonferroni correction for multiple 
comparisons, n=3. 
A. Relative levels of Nrf2 protein, quantified by WB analysis using SCBT Nrf2 h-300 
antibody, normalised to stain free loading control and expressed relative to rAd66 (107) 
control. 
B. Representative Nrf2 blot and stain free loading control. Arrow with tail represents band 
analysed. 
C. Representative images of EGFP-tagged WT-Nrf2 and RAd66 at varying concentrations, 
viewed under fluorescent light. Arrows show cells containing high nuclear levels of Nrf2, 
scale bars represent 15µm. 
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4.2.3.2 OVEREXPRESSION OF NRF2 AND AHSS INCREASED HO-1-mRNA LEVELS 
To further investigate the regulation of the antioxidant response under shear stress, and its 
promotion via Nrf2 activation, the effect of adenoviral-mediated overexpression of Nrf2 was 
examined under AHSS. HUVECs were infected for 18 hours with 1x106 and 1x107 pfu/mL of WT-
Nrf2 containing adenovirus, or rAd66 empty viral cassette control at 1x107 pfu/mL; cells were 
then cultured for an additional 48 hours. After exposure to AHSS at 12dyn/cm2 for 90 and 120 
minutes, relative mRNA levels of HO-1, GCLM and NQO-1 were evaluated by RT-qPCR. 
Owing to variability between independent experiments and data-points, only mRNA levels of 
GCLM were significantly increased in rAd66 controls under AHSS, HO-1 did not significantly 
increase as in section 4.2.1.1., though NQO-1 remained constant which is in concurrence with 
previous results. mRNA levels of all three antioxidant response genes were significantly 
increased following infection of HUVECs with 1x107 pfu/mL WT-Nrf2 compared to rAd66 control, 
under static conditions, providing further validation of Nrf2 protein overexpression. Only levels 
of HO-1 were maintained significantly above rAd66 control samples following application of 
shear stress, at both viral concentrations (FIGURE 4.8.A.). Levels of both GCLM and NQO-1 







 Overexpression of Nrf2 increased HO-1 mRNA levels both in static and flow 
conditions 
Relative mRNA levels of HO-1, GCLM and NQO-1 (A, B and C, respectively) from HUVECs infected 
with WT-Nrf2 containing- or rAd66 control-adenoviruses, at 1x106 pfu/mL and 1x107 pfu/mL, 
and subsequently exposed to AHSS for 90 and 120 minutes or maintained in static conditions. 
mRNA expression data were normalised to b-tubulin and expressed as a fold-change relative to 
rAd66 static control. * indicates p<0.05, ** indicates p<0.01 and *** indicates p<0.001 vs. rAd66 
control (equivalent time-point); $ indicates p<0.05, $$ indicates p<0.01 vs. 1x106 WT-Nrf2 
(equivalent time-point), Two-way ANOVA followed by post-hoc pairwise comparisons with 



















































































































4.2.3.3 DOSE DEPENDENT EFFECTS OF OVEREXPRESSION OF NRF2 ON AHSS-INDUCED PRO-
INFLAMMATORY mRNA LEVELS 
To attempt to corroborate the unexpected observations seen with SFN pre-treatment and 
exposure to AHSS, mRNA levels of pro-inflammatory genes were assessed with and without 
overexpression of WT-Nrf2 using two different adenoviral concentrations (performed as above 
in Section 4.2.2.5.).   
As expected, mRNA levels of all three pro-inflammatory genes increased following exposure to 
AHSS in control cells infected with rAd66. Firstly, MCP-1 levels were reduced following exposure 
to AHSS for 90 and 120 minutes with overexpression of WT-Nrf2, at 1x106pfu/mL, in concurrence 
with SFN pre-treatment at 1µM (FIGURE 4.9.A.). However, WT-Nrf2 overexpression at 
1x107pfu/mL induced a significant increase in levels of all pro-inflammatory genes in static 
conditions (FIGURE 4.9.A., B. and C.). This elevation was maintained under shear stress for both 
MCP-1 and IL-8; though levels of IL-8 were most pronounced of all pro-inflammatory genes after 






 Dose-dependent effect of Nrf2 overexpression of Nrf2 on inflammatory 
mRNA expression 
Relative mRNA levels of MCP-1, IL-6 and IL-8 (A, B and C, respectively) from HUVECs infected 
with WT-Nrf2 containing- or rAd66 control-adenoviruses, at low (1x106 pfu/mL) and high (1x107 
pfu/mL) viral concentrations, and subsequently exposed to AHSS for 90 and 120 minutes or 
maintained in static conditions. mRNA expression data were normalised to b-tubulin and 
expressed as a fold-change relative to rAd66 static control. * indicates p<0.05 and ** indicates 
p<0.01 vs. rAd66 control (equivalent time-point); $ indicates p<0.05, $$ indicates p<0.01 vs. 
1x106 WT-Nrf2 (equivalent time-point); # indicates p<0.05 and ## indicates p<0.01 vs. rAd66 
static control (utilised only as evidence of pro-inflammatory induction in rAd66 controls), Two-


























































































































4.2.4 EFFECT OF INHIBITION OF NRF2 ON THE ENDOTHELIAL RESPONSE TO AHSS 
4.2.4.1 VALIDATION OF DOMINANT-NEGATIVE NRF2 OVEREXPRESSION 
To date, the majority of Nrf2 research has focussed upon its role in cytoprotection, consequently 
there has been little cause for the development of Nrf2 inhibitors. As such, an adenoviral-
mediated overexpression approach was utilised here to attempt to inhibit Nrf2 under conditions 
of injurious AHSS stimulation.  To do so, an adenovirus encoding a dominant negative form of 
Nrf2 (DN-Nrf2) with an EGFP-tag, was used. The DN-Nrf2 adenovirus contains a mutant Nrf2 
which lacks the N-terminal transcriptional activation domain, but the C-terminal DNA-binding 
and heterodimerisation domains are retained (Kraft et al., 2004). It has been demonstrated that 
this DN-Nrf2 mutant protein competes with endogenous Nrf2 for both co-factor interactions 
and binding to the ARE-motif (Alam et al., 1999). 
Increasing adenoviral concentrations (1x105, 1x106 and 1x107 pfu/mL) of DN-Nrf2 were 
evaluated against a maximal concentration of rAd66 control adenovirus (1x107 pfu/mL). HUVECs 
were infected with adenoviruses for 18 hours and cultured for a further 48 hours, after which 
point ECs were analysed for levels of both DN-Nrf2 and endogenous Nrf2 by Western blotting, 
as well as for the presence of EGFP expression, by fluorescence microscopy. Infecting with 1x107 
pfu/mL of DN-Nrf2 significantly increased DN-Nrf2 expression and reduced endogenous Nrf2 
levels, compared to rAd66 viral controls (FIGURE 4.10.A. and B., respectively). Confirmation of 
this was observed by increased EGFP expression, viewed under fluorescent light, following 
infection with the maximal concentration of DN-Nrf2 (FIGURE 4.10.D.).  
 Adenoviral-overexpression of DN-Nrf2 reduced endogenous Nrf2 
Relative DN-Nrf2 and endogenous Nrf2 protein levels were compared in HUVECs infected with 
DN-Nrf2 or rAd66 control adenoviruses at varying concentrations, by Western blot analysis and 
EGFP assessment, viewed under fluorescent light. * indicates p<0.05 and ** indicates p<0.01, 
One-way ANOVA followed by post-hoc pairwise comparisons with Bonferroni correction for 
multiple comparisons, n=3. 
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A. Relative levels of DN-Nrf2 protein (lower band at 25-30kDa), quantified by WB analysis 
using SCBT Nrf2 c-20 antibody, normalised to stain free loading control and expressed 
relative to RAd66 (107) control. 
B. Relative levels of endogenous Nrf2 (upper band at 65kDa), quantified by WB analysis 
using SCBT Nrf2 c-20 antibody, normalised to stain free loading control and expressed 
relative to RAd66 (107) control. 
C. Representative Nrf2 (DN-form and endogenous) blot and stain free loading control.  
D. Representative images of EGFP-tagged DN-Nrf2 and rAd66 at varying concentrations, 
viewed under fluorescent light. Arrows show cells containing high nuclear levels of Nrf2, 
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4.2.4.2 DN-NRF2 REDUCED ANTIOXIDANT mRNA LEVELS 
Having observed increased antioxidant and pro-inflammatory mRNA transcripts under shear 
stress, following Nrf2 activation, it was essential to assess the levels of these genes with 
inhibition of Nrf2 and application of shear stress. To do this, HUVECs were infected either with 
DN-Nrf2 or rAd66 control virus (both at concentration of 1x107 pfu/mL) for 18 hours and 
subsequently cultured for a further 48 hours. HUVECs were then exposed to shear stress at 
12dyn/cm2 for 90 and 120 minutes and antioxidant mRNA (HO-1, GCLM and NQO-1) levels 
assessed by RT-qPCR. 
Levels of all antioxidant genes were significantly reduced, following the application of flow, in 
DN-Nrf2 overexpressing ECs relative to rAd66 controls (FIGURE 4.11.A., B. and C.). However, only 
NQO-1 levels were reduced under static conditions as well, suggesting that in the case of HO-1 
and GCLM, overexpression of DN-Nrf2 alone was not sufficient to prevent the basal Nrf2 













 DN-Nrf2 overexpression reduced antioxidant levels in ECs subjected to AHSS 
Relative mRNA levels of HO-1, GCLM and NQO-1 (A, B and C, respectively) from HUVECs infected 
with DN-Nrf2 containing- or rAd66 control-adenoviruses at 1x107 pfu/mL, and subsequently 
exposed to AHSS for 90 and 120 minutes or maintained in static conditions. mRNA expression 
data were normalised to b-tubulin and expressed as a fold-change relative to rAd66 static 
control. * indicates p<0.05 and ** indicates p<0.01 vs. rAd66 control (equivalent time-point), 
Two-way ANOVA followed by post-hoc pairwise comparisons with Bonferroni correction for 
















































































































4.2.4.3 DN-NRF2 HAD NO EFFECT ON PRO-INFLAMMATORY mRNA LEVELS FOLLOWING AHSS 
EXPOSURE 
HUVECs were infected with either DN-Nrf2 or rAd66 adenoviruses at 1x107 pfu/mL, as above, 
and following exposure to AHSS for 90 and 120 minutes, pro-inflammatory mRNA levels were 
assessed by RT-qPCR. levels of all three pro-inflammatory genes (MCP-1, IL-6 and IL-8) remained 











 DN-Nrf2 overexpression did not affect levels of pro-inflammatory genes 
Relative mRNA levels of MCP-1, IL-6 and IL-8 (A, B and C, respectively) from HUVECs infected 
with DN-Nrf2 containing- or rAd66 control-adenoviruses, at 1x107 pfu/mL, and subsequently 
exposed to AHSS for 90 and 120 minutes or maintained in static conditions. mRNA expression 
data were normalised to b-tubulin and expressed as a fold-change relative to rAd66 static 
control. Two-way ANOVA followed by post-hoc pairwise comparisons with Bonferroni correction 







4.3.1 INTRODUCTORY SUMMARY 
Maintenance of a quiescent, healthy endothelium in the grafted LSV is essential for the 
improvement of graft longevity (Osgood et al., 2014). The activation of ECs is a significant 
contributor to the early pathogenesis of intimal hyperplasia (Motwani et al., 1998). Within the 
vein graft, the loss of endothelial homeostasis contributes to the initiation of VSMC dysfunction 
and enhanced proliferation, as well as enhanced solute permeability and leukocyte recruitment 
to the vascular wall (Motwani et al., 1998; Owens, 2015).  
It is widely recognised that oxidative stress plays an integral role in the development of many 
cardiovascular pathologies, with lipid peroxidation and direct mitogenic effects of ROS being the 
most well-defined examples in vein grafts (Jeremy et al., 2004; Margaritis et al., 2012; Weaver 
et al., 2012). In dysfunctional ECs, the balance between the normal functions of oxygen-based 
gasotransmitters, such as NO and CO, and detrimental effects of ROS is tipped in the favour of 
the latter, thus reducing bioavailability of physiological gasotransmitters and subsequently 
reducing EC function (Shukla et al., 2012). This imbalance is further exaggerated in the venous 
endothelium by the arterial transposition of the LSV, as the endothelium has to adapt to 
approximately three-fold increases in oxygen concentration, relative to venous circulation 
(Joddar et al., 2015). As such, many clinical and experimental vein grafting studies have pursued 
therapeutic angles aimed at the reduction of ROS production, firstly, by antioxidants, such as 
vitamins C, D and E, and also NO-donating nitroaspirins (Jeremy et al., 1997; Antoniades et al., 
2003; Wan et al., 2007; Antoniades et al., 2010). However, these studies have thus far been 
disappointing, perhaps partly owing to the potential negative, pro-oxidant behaviours of many 
vitamins and the fact that up to 50% of CABG patients may develop aspirin resistance after 
surgery (Kempfert et al., 2009; Joddar et al., 2011). 
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Studies of statin-based therapies, in both CABG patients and ECs in vitro, have revealed the 
benefits of statins beyond their lipid lowering functions, particularly in relation to the stress 
response involved in vascular disease (Cannon et al., 2004; Antoniades et al., 2010; Antoniades 
et al., 2011; Kocarslan et al., 2016; Yuan et al., 2017).  Several studies have reported positive 
clinical outcomes and strongly indicate that the indirect, pleiotropic effects of statins on redox 
regulation can promote EC function and even enhance cell survival under injurious mechanical 
stimulation (Kulik et al., 2008; Ali et al., 2009; Margaritis et al., 2014). These cytoprotective, 
redox-based effects of statins have been suggested to function through both Klf2- and  
Nrf2-dependent mechanisms, via distinct actions on eNOS and HO-1, respectively (Ali et al., 
2009; Margaritis et al., 2014). Such studies into the effects of statins, and other antioxidant 
compounds, in the vein graft highlight the potential that endothelial cytoprotection and redox 
state modulation may play in the maintenance of a functional LSV endothelium following 
grafting.  
Despite evidence from the wider cardiovascular field regarding the importance of Nrf2-
dependent cytoprotection and antioxidant response, direct therapeutic targeting of Nrf2 has 
not been robustly evaluated. Dietary antioxidants, including sulforaphane and many vitamins, 
are commonly recognised as strong activators of the Nrf2-driven cytoprotective response. 
Consequently, these types of compounds represent exciting angles for treatment of vascular 
pathologies which are driven partly by oxidative stress, such as vein graft disease and coronary 
artery disease, owing to their ready availability and relative safety (Papaharalambus et al., 2007; 
Kulik et al., 2009; Bocci et al., 2015). Using an ex vivo LSV organ culture model, Joddar et al. were 
able to show that treatment with the dietary supplement and Nrf2 inducer, Protandim, reduced 
IH progression and limited VSMC proliferation through induction of catalase and HO-1 (Joddar 
et al., 2011). Increased HO-1 has also been associated with both direct and indirect effects on 
VSMC proliferation in a murine graft model, which may be explained partly  by the direct action 
on CO and the subsequent effect on VSMC cell cycle arrest, or as an indirect action of reduced 
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inflammation (Durante, 2010; Washington et al., 2017). However, such studies into the 
antioxidant/Nrf2 response in the vein graft observed primarily VSMC responses to Nrf2 
activation and seem to neglect the endothelial response, which remains of paramount 
importance to ultimate graft patency.  
The cytoprotection afforded to ECs by Nrf2 is seen primarily at atheroprotected sites of the 
arterial tree, where the endothelium is exposed to prolonged laminar shear stress; at such sites 
there are readily available reserves of NO and CO, whose production is vital for normal 
endothelial function at these sites (Lehoux et al., 2006; Boon et al., 2009). Both NO and CO are 
able to directly influence the production of one another by increasing levels of HO-1 and binding 
to eNOS, respectively (Washington et al., 2017). The transcriptional regulation of levels of both 
gasotransmitters relies on the concomitant actions between Klf2 and Nrf2, which convey true 
atheroprotection at portions of the vasculature exposed to prolonged protective shear 
(Fledderus et al., 2007; Ali et al., 2009).  
4.3.2 NRF2 TARGET GENE RESPONSE UNDER AHSS 
In the maintainance of bioavailability of NO and CO, the protective effect of mechanical 
stimulation in these endothelial regions is due also to the Nrf2-dependent induction of a number 
of antioxidant response element (ARE) genes (Satta et al., 2017). These ARE genes, collectively 
acting to promote cell survival, are composed primarily of two types, firstly, those that are 
induced and respond upon pro-oxidant insult; and, secondly, those that are responsible for 
maintaining basally low-levels of oxidants under non-stressed conditions (Nguyen et al., 2009). 
In this study, the ARE genes chosen (HO-1, GCLM and NQO-1) were all highly inducible in the 
stress-response, but also have basal protective functions, responsible for breaking the highly 
pro-oxidant heme into CO and bile products, production of antioxidant glutathione (GSH) and 
reduction of quinones, respectively (Nguyen et al., 2009; Franklin et al., 2009; Suzuki et al., 
2017). Somewhat unexpectedly, owing to the acuteness of the time-points evaluated, mRNA 
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and protein levels of HO-1 were increased following EC exposure to pro-inflammatory acute high 
shear stress. Acute shear exposure in vitro is recognised to increase ROS levels, which, in turn, 
is one of the primary inducers of ARE gene expression, which perhaps explains these 
transcriptional responses (Hsieh et al., 2009; Hsieh et al., 2014; Chistiakov Chistiakov et al., 
2017). There was no transcriptional response of NQO-1, however, which may indicate that there 
was not yet any protein/DNA damage induced by shear stress sufficient enough to promote an 
NQO-1 response, as increased levels have been observed following exposure to prolonged shear 
in HUVECs in culture, suggesting that NQO-1 transcription is mechanically responsive (Jaiswal, 
2000; Fledderus et al., 2008).  
Interestingly, however, there was no increase in nuclear Nrf2 levels following 30 minutes of 
shear stress and, in fact, after 90 minutes, there was a reduction in nuclear Nrf2. This is contrary 
to Hsieh et al.’s findings that, following 120 minutes of shear exposure, Nrf2 nuclear 
translocation increased in a PI3K, PKC and ROS-dependent manner (Hsieh et al., 2009). However, 
their study presents primarily representative Western blots (no graphical data) from only a 
single sample and, as such, the results must be interpreted with caution (Hsieh et al., 2009). 
Despite this discrepancy between transcriptional response and Nrf2 localisation, there was a 
significant nuclear export effect of Keap1 observed in the presence of acute shear stress, 
suggesting that the repressive control of Nrf2 by its association with Keap1 was diminished. 
Warabi et al. showed elegantly that shear stress exposure improves Nrf2 stability via lipid 
peroxidation by NOX action, and they propose that this, in turn, is able to oxidatively modify 
Keap1 to induce its dissociation from Nrf2 (Warabi et al., 2007; McSweeney McSweeney et al., 
2016). Additionally, covalent modification of Nrf2, by PKC-induced phosphorylation at Serine 
residue 40, is recognised to further stabilise Nrf2 and further supress its association with Keap1, 
which may possibly explain the increased ARE mRNA response, but reduced nuclear Nrf2 
(McSweeney et al., 2016). Taken together, these data and prior observations suggest that Nrf2 
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can be transcriptionally active, despite nuclear translocation not increasing beyond constitutive 
levels.  
4.3.3 NRF2 ACTIVATION AND THE PRO-INFLAMMATORY RESPONSE TO AHSS 
In addition to the cytoprotective role of Nrf2, activation of the transcription factor has been 
shown to reduce inflammation in several distinct contexts, including cytokine- and LPS-driven 
inflammatory stimulation (Kim et al., 2010; Ahmed et al., 2017). The action of HO-1 is 
responsible for a large proportion of the anti-inflammatory effects observed by activation of 
Nrf2 (Washington et al., 2017). Both directly, via NF-kB inhibition in a hepatic injury model or 
foam cell macrophages, for instance, or indirectly through the actions of its bile-based 
metabolites, biliverdin and bilirubin, which have been proposed to reduce TNF-a and ox-LDL 
driven endothelial dysfunction (Kawamura et al., 2005; Ahmed et al., 2017). However, to date, 
very few studies have investigated the role of Nrf2 in inflammation induced by mechanical 
stimulation. Zakkar et al. demonstrated that, at atheroprotected regions of the arterial tree 
exposed to prolonged, high, laminar shear stress, Nrf2 actions were responsible for the 
suppression of p38-VCAM1 signalling that was differentially observed in the atheroprone 
regions (Zakkar et al., 2009). It was also illustrated in this study that Nrf2 activation with 
sulforaphane (SFN) was able to reverse the pro-inflammatory, p38-VCAM1 response observed 
under conditions chronic, injurious shear stress, in vivo (Zakkar et al., 2009). Therefore, owing 
to its known mechano-responsivity and dual cytoprotective and anti-inflammatory actions, the 
effect of Nrf2 activation was evaluated here under pro-inflammatory AHSS stimulation, in vitro. 
To do this initially, the effect of SFN pre-treatment on the reduction of inflammation (shown by 
pro-inflammatory mRNA levels (MCP-1, IL-6 and IL-8)) under AHSS was assessed. The findings 
observed here were somewhat unexpected, it was hypothesised initially that activation of Nrf2 
would prevent AHSS-driven inflammation, at both the lower and higher concentrations of the 
compound (1 and 5µmol/L, respectively). However, at 1µmol/L, only MCP-1 levels were reduced 
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significantly under acute shear, relative to DMSO control; an observation which was 
corroborated with adenoviral-mediated overexpression of WT-Nrf2 at 1x106pfu/mL. In the 
context of acute shear-induced inflammation in the vein graft, introduced in chapter 3, this 
inhibitory effect of Nrf2 activation on MCP-1 mRNA level is encouraging, as MCP-1 is proposed 
to be one of the primary, inflammatory influences stimulating IH progression (Schepers et al., 
2006). What is of more concern, however, is the effect that Nrf2 activation, at a higher 
concentration (i.e. hyper-activation), either with gene-therapy based overexpression or a 
pharmacological method, has on inflammatory mRNA levels. Using both methods of Nrf2 
activation (SFN at 5µmol/L or WT-Nrf2 at 1x107pfu/mL) increased mRNA levels of IL-8 in static 
conditions, alone, and, following the application of acute shear, IL-8 levels remained significantly 
above control levels. Additionally, with WT-Nrf2 at 1x107pfu/mL, MCP-1 levels were also 
significantly increased, both in static and shear conditions. These data suggest that the anti-
inflammatory effects of Nrf2 activation were entirely dose- and context-dependent. 
4.3.4 NRF2 HYPER-ACTIVATION 
The importance of context regarding Nrf2 and inflammation is also highlighted in studies of the 
NLRP3 inflammasome. Typically, the NACHT, LRR and PYD domain containing protein 3 (NLRP3) 
inflammasome is responsible for protection of the host against bacterial infection by the 
induction of a specific type of cell-death, known as Pyroptosis, but also recognises and responds 
to a wide range of deleterious stimuli, including oxidative stress and ROS (Ahmed et al., 2017). 
In the acute context, activity of the NLRP3 inflammasome is advantageous in protection of a 
tissue against pathogenic infection; whereas, chronic inflammasome activation has been linked 
to atherogenesis and chronic kidney disease (Hennig et al., 2018). Recent studies associating 
Nrf2 activation with reduced acute inflammasome function observed that small-compound Nrf2 
activators, such as tert-butylhydroquinone (tBHQ), can negatively regulate inflammasome 
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expression and activity via Nrf2-dependent ARE induction, in a similar fashion to that seen with 
SFN stimulation (Liu et al., 2017; Garstkiewicz et al., 2017). 
Additionally, Nrf2 is able to directly regulate the expression of numerous pro-inflammatory 
genes, to the extent that the presence of an ARE-binding motif has been identified in the IL-6 
promoter region (Wruck et al., 2011; Kobayashi et al., 2016).  Despite the action of Nrf2 having 
largely been observed as anti-inflammatory (Kim et al., 2010; Ahmed et al., 2017), observation 
of Nrf2 crosstalk with the inflammasome and transcriptional targeting of genes positively 
involved in inflammation, appear to be the only limited evidence for the potential pro-
inflammatory actions of Nrf2. However, the mechanisms behind these potential pro-
inflammatory actions of Nrf2 remain unclear and are likely interconnected at multiple levels of 
regulation (Hennig et al., 2018). One possible explanation for the pro-inflammatory response 
seen with Nrf2 hyperactivation, could be related to overactivity of HO-1. In addition to MCP-1 
and IL-8, HO-1 mRNA levels were significantly increased in both 1x107pfu/mL of WT-Nrf2 and 
5µmol/L SFN, in static and shear conditions. When HO-1 is overactive, there is excessive 
production of CO, a by-product of haem catalysis, which, in physiological conditions, is a 
normally functioning gasotransmitter; however, when CO is produced in excess, it becomes 
severely pro-inflammatory, such as can be seen in cigarette smokers (Washington et al., 2017). 
It would be interesting, in future, to assess levels of HO-1 activity and CO production under AHSS, 
to pick apart further, this unexpected effect. 
Many studies into inflammation and Nrf2, however, have scarcely explored the negative role 
played by Nrf2 hyper-activation, such as has been done in investigations into the function of 
Nrf2 in cancer. In this growing body of evidence into the contradicting functions of Nrf2 in 
cancer, the paradox holds that, at physiological levels, Nrf2 protects tissues against tumour 
development through its cytoprotective, antioxidant actions; whilst, hyper-activation of Nrf2, 
seen in many tumours, in fact protects and favours tumour cell growth (Lau et al., 2008; Rotblat 
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et al., 2012; Sporn et al., 2012; Huang et al., 2015; Menegon et al., 2016). Although it is difficult 
to translate the oncogenic environment into a vascular one, nevertheless, the importance of 
experimental setting and quantity may be relevant. This paradox is highlighted by Sporn et al. 
with the Fumarate paradigm. Fumarate is a necessary, physiologic metabolite produced during 
the Krebs cycle which is both anti-carcinogenic and anti-inflammatory; it is also a potent Nrf2 
activator through sequestration of Keap1 and, at low doses, Fumarate inducing therapeutics, 
like many other Nrf2 activators, can prevent the development of tumours (Sporn et al., 2012). 
However, with the loss of the enzyme which catalyses the breakdown of Fumarate, Fumarate 
Hydratase, there are huge increases in intracellular Fumarate, Keap1 becomes continuously 
sequestered and Nrf2 is hyper-activated, leading to uncontrolled tumourigenesis (Sporn et al., 
2012). This unconstrained activity in cancer studies emphasises the importance of context and 
dose dependency with Nrf2 activation.  
As with the Fumarate paradigm, the results in this chapter concur, to some extent, with the 
dose-dependency notion in the activation of Nrf2. At the lower concentration of both WT-Nrf2 
and SFN, low level activation of Nrf2 prevented the increase in MCP-1 mRNA levels under flow. 
However, at the higher concentrations of both virus and compound, there was a significant pro-
inflammatory response, which, in certain cases, was increased further with the application of 
acute shear stress. This effect cannot be explained merely as one of cytotoxicity induced by high 
concentrations of virus or compound, as the vehicle control samples (DMSO and rAd66 empty 
vector adenovirus) used here were always at the maximal concentration. One other possible 
explanation for the observation of dose-dependent pro-inflammatory induction by Nrf2 hyper-
activation, may be related to the interaction between Keap1 and the NF-kB pathway. Lee et al. 
showed that Keap1, and its associated complex (Cul3 and Ring box 1 (Rbx1)), functions as an E3 
Ubiquitin Ligase for IKKb of the NF-kB classical pathway (Lee et al., 2009). This Keap1 complex, 
under basal conditions, functions to ubiquitinate IKKb and target it for degradation, thus limiting 
NF-kB driven pro-inflammatory signalling. Following depletion of Keap1, IKKb was stabilised and 
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accumulated, which led to an activation of NF-kB-dependent transcription, entirely 
independently of the actions of Nrf2 (Lee et al., 2009).  
The relevance of this to pro-inflammatory signalling activation in the present study is because, 
firstly, Keap1 was inactivated and depleted following acute shear stress exposure, shown by 
nucleo-cytosolic shuttling and an increase in ARE mRNA transcription. And secondly, both 
pharmacological and gene-therapy based methods of Nrf2 activation lead to a dysregulation or 
inactivation of Keap1 by ubiqutination or electrophilic alteration (Zhang et al., 2005; Hong et al., 
2005). Consequently, there is an unrestrained activation of Nrf2 in ECs exposed to flow when 
high levels of Nrf2 activation are already present, such as with high concentrations of SFN and 
WT-Nrf2. There may also be a de-regulation and loss of Keap1-dependent negative regulation 
of pro-inflammatory NF-kB signalling, as, in this experimental context, Keap1 is being ‘doubly’ 
inactivated, by both shear stress and Nrf2 hyper-activation. Together, these models, of excessive 
CO production or dysregulation of Keap1-dependent NF-kB signalling conservation, may partly 
explain why Nrf2 hyper-activation, with high concentrations of activators and acute shear stress, 
leads to an increase in inflammation. However, further direct evidence regarding Keap1 
inactivation and potential degradation on shear-induced inflammation would be necessary, in 
the presence of either NF-kB or proteasome inhibitors, to unequivocally create the association 
between Keap1 inactivation and NF-kB signalling under AHSS-driven inflammation and Nrf2 
hyper-activation. 
4.3.5 CONCLUSION 
The purpose of the current chapter was to evaluate the feasibility of activation of the 
cytoprotective, antioxidant signalling system, driven by Nrf2/Keap1, as a potential target in the 
resolution of EC inflammation induced by acute shear stress. There appears to be an antioxidant 
transcriptional response, of ARE genes, under acute shear that is regulated not by the 
translocation of Nrf2, but perhaps by the nuclear export of its repressor, Keap1. Furthermore, 
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activation of Nrf2 prior to shear stress exposure, induced divergent inflammatory responses 
dependent on the concentration of the activator, be it adenoviral or pharmacological. With low-
level Nrf2 activation, there appeared to be a degree of inflammation resolution in response to 
shear; whereas, when Nrf2 was hyper-activated, the opposite effect was observed, and 
inflammation was increased. Although the mechanism remains unclear, further investigation 
into the activity of HO-1 and dysregulation of Keap1-dependent NF-kB inhibition may certainly 
































 EC involvement of the Nrf2/Keap1 pathway under acute shear stress 
Summary diagrams to represent findings from Chapter 4 to indicate the activity of Nrf2 in ECs 
under (A) static conditions, (B) AHSS with low/no Nrf2 activation and (C) AHSS with Nrf2 
hyperactivation. Black block arrows represent pathway activation, green arrows represent 






5. GENERAL DISCUSSION 
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5.1 INTRODUCTORY SUMMARY 
Endothelial cell dysfunction and vascular inflammation are major contributors to vein graft 
failure. Vascular inflammation in vein grafts is driven by the innate immune response to a 
complex cytokine milieu, interactions with circulating leukocytes, generation of harmful oxygen 
radicals, vessel damage during surgical harvest and injurious haemodynamic stimulation (Sabik, 
2011). Following initiation of vascular inflammation, the effects of the arteriovenous 
transposition are transduced from the endothelium to VSMCs in the medial layer of the LSV. This 
partly contributes to enhanced VSMC migration and proliferation, ultimately leading to IH 
development, accelerated atherosclerosis and vein graft failure (Newby et al., 2000). The 
molecular mechanisms leading to the initiation of, and transition between, each distinct phase 
of vein graft disease, however, are not yet fully elucidated.  
When adapting to an entirely new haemodynamic environment, including approximately  
10-fold increased shear stress rates, the adaptive ability of the LSV endothelium is pushed 
beyond its innate capacity. This early, adaptive response to altered flow begins a harmful spiral 
towards endothelial inflammatory activation, defined by the induction of inflammatory 
cytokines and chemokines, loss of vasomotor tone, increase in permeability, monocyte adhesion 
and extravasation which can ultimately result in dysfunction of ECs and surrounding VSMCs, 
leading to the initiation of IH pathogenesis (Golledge, 1997; Kwei et al., 2004; Schepers et al., 
2006). However, to date, no therapeutic approaches have proved successful in preventing VGF, 
which may partly be due to the complexity of the physical and molecular environment that 
immediately ensues following implantation. The introduction of practices such as low-pressure 
vessel distension and the use of the ‘no-touch’ technique, have enhanced long term patency of 
vein grafts (Angelini et al., 1990; De Souza et al., 2002), but not eradicated graft failure. 
Interestingly, both of these surgical techniques focus primarily on the preservation of the 
endothelium prior to, and immediately after, implantation of the graft (Wise et al., 2016). 
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5.2 HYPOTHESES, AIMS AND IMPLEMENTATION 
This thesis aimed to investigate the vEC response to increased haemodynamic stimulation 
experienced by saphenous vein grafts by subjecting vEC to AHSS using in vitro- and tissue-based 
models. The focus of the investigations was into the role of two transcription factors, NF-kB and 
Nrf2, which were independently evaluated, to characterise their responses under AHSS and 
assess the therapeutic potential of their use as targets for the reduction of biomechanically-
induced EC inflammation. 
It was hypothesised, that the exposure of vECs to AHSS induces inflammation involving both pro-
inflammatory actions of NF-kB and inactivation of the protective Nrf2 pathway. And secondly, 
that independent inhibition of NF-kB and activation of Nrf2 will prevent the vEC  
pro-inflammatory response to AHSS. 
Two parallel studies were employed to test these hypotheses. Firstly, in vitro and ex vivo models 
of AHSS, using HUVECs and human LSV respectively, were utilised to determine the involvement 
of NF-kB in AHSS-driven inflammation. Subsequently the potential of NF-kB inhibition as a 
prevention for acute vein graft inflammation was investigated. Secondly, the activity of the 
Nrf2/Keap1 pathway in the adaptive shear response was explored in HUVECs subjected to AHSS, 






5.3 NF-kB PATHWAY INVOLVEMENT IN vEC ACTIVATION 
Initially, it was necessary to validate several previous formative mechanotransduction studies 
by investigating whether, in the model used here, vECs exposed to AHSS up-regulated pro-
inflammatory chemokine and cytokines (Dewey et al., 1981; Shyy et al., 1994; Davies, 1997; Chiu 
et al., 2004; Chiu et al., 2011). Initial results corroborated these studies, showing that AHSS 
increased the levels of a number of pro-inflammatory genes (MCP-1, IL-6, IL-8, ICAM-1) at the 
transcript and protein levels, in both vECs in culture and in the LSV endothelium, as shown by 
en face imaging methods. When addressing the potential involvement of NF-kB in the co-
ordination of this pro-inflammatory response to AHSS, it was demonstrated that NF-kB was 
activated, and translocated to the nucleus, as quickly as 30 minutes after the onset of AHSS in 
vitro and ex vivo. Next, a causative link between these two elements was investigated. Using 
pharmacological and adenoviral-based approaches, it was shown that the pro-inflammatory 
response to shear stress was abrogated, in vitro and in human LSV ECs by the inhibition of the 
NF-kB classical pathway. This observation was also substantiated in functional assessments of 
endothelial inflammation, whereby NF-kB inhibition was able to reduce AHSS-driven 
endothelial-monocyte interaction and rescue AHSS-induced disruption of EC cell-cell contacts, 
which provided additional and functional evidence for the involvement of NF-kB inhibition in 
vein graft inflammation. These findings suggest a critical role for the NF-kB classical pathway in 
acute vein graft inflammation caused by AHSS and suggest that inhibition of this pathway offers 
the potential to reduce endothelial inflammation under such conditions.  
Endothelial monolayer integrity and permeability represent a critical feature which must be 
regulated in the dysfunctional vein graft endothelium. It is widely reported that acute shear 
stress triggers significant changes in permeability to albumin, modified-LDL and dextran-based 
solutes across the endothelial barrier, as quickly as one hour after exposure; an effect which is 
lost after chronic shear exposure when the endothelial barrier has ‘strengthened’ again (Jo et 
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al., 1991; Warboys et al., 2010; Tarbell, 2010). Here, it was demonstrated that the in vitro 
inhibition of NF-kB prevented shear stress-induced disruption of EC cell-cell contact after four 
hours, albeit by a surrogate measure of VE-Cadherin adherens junction (AJ) structure. EC barrier 
integrity of controls also recovered to equivalent levels to those observed in cells with NF-kB 
inhibition, which supports the concept of a transient reduction in shear-induced permeability 
proposed by Warboys and colleagues (Warboys et al., 2010). 
These findings, regarding the role of NF-kB in vein graft EC inflammation, illustrate the rapid and 
transient nature of the process when induced by acute increases in shear stress. Observations 
of MCP-1 protein expression under flow at six hours, transient MCP-1 reduction with NF-kB 
inhibition and transitory endothelial barrier disruption, all highlight the fact that the acute 
period immediately after flow onset is vital to maintaining a mostly functional endothelium. 
However, the ex vivo evidence presented here suggests that this transitory inflammation occurs 
slightly later in the LSV endothelium ex situ, and perhaps this will be later still in the in vivo 
setting. This tight window of opportunity, whereby inhibition may be vital to prevent an EC 
inflammatory response, appears to lie between 0-4 hours and 0-6 hours, in vitro and ex vivo, 
respectively. These findings in the LSV offer some insight into the critical temporal nature of this 
acute inflammatory period after arteriovenous transposition, highlighted by Pearce et al. and 
Golledge et al. over two decades ago (Pearce et al., 1985; Golledge, 1997). In addition to the 
timing of EC inflammation in the vein graft, these findings also elucidate a possible mechanism 
behind vein graft EC activation and offer a potential therapeutic target for pharmacological 
modulation. However, further investigation into the temporal dynamics of acute inflammation, 
and its progression to a more chronic response, would help reveal more about the transience of 
endothelial inflammation in the context of numerous other inflammatory factors and the length 
of NF-kB inhibition necessary to achieve effective inflammatory reduction.  
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In the future, local pre-treatments of the LSV immediately upon harvest may offer an exciting 
therapeutic possibility. This is particularly pertinent when inhibiting NF-kB, as the pathway plays 
critical and hugely pleiotropic roles throughout various tissues of the body (Lawrence, 2009). As 
such, the local method of pre-treating solely the vessel avoids the possible complications 
associated with systemic NF-kB inhibition in vivo, such as disruption to homeostatic and normal 
cell cycle functions (Fraser, 2006). Alternatively, if longer term NF-kB inhibition is necessary to 
prevent neointimal formation, as Miyake et al. suggest, a dual therapeutic approach could be 
adopted, the in-situ graft pre-treatment, prior to implantation may be performed first; and, if 
necessary, drug-eluting nanoparticles, targeted to adhesion molecules (ICAM-1 or VCAM-1) for 
instance, may also be used to specifically act upon the dysfunctional endothelium (Arruebo et 
al., 2007; Yang et al., 2013).  
Finally, gene-therapy approaches may also be utilised for localised inhibition of the vein graft 
upon harvest (George et al., 2011; Wan et al., 2012). The use of recombinant adenoviruses, 
however, triggers adaptive immune responses. Thus, the use of helper dependent adenoviruses, 
lacking viral coding sequences may represent a viable option when trying to limit immune 
responses and induce longer expression of the transgene (Vetrini et al., 2010). This approach, 
combined with the pre-treatment, would provide acute and prolonged NF-kB inhibition 
throughout the graft, thus preventing NF-kB induced mitogenic effects seen in neointimal 
lesions in vivo in the prolonged context (Miyake et al., 2006; Vetrini et al., 2010; Miyake et al., 
2014).  
5.4 NRF2 PATHWAY INVOLVEMENT IN vEC ACTIVATION 
In a parallel study, the involvement of another transcription factor, Nrf2, in response to pro-
inflammatory AHSS was assessed. Initially, the activation of Nrf2 target (ARE) genes was 
examined under AHSS in vECs in vitro, which revealed an increase in the mRNA levels of ARE 
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genes, HO-1 and GCLM, and HO-1 at the protein level. This led to the investigation of the activity, 
by cellular localisation, of both Nrf2 and its repressor, Keap1. Interestingly, and despite the 
increases in ARE gene transcript levels, Nrf2 appeared to be exported from the nucleus following 
90 minutes of AHSS exposure. This nuclear export of Nrf2 was associated with nuclear export 
and subsequent cytosolic increase of Keap1 following 30 minutes AHSS exposure. Together, 
these transcriptional and cellular localisation data suggest that the Nrf2 pathway is acutely 
activated by AHSS, perhaps by a dissociation from Keap1 within the nucleus. In the light of these 
results, it was examined whether exogenous activation of Nrf2, before EC exposure to AHSS, 
could reduce the inflammatory response induced by AHSS. Results showed that, high level 
activation (or hyperactivation) of Nrf2, using either a pharmacological or adenoviral-mediated 
approach, greatly increased the levels of pro-inflammatory mRNA transcripts in vECs subjected 
to AHSS. Whereas, low level activation of Nrf2 was only able to reduce mRNA transcript levels 
of MCP-1. Moreover, the inhibition of the Nrf2 pathway, using a dominant-negative adenovirus, 
had no effect on pro-inflammatory mRNA transcript levels, despite reducing transcript levels of 
ARE genes, HO-1, GCLM and NQO-1, in vECs subjected to AHSS. These results represent a new 
insight into the activity of Nrf2 in vECs exposed to AHSS and suggest that the pathway may play 
a role in acute vascular inflammation. However, further investigation into the effects that Nrf2 
hyperactivation in vECs exposed to various inflammatory mechanical stimuli is necessary to 
substantiate this. 
Investigating the regulation and activation of the cytoprotective Nrf2 pathway under acute 
arterial shear stress, surprisingly revealed a discrepancy between the ARE-gene response and 
Nrf2 localisation following shear stress exposure. Under pro-inflammatory AHSS stimulation, 
HO-1 was increased, indicative of the ARE-gene response, at both the mRNA transcript and 
protein level by two and four hours, respectively. Unexpectedly, this was not associated with 
increased nuclear translocation of Nrf2, but, in fact, an increased nuclear export of the Nrf2 
repressor, Keap1. Despite this, transcriptional regulation of HO-1, however, is not necessarily 
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attributable to Nrf2; there is some evidence that NF-kB also plays a role in the control of HO-1 
regulation, due to its dual roles in inflammation regulation and stress-response (Durante, 2010). 
In contrast, GCLM, which is also upregulated here at the transcript level under AHSS, is regulated 
primarily by the actions of Nrf2 and the gene does not contain a kB oligonucleotide consensus 
sequence; though, interestingly, transcriptional regulation of the catalytic subunit is controlled 
by both TFs (Dickinson et al., 2004). The fact that GCLM is transcribed almost exclusively by Nrf2, 
and that levels increase in response to AHSS, suggests that Nrf2 is in fact transcriptionally active. 
To add further complexity to the current Nrf2 target gene picture, there is also evidence that 
the transcriptome controlled by AP-1 also contains many parallel genes, as there exists an AP-1 
consensus sequence within the ARE motif (Biswas et al., 2014). Stress response regulation is 
clearly an extremely complex series of finely-tuned, yet overlapping elements and, 
consequently, these data must be interpreted with caution, because, although plausible, the 
findings are still in their preliminary stage. Further investigation would be necessary to examine 
true Nrf2 transcriptional activation, such as evaluation of Nrf2 phosphorylation at Ser40 as an 
indicator of active and dissociated Nrf2, an ARE-luciferase assay and perhaps an Nrf2-ARE 
binding assay. 
It is thought that exogenous Nrf2 activation, either with gene-therapy-based or pharmacological 
approaches, could protect ECs against the inflammatory effects of AHSS. However, high-level 
activation of Nrf2 (hyperactivation), with sulforaphane pre-treatment (5µmol/L) and adenoviral-
mediated WT-Nrf2 overexpression (1x107pfu/mL), concomitantly with AHSS, increased MCP-1, 
IL-6 and IL-8 mRNA transcript levels in vECs exposed to AHSS. However, there was a reduction 
of MCP-1 transcript levels following shear stimulation with the lesser degree of Nrf2 activation. 
As alluded to earlier, these findings emphasize caution when investigating Nrf2 activation and 
that, as in many oncology studies, hyper-activation of Nrf2 and dysregulation of Keap1 may 
promote inflammation and harm, rather than protection (Lau et al., 2008; Sporn et al., 2012; 
Menegon et al., 2016).  
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The findings presented here, regarding the possible pro-inflammatory function of Nrf2 in acute 
shear, represent a contrasting view from the widely accepted notion that Nrf2 possesses anti-
inflammatory potential. It has been well established that Nrf2 activation can prevent p38-
mediated VCAM-1 signalling in TNF-a stimulated ECs, in vitro, and in portions of the arterial 
vasculature exposed to chronic, low shear stress, in vivo (Zakkar et al., 2009). The same study 
also observed an increase in TNF-a-driven induction of VCAM-1 transcript levels in cells 
overexpressing the same DN-Nrf2 form, used here (Zakkar et al., 2009). It is well understood 
that Nrf2 is induced by a variety of mechanical stimuli, however, these stimuli are largely of the 
prolonged and protective type, under which, Nrf2 acts to positively regulate redox balance, 
which, in turn is thought to prevent inflammation (Lee et al., 2015; Kobayashi et al., 2016). 
Nevertheless, in the context of acute shear stress, no increase in pro-inflammatory transcript 
levels following Nrf2 inhibition was observed in this study, though there was when Nrf2 was 
hyperactivated, indicating that dual Nrf2 activation exogenously and under shear stress, 
paradoxically, induces inflammation. This suggests that, under acute shear, Nrf2 does not play 
an integral role in the subsequent inflammatory response, unless it is hyper-activated. Though 
this may be less to do with Nrf2 hyperactivity than the inactivation of Keap1 and its possible 
degradation, thus preventing Keap1 from regulating the NF-kB pathway through Keap-1 
dependent IKKb degradation; or, alternatively, due to excessive HO-1 activity and CO production  
(Lee et al., 2009; Washington et al., 2017). Whilst these findings did not support the anti-
inflammatory role of Nrf2 pre-activation in the context of acute shear, they are able to provide 
some initial insight into the stimulation- and dose-dependent effects of Nrf2 regulation in early 
mechanotransduction events. The results described here also highlight that much more detailed 
study into the actions of Nrf2 activation in human LSV tissue, particularly upon exposure to acute 
arterial haemodynamics, is needed, in order to translate these findings from an EC mechanical 
adaptive response, to findings genuinely translatable to vein grafting. 
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5.5 FUTURE WORK 
5.5.1 NF-kB AND VEIN GRAFT FAILURE 
In order to truly establish the role played by NF-kB in driving AHSS-induced inflammation in the 
vein graft endothelium, in vivo porcine translational studies, employing either an interpositional 
or coronary vein graft, would be necessary to corroborate the ex vivo findings presented in 
Chapter 3. Further to this, it would be of great interest to validate, firstly, whether the NF-kB 
inhibitor, BAY11-7085, was capable of reducing chemokine and cytokine expression and 
monocyte-endothelial interaction acutely in the vein graft, using an in vivo model. Secondly, it 
would be pertinent in such a model, to assess the therapeutic efficacy of an acute vein graft pre-
treatment on a longer-term outcome, such as neointimal size or monocyte infiltration into the 
vein graft wall. Lastly, using the tissue-based models established in this thesis, evaluating the 
effect that NF-kB pre-inhibition has on endothelial preservation and apoptosis at later time-
points (>24 hours) represents a currently unexplored and essential area for the continuation of 
this work. 
5.5.2 NRF2 AND THE AHSS RESPONSE 
Having established that Nrf2 hyperactivation induced a pro-inflammatory response under AHSS, 
it became clear that Nrf2 activation did not represent a viable strategy to retard acute vein graft 
inflammation. However, further temporal characterisation of the basal activity of the 
Nrf2/Keap1 axis under shear stress stimulation in vitro, beyond 30 minutes-six hours, may 
provide some important detail as to how ECs switch from an inflammatory-prone to a protected 
phenotype. Furthermore, since ex vivo responses may differ from in vitro experiments, 
investigation of the Nrf2 response to AHSS in the LSV endothelium may be of interest in better 
defining the role of Nrf2 in early shear, mechanotransduction events. 
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5.5.3 NF-kB AND NRF2: POTENTIAL CROSSTALK 
Finally, with the known involvement of ROS and NOXs in the shear stress mediated activation of 
NF-kB, it is conceivable that there is a role for antioxidant response pathway involving Nrf2, via 
crosstalk in the activation of NFκB. The interaction between NF-kB activation and Nrf2 remains 
poorly understood; NF-kB is known to disrupt the transcriptional activity and binding of Nrf2 to 
antioxidant response elements (ARE) through interaction with Creb-binding protein (CBP) (Liu 
et al., 2008). However, Liu et al. were only able to establish a unidirectional mechanism of 
interaction (i.e. from NF-kB to Nrf2). In contrast, Lee et al. established a link between the two 
pathways which worked in the opposite direction, whereby, a Keap1-dependent complex 
functioned to regulate IKKb activity, by ubiqutination, independently of Nrf2 (Lee et al., 2009). 
As suggested earlier, this interaction may offer a possible explanation for the findings associated 
with Nrf2 hyperactivation and this would represent a logical further investigation in the AHSS 
context.  
5.6 CONCLUSION 
In summary, the results of this thesis have demonstrated that acute exposure of vECs to arterial 
levels of shear stress is associated with the induction of a pro-inflammatory response, both in 
vitro and ex vivo, which was driven by activation of the NF-kB classical pathway. Inhibition of 
the NF-kB classical pathway, was able to prevent AHSS-induced inflammation. Activation of the 
Nrf2/Keap1 cytoprotective signalling system, in vitro, was also seen in response to AHSS, which, 
when activated at low-levels or hyper-activated, prior to shear stress exposure, initiated highly 
divergent pro-inflammatory responses. The findings with regards to Nrf2, raise many interesting 
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 Mechanistic summary figure 
A summary of the working model for this thesis, including the potential mechanisms of 
activation (black arrows) of the NF-kB classical pathway (left-hand side) and Nrf2/Keap1 
pathway (right-hand side) in vECs exposed to AHSS. Additionally, the effects that NF-kB 
inhibition (red arrows) and Nrf2 hyperactivation (green arrows) are included, as well as a 
proposed mechanistic explanation and link (red question mark) between the pathways to 












SUPPLEMENTARY FIGURE 1.    IgG CONTROL IMAGES FOR IMMUNOCYTOCHEMISTRY 
All immunocytochemistry analysis was performed in conjunction with concentration- and 
species-matched Anti-IgG control antibodies. Here, the Anti-IgG control images are presented 
for MCP-1 and VE-Cadherin, at primary antibody concentrations of 3.33µg/mL and 4µg/mL, 
respectively.  












SUPPLEMENTARY FIGURE 2.   IgG CONTROL IMAGES FOR MCP-1 EN FACE 
IMMUNOFLUORESCENCE  
All NF-kB immunofluorescent analysis was performed in conjunction with concentration- and 
species-matched Anti-IgG control antibodies. Here, the Anti-IgG control images are presented 
for MCP-1 and vWF, at primary antibody concentrations of 3.33µg/mL and 200µg/mL, 
respectively.  






SUPPLEMENTARY FIGURE 3.   IgG CONTROL IMAGES FOR NF-kB EN FACE 
IMMUNOFLUORESCENCE  
All NF-kB immunofluorescent analysis was performed in conjunction with concentration- and 
species-matched Anti-IgG control antibodies. Here, the Anti-IgG control images are presented 
for NF-kB and vWF, at primary antibody concentrations of 0.33µg/mL and 200µg/mL, 
respectively.  







SUPPLEMENTARY VIDEO 1.      Z-STACK OF MCP-1 EN FACE IMMUNOFLUORESCENCE 
MCP-1 protein immunofluorescence in the LSV endothelium, described in sections 2.7.2., 2.9.1., 
2.9.4. and 3.2.2.2., was assessed using en face preparation and immunofluorescent analysis of 
portions of the LSV. Confocal microscopy was used to acquire Z-stacked image sets at 5 equally-
distributed points across the endothelial surface. Supplementary video 1. shows a 
representative Z-stack from LSV immunofluorescence staining for MCP-1 (red), vWF (green) and 
TO-PRO3/nuclei (blue) from a portion of LSV which was exposed to 6 hours AHSS in section 
3.2.2.2. The video pans from the bottom to top, showing first the underlying VSMCs and then 




SUPPLEMENTARY VIDEO 2.     Z-STACK OF MCP-1 EN FACE IMMUNOFLUORESCENCE WITH     
MCP-1 SEGMENTATION OVERLAID  
As above, MCP-1 protein immunofluorescence in the LSV endothelium, described in sections 
2.7.2., 2.9.1., 2.9.4. and 3.2.2.2., was assessed using en face preparation and immunofluorescent 
analysis of portions of the LSV. Supplementary video 2. shows a representative Z-stack from LSV 
immunofluorescence staining for MCP-1 (red), vWF (green) and TO-PRO3/nuclei (blue) from a 
portion of LSV which was exposed to 6 hours AHSS in section 3.2.2.2. Overlaid on the 
immunofluorescent images are the object maps from the segmentation of MCP-1 protein, 
obtained using FIJI. The segmentation of objects for the same image is also represented in 2D in 
section 2.9.4. The video pans from the top to bottom, showing first the ECs, marked by vWF co-
staining (green), and then underlying VSMCs. Co-localised with the MCP-1 staining are the 




 SUPPLEMENTARY VIDEO 3.      Z-STACK OF NF-kB EN FACE IMMUNOFLUORESCENCE 
NF-kB protein immunofluorescence in the LSV endothelium, described in sections 2.7.2., 2.9.1. 
and 3.2.4.1., was assessed using en face preparation and analysis of portions of the LSV. 
Supplementary video 3. shows a representative Z-stack from LSV immunofluorescence staining 
for NF-kB (red), vWF (green) and TO-PRO3/nuclei (blue) from a portion of LSV which was 
exposed to  30 minutes AHSS in section 3.2.4.1. The video pans from the the top to bottom, 




SUPPLEMENTARY VIDEO 4.      REAL-TIME MONOCYTE ADHESION TO vECs IN VITRO 
THP-1 monocytic-like cell adhesion to the vEC monolayer, in vitro, was performed in real-time 
using the Fluxion Bioflux 200, as described in sections 2.6. and 3.2.7.4. Briefly, HUVECs were pre-
treated using the NF-kB inhibitor, BAY11-7085 (upper red channel in video), or DMSO (lower 
channel in video). Following which, they were exposed to AHSS for 6 hours and then dynamically 
co-cultured with THP-1 monocytes under shear stress for 10 minutes using the Bioflux 
microfluidic channel system, during this time sequential images were acquired (33milliseconds 
apart) to assess adhesion in real-time.  Supplementary video 4. shows 10 minutes (sped up to 
one minute in length) of dynamic co-culture of THP-1 monocytes with ECs and subsequent 
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